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Alzheimer’s disease
Clinical features and prevalence
Alzheimer’s disease (AD) is the most common form of dementia, accounting 
for an estimated 60 to 80% of all dementia cases [1]. Clinical symptoms include 
memory loss, disorientation, mood and behavioral changes. In general, 
symptoms develop slowly and worsen over time, finally resulting in total loss 
of independence. AD dramatically decreases a patient’s life expectancy, after 
the onset of symptoms, patients live on average another 8 years [2].
Over the last decades the interest in age-related diseases such as AD has grown 
substantially. This is attributed to the increasing average life span and growing 
elderly population. AD affects currently over 35 million people worldwide (WHO 
2012), however prevalence numbers are predicted to be more than tripled in 2050 
[3]. Of individuals at the age of 65-69 years, approximately  1% is affected, however 
prevalence numbers increase fast up to 22% in the age group over 90 years [4]. 
Genetic risk factors
Besides age as the major risk factor, other factors such as high cholesterol, 
atherosclerosis, overweight, hypertension are also associated with AD [5]. 
Patients can be divided into two categories; sporadic and familial AD. The former 
subtype, also known as late-onset AD, typically occurs after 65 years of age and 
accounts for about 99% of all cases. Familial AD is very rare and is characterized 
by genetic mutations in genes related to the metabolism of the Amyloid-β 
(Aβ) protein [6, 7]. Mutations in the Amyloid Precursor Protein (APP) or in the 
γ-secretases presenilin 1 or 2, which cleave APP, can lead to development of AD 
at a young age, sometimes as early as 30 years. APP mutations generally lead 
to increased production of Aβ and presenilin mutations lead to an alteration 
in the production of Aβ isoforms, shifting the balance towards increased 
production of the more toxic isoform  [8, 9] (see paragraph 1.2). However, the 
risk of sporadic AD is dependent on a genetic predisposition. Different variants 
of the Apolipoprotein E (ApoE) gene correspond with varying likelihoods for 
developing the disease. The ApoE ε3 allele is the most common, however 
the ε2 variant decreases one’s risk of AD, while the ε4 variant increases the 
risk even up to 15-fold in ε4/ε4 carriers [10]. In addition, mean age of onset 
decreased from 84 in non-carriers to 68 years in ε4/ε4 carriers [11]. More than 
half of the diagnosed AD patients carry the ε4 allele [12]. The role of ApoE in AD 
is described into more detail in paragraph 1.5.
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Pathological features
Alois Alzheimer described in 1907 for the first time the brain pathology of 
a patient suffering from dementia [13]. During autopsy, he found abnormal 
deposits in her brain. These extracellular accumulations are now known as 
senile plaques and neurofibrillary tangles.
The plaques were later discovered to consist mainly of Aβ [14]. Aβ deposition 
occurs as a consequence of aggregation of the protein and senile plaques can 
roughly be divided into two categories; diffuse plaques consisting mainly of 
non-fibrillized Aβ and neuritic or classic plaques with a dense core composed 
of fibrillar Aβ. Diffuse plaques are believed to develop into classic plaques as 
they mature [15].
In addition, another form of Aβ accumulation that is found in 75-98% of AD 
patients, is cerebral amyloid angiopathy (CAA) [16, 17]. This is defined as 
deposition of Aβ within the smooth muscle layer of cerebral blood vessel walls 
[18]. Vascular accumulation of Aβ can lead to degeneration of endothelial cells 
[19, 20], which subsequently can initiate loss of integrity and dysfunction of 
the blood-brain barrier (BBB) [21]. Also, CAA can induce microbleeds that can 
lead to neuronal damage and accelerate cognitive decline [18]. Therefore, CAA 
is believed to contribute to the progression of the AD pathology.
Another important pathological event in AD is accumulation of tau protein. 
Tau is mainly found in axons and plays a role in the assembly and stabilization 
of microtubules, neurite outgrowth and organelle transport [22]. In AD, 
abnormally hyperphosphorylated tau (p-tau) can self-assemble and form 
intracellular neurofibrillary tangles. The hyperphosphorylation of tau is 
believed to lead to destabilization of microtubules and compromised axonal 
transport [23].
In the early stages of AD, the first brain area affected with Aβ deposition is the 
entorhinal-hippocampus system, a part of the neocortex involved in memory 
processing [24]. As the disease progresses, plaque deposition spreads through 
other parts of the cortex, and finally, in the end stages affects the brain stem 
and cerebellum [25]. Tau pathology first becomes evident in the entorhinal 
region of the brain and later spreads to the hippocampus. Finally, in several 
stages of the disease tangles are extensively found in the neocortex. Tau 
pathology is classified by Braak stages I-VI, referring to the progression of 
neurofibrillary tangle distribution [26]. In severe stages of the disease, total 
brain volume decreases and shrinkage of the gyri and enlargement of the 
ventricles becomes evident.
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Amyloid hypothesis
The pathological changes caused by Aβ are described in the Amyloid cascade 
hypothesis, which focuses on Aβ as a causative agent for AD [27]. Although 
Aβ is also found in healthy subjects, increased aggregation and/or decreased 
clearance of Aβ from the brain is believed to lead to accumulation of the 
protein and consequently trigger pathology.
APP processing
Aβ is a small, 4 kDa, protein that is cleaved from APP, a large type I 
transmembrane protein. α-Secretase cleaves APP within the Aβ domain 
and therefore represents the non-amyloidogenic pathway (Fig. 1) [28, 29]. 
However, in an alternative pathway via sequential proteolytic processing by 
β- and γ-secretases, Aβ peptides are released into the endosomal lumen and 
finally into the extracellular space. The ability of the γ-secretase to cleave the 
protein at slightly different sites within APP, causes a diversity in Aβ peptides, 
varying slightly in length [30]. Aβ40 is most common, but the second most 
abundant peptide, Aβ42, has a higher propensity to aggregate due to its 
increased hydrophobicity and is most commonly found in senile plaques [31].
Aβ aggregation and toxicity
Self-aggregation of Aβ in the brain leads to accumulation of the protein 
through a well described aggregation pathway (Fig. 2). The aggregation starts 
with the self-adherence of the monomeric protein, leading to the formation 
of small low molecular weight oligomers, then larger high molecular weight 
oligomers, protofibrils and finally insoluble mature fibrils. Oligomers exist in a 
variety of different sizes and shapes, for more details see chapter 2. Based on 
current knowledge, the consensus on Aβ toxicity is that the oligomeric species 
represent the most neurotoxic form of the protein. Previous observations 
revealed that the plaque load in the brain poorly correlates with disease 
severity [32] and in addition, in a subset of non-demented individuals also 
low numbers of plaques can be detected. Soluble oligomers have been 
demonstrated to cause more extensive neuronal death than fibrils [33, 34]. 
Fibrillar Aβ, deposited in plaques, is believed to be inert or even protective 
to the AD pathology. It has been hypothesized that plaques can sequester 
oligomers in order to prevent them exerting their toxicity [35].
15
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Fig. 1) Processing of APP, leading in abnormal cases to accumulation and aggregation of Aβ [129]. 
Reprinted from Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of 
Alzheimer disease, Canadian Medical Association Journal. © Canadian Medical Association (2008). 
Fig. 2) Different stages in the aggregation pathway of Aβ [130]. ADDL, Aβ-derived diffusible ligand. 
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The mechanism by which oligomers exert their toxicity remains largely 
unknown. One of the earliest pathological effects of Aβ is synapse loss. In the 
preclinical disease phase, before significant neuronal death occurs, synaptic 
failure can already be detected. In vitro oligomers have been demonstrated 
to bind to phospholipid membranes and exert direct toxic effects on synapses 
[36, 37]. More specifically, oligomers can cause pores in the membrane, 
inducing abnormal calcium mobility [38]. Alternatively, oligomers have been 
proposed to bind to several receptors, such as the PrPc, NMDA, insulin and 
NGF receptors, possibly altering receptor density and inducing dysfunctional 
cellular pathways (for an overview see [39]).
Aβ clearance
Although in familial AD the production of Aβ is enhanced, in late onset AD there 
is a defect in clearance mechanisms, which leads to accumulation of Aβ [40]. It 
was demonstrated that Aβ clearance is reduced by around 30% in late onset 
AD patients [41]. Different pathways contribute to the clearance of Aβ from 
the brain. Firstly, Aβ can be degraded by proteases, either extracellularly or 
intracellularly in phagocytic cells such as microglia and astrocytes, that become 
activated and accumulate around plaques. Reduced levels of proteases may be 
related to AD pathology [42, 43]. Both extra- and intracellular degradation of 
Aβ may be mediated by ApoE and the efficiency of this mediation is dependent 
on ApoE isoform and lipidation state [44, 45]. The association between Aβ and 
ApoE is described more thoroughly in paragraph 1.5.
Secondly, there is receptor-mediated transport of Aβ across the blood-brain-
barrier (BBB) by  LRP-1 and p-glycoprotein (efflux) and RAGE (influx), present in 
endothelial cells and pericytes [46, 47]. ApoE influences this transport, either 
by binding to Aβ [48] or by competing for the same receptors [49], thereby 
influencing the equilibrium between Aβ in plasma and brain interstitial fluid 
and cerebrospinal fluid (CSF). The expression of LRP-1 declines in AD, which 
might partly explain the impaired clearance of Aβ [48, 50].
In addition, Aβ moves from the brain interstitial fluid to the CSF, whereby the 
CSF acts as a sink for brain extracellular solutes. How this movement occurs 
remains still unclear. Since the brain lacks a lymphatic circulation, waste 
products and extracellular proteins must be cleared via an alternative manner. 
Recently it was demonstrated, by injecting fluorescent tracers in the CSF of 
mice, that movement of solutes also occurred by CSF flow through the brain via 
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distinct routes [51]. Particles moved alongside cerebral veins and eventually 
were transported into deep blood vessels by astrocytes, via their aquaporin 
4 (aqp4) water channels. Aqp4-knock-out mice cleared fluorescently labeled 
Aβ about 70 more slowly than wild-type mice [51]. This alternative clearance 
mechanism was designated as the glymphatic system.
Inflammation and microglial cells
Besides deposition of Aβ and tau proteins, there are other factors that contribute 
to AD pathology and substantial evidence points to an implication of chronic 
neuroinflammation in AD [52, 53]. The most obvious sign of an inflammatory 
involvement is the activation and attraction of innate immune cells, such as 
microglia and astrocytes, around plaques. Microglial cells are the macrophages 
of the brain, the first line of defense that constitute about 10% of all brain 
cells [54]. Glial cells search the central nervous system for damaged neurons 
and pathogen-derived ligands and in addition respond to senile plaques. In 
AD, microglia are present in the center of and around senile plaques, while 
astrocytes accumulate around plaques and extend their processes towards 
the center [52]. Activation of microglia is believed to be an early event in the 
AD pathology, as post mortem brain examination of early stage AD patients 
revealed microglia accumulation coincides with Aβ deposition even before tau 
pathology occurs [55, 56]. In addition, a PET study using tracers specific for Aβ 
and microglia visualized Aβ deposition accompanied by microglia activation 
in half of the patients diagnosed with mild cognitive impairment (MCI) [57].
The composition of microglia activation stages is usually heterogeneous, 
however two extremes in differentiation have been defined, the M1 and 
M2 stage. The M1 phenotype represents a pro-inflammatory state and is 
characterized by the secretion of pro-inflammatory cytokines, while M2 
proliferated cells react in a immunosuppressive fashion and are involved 
in repair mechanisms and phagocytosis [58, 59]. In AD, initially, microglial 
cells are attracted to play a beneficial role in the clearance of Aβ and debris 
of damaged neurons by phagocytosis [60]. However, when inflammation 
becomes unregulated, it can attribute significantly to disease progression. In 
addition, Aβ oligomers were demonstrated to induce the M1 phenotype more 
potently than fibrils [58]. M1 activated microglial cells produce a wide range 
of pro-inflammatory factors, such as cytokines, chemokines, complement 
factors and reactive oxygen species, that have detrimental effects on neuronal 
General Introduction
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viability [53, 61, 62]. Levels of multiple of these factors have been demonstrated 
to be altered in the brains of AD patients. For example, complement factors 
and interleukin (IL) 1beta, IL-8, transforming growth factor beta1 (TGF-beta1) 
and CD40 ligand, have been described to be upregulated in the brains of AD 
patients [63-69]. In addition, IL-6 was described to be present in the brains 
of AD patients and not in non-demented controls [70, 71]. IL-6 was found 
predominantly in early stage plaques and was suggested to contribute to 
plaque maturation and the development of dementia [71].
Aβ associated proteins
A variety of different proteins co-localize with Aβ in senile plaques and 
many of these proteins have been shown to be binding partners for Aβ. It is 
believed that these amyloid associated proteins (AAPs) play a major role in Aβ 
metabolism, aggregation and toxicity. In addition, measurable levels of AAPs 
in biological fluids might function as biomarkers. AAPs either by themselves 
or in complex with Aβ can possibly be a specific indicator for AD and in 
addition, the identification of novel AAPs can give more insight in disease 
pathology. The most extensively studied AAPs are heat shock proteins, ApoE 
and ApoJ (clusterin), heparan sulphate proteoglycans, acute-phase proteins, 
complement factors, inflammatory cytokines, but novel AAPs continue to be 
discovered.
Small heat shock proteins (sHSPs)
The human sHSP family consists of ten proteins with a molecular weight of 
approximately 20 kDa, among others αB-crystallin, Hsp20, HspB8, HspB2, 
HspB3, Hsp27 [72]. sHSPs are upregulated intracellular due to stressful 
stimuli and possess a chaperone function, preventing protein misfolding 
and aggregation. They are believed to assist larger HSPs, that possess ATPase 
activity, by binding to misfolded proteins and attenuate aggregation [73-
76]. In addition, HSPs have been described to function extracellularly as pro-
inflammatory agents and induce the production of cytokines in immune cells 
[77-79]. These findings suggest sHSPs might be involved in the AD pathology of 
various levels, namely they might be implicated in misfolding and aggregation 
of Aβ and induce an inflammatory response.
Several sHSPs have been found to co-localize with senile plaques, for instance 
Hsp20, HspB2 and HspB8 [80, 81]. In addition, αB-crystallin and Hsp27 were 
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upregulated in AD patients’ brains and expressed in astrocytes around senile 
plaques and neurofibrillary tangles [82-85]. In vitro studies have demonstrated 
that sHSPs can influence the aggregation of Aβ, by either inhibiting its 
aggregation [80, 86] or even retaining Aβ in a protofibrillar state, thereby 
enhancing its neurotoxicity [87].
Apolipoprotein E (ApoE)
ApoE is a 34 kDa lipoprotein and is in the brain predominantly produced by 
astrocytes [88]. It exists in three isoforms (ApoE2, E3 and E4), that vary from 
each other by one or two amino acids. These differences lead to changes in 
both structure and function [89]. ApoE has a major role in lipid and cholesterol 
transport and circulation in the brain, especially during membrane repair and 
synaptic plasticity [90, 91]. ApoE co-localizes with Aβ in senile plaques [92, 
93] and binds to Aβ in a manner that is dependent of its isoform and level of 
lipidation [94-97]. More specifically, most studies show that Aβ binds with the 
highest affinity to lipidated ApoE2, followed by E3 and E4 [98]. This might be 
related to the finding that ApoE4 is less lipidated, which decreases its stability 
and results in less binding with Aβ compared to ApoE3 [99]. In addition, binding 
of ApoE with Aβ possibly alters the aggregation rate of Aβ. However, results 
are contradicting, as ApoE was found to either decrease [100] or increase Aβ 
aggregation [101, 102]. Overall, the effects of ApoE on Aβ kinetics are likely 
influenced by multiple variables, including ApoE isoform, Aβ conformation 
and the concentrations of both peptides [103].
Another possible finding that might explain the different influences that ApoE 
isoforms have on AD risk, demonstrated that ApoE4-mediated clearance of Aβ 
was slower than E3 and E2-mediated clearance [104].
Diagnostics
Setting a precise diagnosis for AD and neurodegenerative diseases in general 
is of great importance. Although there’s still a lack of successful medication 
for dementia syndromes, some drugs might reduce symptoms or slow down 
disease progression. In addition, a correct diagnosis is desirable to include 
patients in clinical trials, to provide appropriate care, to predict disease 
progression and simply because there’s a great need for most patients to be 
informed about their condition.
General Introduction
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Diagnostic differentiation
The diagnosis of AD and other dementias is primarily made by a patients 
neurologist or geriatrician, according to guidelines and established criteria 
[105-107]. Besides AD, the other most common forms of dementia  are 
dementia with Lewy bodies (DLB), frontotemporal dementia (FTD) and 
vascular dementia (VaD). Pathologically, DLB is characterized by the formation 
of intraneuronal Lewy body inclusions, containing α-synuclein protein, 
throughout the brain [108]. In FTD mainly the cortex of the frontotemporal 
lobe is affected. Intracellular inclusion bodies containing tau or the protein 
TDP-43 are commonly found [109]. Vascular dementia is caused by ischemic 
injury in the brain, often as a consequence of multiple strokes [110].
Medical and family history, cognitive, neurological and physical testing all 
contribute to determining the clinical picture. However, setting a diagnosis is 
in many cases challenging or uncertain. Clinical symptoms between different 
forms of dementia can overlap. For instance, early stage memory problems 
and cognitive function decline can present very similar in AD and in DLB and 
vascular dementia. Increasing evidence indicates that very commonly patients 
display more than one type of dementia, so called mixed dementia, which 
complicates the diagnosis. Recent studies indicate as much as half of the 
demented patients suffers from mixed dementia [111, 112]. Furthermore, there 
is a great need for early stage biomarkers, that predict whether a patient is at 
risk of developing AD even in a preclinical stage. It is believed that AD onset 
starts up to 20 years before symptoms become evident [113-115]. Diagnostic 
tests, for instance PET and MRI scanning, can be applied to gain more insight 
in the underlying pathology. To visualize Aβ deposition with PET scanning, 
a specific tracer is used that detects Aβ, thereby generating an image that 
corresponds with plaque load. The first human tests with an amyloid tracer, 
Pittsburg Compound-B (PiB), were reported in 2004 [116]. Since then a variety 
of novel tracers has been developed. Alternatively, MRI scanning can be used 
to aid dementia diagnosis. This method is used more commonly and enables 
the visualization of brain atrophy and vascular damage. However, in this thesis 
we focus on the detection of biomarkers in CSF, a third diagnostic tool to 
predict AD onset and progression and support the diagnosis.
Cerebrospinal fluid biomarkers
CSF surrounds the brain and spinal cord and provides a mechanical and 
immunological protection for the brain. CSF is mainly produced by the choroid 
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plexus and its content mirrors the brain’s biochemical, including pathological, 
processes. Via lumbar puncture, CSF can be routinely obtained for analysis and 
quantification of specific biomarkers that can aid in diagnostic differentiation.
Related to AD, three established biomarkers can be measured. First of all Aβ42 
is decreased in CSF from AD patients [117, 118]. This observation might be 
explained by deposition of Aβ42 in the brain [119, 120] and/or the enhanced 
property of Aβ42 to form oligomers and complexes with other proteins causing 
the peptide to be less efficiently measured [121]. An increase in both total tau 
protein and phosphorylated tau (p-tau) in CSF is also indicative for AD [122]. 
These changes relate to accumulation of intraneuronal tangles and neuronal 
degeneration. According to the amyloid cascade theory, abnormal processing 
of APP and deposition of Aβ are the initial events in the AD pathology (Fig. 
3). Even before changes in brain structure and disease symptoms occur, Aβ 
levels are believed to be altered, making CSF biomarkers particularly suitable 
for early disease detection [123].
A combination of CSF Aβ42, tau and p-tau levels can provide a good 
discrimination between AD patients and non-demented controls, with 
sensitivity and specificity between 80 and 90% [124, 125]. In addition, the 
discrimination between MCI patients that convert into AD patients and those 
that remain cognitively stable can be predicted with sensitivity and specificity 
of resp. >83% and >72% [126-128]. However, distinguishing AD from other 
General Introduction
Fig. 3) Pathological model of AD progression, based on the amyloid cascade [123].
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neurodegenerative disease causes, as mentioned above, more difficulties. 
Therefore, there’s still a great need for novel, specific biomarkers. One of the 
main focuses of this thesis is the discovery and development of novel potential 
biomarkers and detection methods for AD. The measurement of CSF levels of 
certain isoforms or conformations of Aβ can possibly add in the AD diagnosis. 
Finally, complexes of Aβ with certain AAPs might also possess discriminating 
biomarker abilities and in addition, can provide more insight into the AD 
pathology. 
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Aims of the thesis
The main focus of this thesis was on two aspects:
 
-  Investigate the potential of several novel Aβ related biomarkers
 in AD diagnosis.
 
 -  Study the characteristics of AAPs in terms of co-localization or complex 
 formation with Aβ and effects of co-incubation on microglial 
 inflammation.
Outline of the thesis
Part 1 focuses on Aβ aggregates and isoforms. Chapter 2 discusses multiple 
methods to analyze Aβ aggregates and compares these in terms of their (dis)
advantages, usefulness and applicability. In Chapters 3 and 4, we describe the 
development and validation of two different assays to measure Aβ oligomers 
in CSF and investigate their biomarker potential to diagnose AD patients and 
predict their disease progression. Chapter 5 examines the diagnostic value of 
the Aβ43 isoform to discriminate between different forms of dementia.
Part 2 of this thesis concerns AAPs. Chapter 6 describes the discovery of a novel 
potential AAP, dickkopf-related protein 3 (Dkk-3). We studied the co-localization 
of Dkk-3 with Aβ in the human brain and its levels in CSF. In Chapter 7, we 
report the development and validation of an assay that measures complexes 
of Aβ and ApoE. This assay was applied to study the biomarker potential of 
these complexes in human serum. Chapter 8 discusses the preparation and 
characteristics of complexes of Aβ and sHSP αB-crystallin, and methods to 
specifically detect these complexes. In Chapter 9 we investigate the effects 
of sHSPs and Aβ on IL-6 secretion in microglial cells. Finally, Chapter 10 
summarizes and discusses the main findings and describes recommendations 
for future research.
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Abstract
Amyloid-β protein (Aβ) accumulation is one of the major hallmarks of 
Alzheimer’s disease and plays a crucial role in its pathogenesis. Aβ aggregates 
into fibrils, but rather than these end-products of the aggregation process, 
intermediate species, referred to as oligomers, have been identified as the 
most neurotoxic Aβ aggregates. To characterize the different Aβ species and 
to study the aggregation process, a wide range of techniques has been applied 
over the past years. These techniques aim to  visualize the different Aβ species 
and study their structure, to separate them and to quantify the aggregated Aβ 
forms by immunology-based methods. In this review we provide an overview 
and discussion of the most important techniques used for these aims. Often 
a combination of techniques will be appropriate to obtain the most optimal 
information.
Introduction
Alzheimer’s disease (AD) is the most common cause of dementia in elderly 
worldwide. An estimated amount of 20-30 million people are affected [131]. 
Characteristic symptoms comprise memory loss, cognitive decline and mood 
changes [132]. AD is characterized by neuronal degeneration and cell loss in 
the hippocampus and various cortical areas. Central in AD pathology is the 
amyloid-β (Aβ) protein, which polymerizes and deposits extracellularly in the 
form of cerebral senile plaques and cerebral amyloid angiopathy (CAA) [133]. 
In the non-amyloidogenic pathway, the amyloid-β protein precursor (AβPP) is 
cleaved by α- and γ-secretase, whereas Aβ is produced in the amyloidogenic 
pathway when AβPP is cleaved by β-secretase instead of α-secretase [134]. 
Several Aβ isoforms exist in the brain. The main isoforms are Aβ40 and Aβ42, 
differing only by two amino acids at the C-terminus of the protein, of which 
the former one is most prevalent, but  Aβ42 is more prone to aggregate [135]. 
The aggregation pathway of Aβ (Fig. 1) is very similar to that of other 
amyloidogenic proteins and can be modeled as follows [136, 137]. Monomers 
attach to each other to form larger complexes, ranging from dimers to 
heptamers. These heptameric paranuclei then grow into larger oligomers 
that eventually form protofibrils. Finally, protofibrils grow into mature fibrils. 
This process of Aβ aggregation is dependent on several factors, including 
concentration, pH and temperature [138]. 
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Many different prefibrillar multimers have been described, which are 
collectively termed oligomers. This term refers to complexes roughly ranging 
from dimers to 24-mers, with a heterogeneity in quaternary structures (for 
an overview see [39, 139-141]). Usually a few different oligomeric species are 
discriminated. Low molecular weight (LMW) oligomers are defined as oligomers 
consisting of less than 8 Aβ subunits. The high molecular weight (HMW) 
oligomers may contain Aβ aggregates from ~42 kDa up to 1 mDa. Oligomers 
are referred to with different defining terms, based on their morphology, but 
also on the origin of different Aβ-isoforms [142]. For example, oligomers are 
Methods for analysis of Amyloid-β aggregates
Fig. 1) A proposed pathway for aggregation of amyloidogenic proteins. ([136] Copyright 2011 
National Academy of Sciences, U.S.A. Reproduced with permission.)
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defined as “Aβ-derived diffusible ligands (ADDLs)” [143], which comprises a 
heterogeneous collection of Aβ oligomers, from LMW up to aggregates larger 
than 1 mDa [144]. Their common feature is their globular shape. Another 
subgroup often mentioned are the “annular oligomers”, which have an outer, 
somewhat larger diameter than ADDLs (8-12 nm) and are doughnut shaped 
[145, 146]. An even larger form are the spherical intermediates with a diameter 
of 15-35 nm and a molecular weight of 650 kDa. These round-shaped, Aβ40-
derived species already display an ordered β-sheet conformation [147]. 
Although protofibrils are often regarded as species distinct from oligomers, by 
definition these are also HMW oligomers. Protofibrils are more ordered than 
smaller oligomers, contain predominantly β-sheets and can be visualized by 
EM and AFM. They are regarded as intermediates in the fibrillization process 
and are the precursors to fibrils, or – alternatively – may disassemble into 
smaller oligomers [136, 140]. However, they should not be confused with 
protofilaments, which are the substructures of fibrils and appear as a twisted 
thread [144]. Protofibrils in contrast, consist of a heterogeneous group of 
oligomers and can be annular or linear (5 nm in diameter and less than 200 nm 
in length). Finally, fibrils are the end product of the aggregation process. These 
are insoluble, filamentous structures longer than 1 µm and with a diameter of 
8-12 nm. For a more detailed overview of these subspecies we recommend 
an article by Jan et al. (2010) [144]. A current and widely accepted opinion 
is that oligomeric Aβ is the most neurotoxic species in the spectrum of Aβ 
aggregation forms [148].  Several studies have been conducted on the toxicity 
levels of different Aβ oligomers. One important neurotoxic oligomer is the 56 
kDa species, also referred to as Aβ*56. These oligomers were derived from the 
brains from transgenic mice and were demonstrated to correlate with memory 
deficits  and induce transient memory impairment [149]. Also it was shown 
that dimers derived from AD brains are potent neurotoxic species and impair 
synaptic plasticity and memory [150]. In another study, highly toxic 10-15 nm 
synthetic spherical oligomers were produced, as the end products of a distinct 
assembly pathway that does not lead to fibrils. These oligomers were termed 
amylospheroids (ASPDs) [146]. Native ASPDs have also been isolated from 
patient brains and were shown to cause neurodegeneration in vitro [151].
With the recognition that Aβ aggregation plays a crucial role in AD pathogenesis, 
many techniques to analyze this aggregation process have been employed. 
These techniques include various microscopic techniques that enable 
visualization and structural determination (chapter 1), separation techniques 
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to analyze and obtain Aβ species of a certain size (chapter 2), spectroscopic 
techniques to follow the aggregation process and determine protein shape 
(chapter 3) and immunology-based methods for quantification of Aβ (chapter 
4). Many of the studies we refer to are based on synthetic Aβ; if brain-derived 
Aβ was used, this is specifically indicated. The aim of this review is to provide an 
overview of all the different techniques that are currently in use to analyze Aβ 
aggregates, their specific applications, and advantages and disadvantages. This 
is of importance, because the analysis of Aβ aggregates may be more difficult 
than analysis of non-aggregating proteins. Since Aβ aggregates often exist as 
a dynamic mixture of species with a broad range in sizes, that are unstable, 
may disassemble or assemble during analysis, and since the concentration 
of each particular aggregate in vivo is usually very low, this all may hamper 
discrimination of the various types of Aβ assembly and their specific analysis. 
From this overview we conclude that a thorough characterization and 
quantification of Aβ aggregates requires a combination of different techniques 
to obtain an accurate analysis. To illustrate this, we provide some successful 
examples of combined techniques in the concluding section.
Techniques to determine morphology and 
structural conformation
Different aggregation states of Aβ can be visualized by using microscopic 
techniques. Numerous studies have been performed using light, electron 
and atomic force microscopy (for an overview on microscopic techniques to 
visualize amyloid plaques and fibrillogenesis, see Harris (2005) [152]). Here, we 
will consider aggregation forms of Aβ and its appearance using high-resolution 
microscopic techniques. Note that none of the microscopic techniques 
described here are useful for determination of  sample concentration. 
Electron Microscopy  
Electron Microscopy (EM) has been used to study plaque morphology and to 
obtain structural information on Aβ fibrils. Although not specifically for Aβ, 
already in 1967 amyloid-laden tissue of the liver and the spleen was visualized 
under the electron microscope to differentiate between amyloid fibrils, 
protofibrils and subfibrillar structures [153]. Later, Aβ40 and Aβ42 were visualized 
by using the electron microscope, as a mesh of fibers with diameters between 
6 and 10 nm. Here, a difference between short, curly fibrils, that were termed 
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protofibrils, and mature fibrils could be made according to their length [154]. By 
using transmission electron microscopy (TEM), it was possible to identify small 
pseudo-spherical structures with a diameter ranging from 9-25 nm, in Aβ40 
preparations incubated for less than a day [155]. Protofibrils with diameters 
of ~8.5 nm developed within an incubation period of two days. Finally, after 
two days of incubation, long mature fibrils with a diameter of up to 10.5 nm 
could be detected. The TEM images also revealed structural diversity in the 
fibrils. Fibrils either formed coiled structures or multistranded ribbons of two, 
three, four or more strands which might have formed by parallel association 
and annealing of protofibrils.  
EM is a very useful technique for visualizing fibrils and protofibrils and their 
structural morphologies, but EM is not suitable for detecting and differentiating 
small, LMW oligomeric species. Usually, synthetic Aβ mixtures are studied at an 
initial concentration of approximately 200 μM [156] to allow Aβ to aggregate 
and measure it at different incubation times to test the influence of different 
conditions, such as buffer solutions, pH or temperature on aggregation and 
morphology. Important disadvantages of EM are the need for expensive 
equipment and highly specialized operators and the fact that only small 
sample volumes of 3-10 μl can be studied, which may lead to selection bias. 
Furthermore, during the preparation and visualization protocols, unintended 
changes to the peptides may occur, such as breakdown or altered aggregation. 
To prevent this, formaldehyde or glutaraldehyde in combination with osmium 
tetroxide can be used for fixation. It should be noted that only highly pure 
glutaraldehyde should be used and that, due to its crosslinking activities, it 
might change the aggregation of structures. Samples can also be prepared in 
solution and imaged with cryoEM, a transmission EM variant that makes use of 
very low (cryogenic) temperatures by which the structure of proteins remains 
better preserved. 
Atomic Force Microscopy 
Atomic Force Microscopy (AFM) (Box 1) can produce high resolution images 
in the nanometer range by scanning the surface of a sample and drawing 
a topographical map. The major advantage of AFM compared to EM is the 
ability to visualize biological material in solution and thus under physiological 
conditions (Fig. 2). This way, the natural appearance of these structures are 
conserved during the scanning process and, by applying time-lapse AFM, even 
structural changes in one sample can be followed [157]. 
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AFM can be used to visualize Aβ40 and Aβ42 in different aggregation states, such 
as ADDLs, subfibrillar assemblies and protofibrils [158]. Over time, formation 
of oligomers were visualized that, after longer incubation, changed into 
larger structures, resembling protofibrils. Upon extended incubation, these 
protofibrils converted into two types of fibrils: Type-1 fibrils with nodules, 
that appear in a periodic pattern along the fibrils (“nodular fibrils”), and type-
2 fibrils without these nodules (“smooth fibrils”) [159]. 
Using AFM, deposition of Aβ42 in diffuse plaques, as the initial step in the amyloid 
cascade hypothesis [160, 161], was mimicked [162]. Aggregation was most efficient 
when soluble Aβ42 was added to fixed Aβ42 oligomers on the template, which 
indicated that Aβ42 contributes more to amyloid plaque growth than Aβ40. 
Time-lapse AFM allows to visualize single fibrils and fibril elongation over 
several hours [163]. This method can be useful in studies testing Aβ-inhibitors. 
Accordingly, the technique can also deliver information on the fibril-nucleating 
ability and structural incorporation of other molecules into Aβ aggregates. 
Compared to EM, AFM is able to clearly distinguish between Aβ oligomers, 
protofibrils and fibrils and has superior resolution [164]. AFM has enabled 
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Fig. 2) Atomic Force Microscopy images. Aβ40-fibril seeds were attached to a mica surface and 
non-fibrillar Aβ40 in solution was added. The growth of the fibrils was imaged by time-lapse 
atomic force microscopy at time points t = 5, 45, 75, 155, 200 minutes. (Reprinted from [163], 
Copyright 2011 with permission from Elsevier.)
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detailed structure analysis of Aβ aggregates, made it possible to follow the 
fibrillization pathway [159] and contributed to the understanding of Aβ 
behavior in vivo. To measure Aβ, concentrations as low as 2.5 μM can be 
used, but higher concentrations of 50-100 μM are more often applied [156]. 
However, AFM also enables visualization of only small sample volumes (~5-
50 μl), requires the availability of very expensive equipment, and  specialized 
operators. 
Circular Dichroism
Only few techniques are available to study structural properties of proteins. 
In studying structure of Aβ aggregates, fancy techniques based on nuclear 
magnetic resonance spectroscopy [147, 165-168] and mass spectrometry 
[169, 170] are currently in use, but mainly to study Aβ-peptides or fragments. 
An often used and validated technique for analyzing secondary and tertiary 
structure and conformation of proteins and complex molecules is circular 
dichroism (CD), and many studies have been performed on Aβ.
Structural asymmetry causes light to polarize in different angles and these 
differences are detected by CD spectroscopy. The CD spectrum in the far-UV 
region (190-250 nm) indicates the presence of α-helices, β-sheets, β-turns or 
random coils within proteins (Fig. 3). CD has been used to monitor changes in 
secondary structure and to define the conformational state of Aβ40 and Aβ42. It 
was demonstrated that Aβ fibrils predominantly adopt a β-sheet conformation 
[171], whereas other amyloid peptides or fragments display also other 
secondary structures [172]. During the aggregation process, Aβ undergoes 
conformational changes from random coil and α-helix to β-sheet structure. 
In CD this is recognized as a drop in the signal at 218 nm in time, indicating 
formation of β-sheets [173]. At the same time an increase in signal at 195 nm is 
observed, indicating the disappearance of α-helices (Fig. 4a) [174]. By plotting 
the absolute CD signal at 215 nm against time, a sigmoid curve is obtained 
with a lag phase, an exponential growth phase and a plateau phase in the 
aggregation process (Fig. 4b). This kind of curve is also observed in dynamic 
light scattering studies and Thioflavin T assays. 
Besides monitoring the aggregation process, CD is also often used to study the 
conformational stability of molecules upon environmental changes, such as ionic 
strength, temperature and the concentration of Aβ [174]. For instance, pH affects 
Aβ conformation; at pH 5.5, both Aβ39 and Aβ42 adapted predominantly a β-sheet 
formation [175], whereas at lower or higher pH, both peptides display predominantly 
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α-helices. Furthermore, CD analysis demonstrated that when Aβ40 was in contact 
with the surface of hydrophobic membranes or lipid vesicles, it displayed β-sheet 
formation [176]. In contrast, when the peptide was incorporated into membranes, 
it was stabilized by lipid surrounding into an α-helical conformation.  
Changes in the amino acid composition of Aβ may strongly affect its 
conformation. When valine 18 is replaced by alanine, or glutamic acid 22 
by glutamine, the propensity of Aβ to form an α-helix is increased, which 
indicates that there is a reduction in aggregation. Indeed, CD spectroscopy 
confirmed the formation of more α-helices and reduced formation of 
β-sheets. Furthermore, CD studies demonstrated that the GxxxG motif, which 
appears three times within the Aβ25-37 sequence, may be responsible for 
the conformational changes in Aβ that promotes oligomerization, but less 
fibrillization, and thus neurotoxicity [177]. Replacement of one glycine of the 
GxxxG motif into a leucine residue results in a conformational change over 
time, from predominantly random coil into a primarily β-sheet formation, 
which increased the rate of fibril formation and decreased the concentration 
of small soluble and neurotoxic oligomers [178]. 
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Fig. 3) Determination of secondary structure by CD spectroscopy. Typical spectra representing 
alpha helix, beta sheet and random coil conformations are detected in the far-UV spectral region 
at a wavelength of 190-250 nm. (http://employees.csbsju.edu/hjakubowski/classes/ch331/
protstructure/olcompseqconform.html)
34
CD spectroscopy can be a useful tool to follow Aβ aggregation and determine 
optimal conditions for obtaining synthetic monomers, oligomers and fibrils. 
The effects of solvents (e.g. NaOH, HCl or H2O) on Aβ40 conformation has 
been studied by CD [179]. For instance, Aβ40 dissolved in water, gradually 
changed form from random coils into an α-helix structure, whereas, when 
Aβ was dissolved in NaOH almost 50% of Aβ40 adopted a β-sheet structure. 
In another study the effect of hexafluoroisopropanol (HFIP) on Aβ40 and Aβ42 
was investigated [138]. This reagent is known to break-down β-sheets, and is 
therefore often used to force synthetic Aβ into its monomeric state [172, 180]. 
CD analysis confirmed that HFIP was able to keep Aβ in an unaggregated form, 
since CD spectra indicated that the peptides almost completely were in an 
α-helix or random coil form, with very little β-sheets.  
In summary, CD is a very useful technique for the identification of the 
secondary protein structure that is most abundant in a sample. The most 
important advantage is the real-time monitoring of the conformation of 
proteins in aqueous solutions. However, determining the structure of different 
Aβ aggregates in one solution can be difficult, because solutions with Aβ40 or 
Aβ42 often contain different stages of aggregation and may contain mixtures 
of secondary conformations. In particular Aβ oligomers comprise different 
conformational states of Aβ and CD spectroscopy can only determine the 
dominant secondary structures in that solution [138]. To do measurements, 
only a small volume of sample is required (less than 100 μl), but a relatively 
large amount of material (1 mg protein per titration) must be present in the 
sample [181]. Experiments can take 10 minutes or up to 3 hours, dependent 
on the number of records [181]. Another drawback is that CD analysis is not 
compatible with a number of frequently used buffer components that absorb 
UV light in the far-UV region (e.g. high concentrations of DTT, histidine, 
imidazole), and thus can interfere with measurements. Transparent solvents 
such as phosphate, Tris and borate buffer do not interfere, however [182].
Techniques to determine molecular weight 
Techniques to separate Aβ species by size are ubiquitously used both for 
analytical and fractionation purposes. However, the influence of the conditions 
during sample pretreatment and the experiment can be substantial and can 
affect the composition of Aβ species that are present.
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Polyacrylamide Gel Electrophoresis
An often used, reasonably simple, inexpensive technique to separate 
proteins in a complex sample based on molecular weight is Polyacrylamide 
Gel Electrophoresis (PAGE) [183, 184]. The most widely used variant of 
electrophoresis is SDS-PAGE [185]. SDS causes denaturation of secondary and 
non-disulfide-linked tertiary structures. Moreover, protein complexes can be 
disassembled in SDS-PAGE by addition of a reducing agent, such as dithiothreitol 
(DTT) or β-mercaptoethanol, which breaks up disulfide bonds. SDS-PAGE is 
most often followed by Western blotting, which increases both specificity and 
sensitivity of the detection. To visualize pure synthetic Aβ protein, a range of 
concentrations has been applied to the gel, from around  1 ng [186] up to 1 µg 
[187], depending on antibody quality, sensitivity of the analysis method and 
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Fig. 4) CD spectroscopy kinetic study of Aβ42. Overlaid CD spectra recorded at 45 min time 
intervals (A). The light grey curve represents the spectrum recorded after 1h, the black curve 
represents the spectrum recorded after 12 h (see arrows). A sigmoidal curve representing the 
formation of β-sheets over time is obtained,  when absolute CD signal at 215 nm is plotted against 
time (B).  ([174] Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission.)
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homogeneity of the Aβ species. To determine Aβ in brain lysate a total protein 
amount of 0,5 – 50 µg is used, in a typical volume of 25-40 μl. To perform an 
SDS-PAGE and Western blot experiment about 1 to 1.5 days are required.
PAGE techniques have been helpful in the past to identify brain derived Aβ as 
a pathological protein in AD [14] and to elucidate the aggregation properties 
of synthetic Aβ [188]. Until 2005, SDS-PAGE was the most commonly used 
method to detect and characterize Aβ oligomers (Fig. 5) [189]. However 
critical notes can be placed on the protein stability in PAGE. It has been shown 
that conditions in SDS-PAGE electrophoresis cause disassembly of the larger 
oligomers into smaller ones. Oligomers of around 50 kDa and up, obtained 
after size exclusion chromatography (SEC; see par. 2.2), appeared mainly in 
the form of monomers to tetramers on immunoblot after SDS-PAGE separation 
[190, 191]. Furthermore, samples that were boiled in denaturing, reducing 
sample buffer and analyzed by western blotting almost exclusively consisted 
of monomers and dimers, which seem to be heat-stable, in contrast to the heat-
instable high molecular weight oligomers. Also, in another study, monomeric 
Aβ, ADDLs and fibrils were prepared and analyzed by SDS-PAGE [186], resulting 
in practically the same band pattern for all three samples, corresponding with 
monomers, dimers and tetramers. This indicates that the ADDLs and fibrils are 
SDS-instable species. 
To avoid denaturing effects, polyacrylamide gels can also be prepared without 
SDS (native PAGE [192]). A disadvantage of this application is that besides 
molecular weight, protein conformation and charge also affect the migration 
process, complicating exact molecular weight determination. Although native 
PAGE has been used to study Aβ aggregation, it seems inevitable to combine 
this technique with other techniques like SEC or microscopic techniques, 
because of the inherent limited molecular weight information derived from 
native PAGE [135, 158, 193]. 
Another method to avoid disassembly of Aβ oligomers in gel is stabilization by 
chemical crosslinking. This probably enables more reliable results in SDS-PAGE, 
because oligomers become SDS- and thermostable. A technique to crosslink 
Aβ is Photo-Induced Crosslinking of Unmodified Proteins (PICUP) [194, 195], 
which uses visible light and a tris-bipyridyl Ru(II) complex to form covalent 
bonds between polypeptide chains. 
To study smaller and larger Aβ oligomers simultaneously, a gradient PAGE gel 
can be used. Gradient gels can be of additional value to separate proteins with 
closely related sizes like Aβ monomers and dimers, by enhancing the resolution 
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in a certain range of molecular weights. Using this type of gel, a striking 
ladder-like pattern of oligomers could be visualized [191]. In addition, buffer 
composition in SDS-PAGE significantly affects separation of Aβ peptides. This 
characteristic can also be used to enhance Aβ separation. Small complexes 
of synthetic Aβ40 and Aβ42 (from mono- to tetramer) were readily visible on 
a 16.5% Tris-Tricine gel, whereas high molecular staining corresponding  to 
fibrillar Aβ were only visible on a 16% SDS-PAGE Tris-Glycine gel [196]. These 
results are in agreement with the property of Tris-Tricine gels to increase the 
resolution of proteins with molecular weight between 5-20 kDa relative to Tris-
glycine systems [197]. 
In summary, the advantage of PAGE is its simplicity, and it is a rapid, inexpensive 
and reproducible technique to visualize the different forms of Aβ present in a 
sample. However, a major disadvantage is the influence of the denaturing and 
reducing conditions used in the assay, and as a result analysis of SDS-labile 
protein complexes may yield unreliable data. This may be counteracted by 
using native PAGE or by applying crosslinking techniques. Besides, additional 
assays, e.g. SEC (paragraph 2.2) or quasi-elastic light scattering (paragraph 
2.3), can be used to verify the molecular weight of the Aβ molecules.
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Fig. 5) Overview of biophysical methods used for detection and characterization  of 
amyloidogenic oligomers. Data are derived from publications in the first six months of 2004. 
([189] Reproduced with permission.)
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Size Exclusion Chromatography
Another method to separate molecules by size is Size Exclusion Chromatography 
(SEC) [198, 199], also referred to as gel filtration/permeation chromatography. 
The principle of SEC is separation over a gel filtration column, which consists 
of porous particles. Molecules will flow through the column with different 
retention times, based on their size. Larger molecules will only be able to 
pass through the inter-particle space, whereas smaller particles can also pass 
through the pores inside the particles. For Aβ chromatography most often 
Superdex 75 or 200 columns are used, depending on the desired fractionation 
range [158, 186, 200, 201]. However columns containing matrixes of different 
material and other particle sizes have also been used [186, 202, 203]. With flow 
rates of 0,5-1 ml/min an experiment can be conducted within one hour (sample 
preparation and column calibration excluded). However, rather high amounts 
of Aβ are needed, namely volumes between 100-500 μl with concentrations 
of  1-2  mg/ml.
SEC has generally been applied in two ways. First, for analytic purposes, 
the Aβ size distribution of a sample can be determined. For instance, the 
protofibrillar Aβ intermediate was for the first time extensively studied, after 
it appeared over time as a second peak in the analysis of chromatographed 
synthetic Aβ [154]. Also the presence of Aβ oligomers in brain homogenates 
and body fluids could be demonstrated by using SEC, both in humans [203, 
204] and transgenic mice [149]. Second, SEC has been used for preparative 
purposes to obtain a sample enriched for oligomeric Aβ of a certain size. Both 
naturally isolated [205], cell derived and synthetically derived oligomers [206], 
obtained by SEC, have been used to investigate their toxicity  and to study 
aggregation pathways in vitro [207-209]. 
SEC offers an advantage in comparison with SDS-PAGE, because the separation 
of proteins is conducted under non-denaturing conditions and therefore 
is supposed to present a more realistic picture of the sample content. 
Furthermore, buffer conditions in SEC resemble physiological conditions much 
better than in SDS-PAGE, because there is no need for detergents or reducing 
reagents. This advantage results in a better reflection of natural conditions for 
oligomers
It cannot be excluded, however, that during SEC oligomers and aggregates 
are dissociated to a certain extent (or, alternatively, stimulated to aggregate) 
because of dilution, change of solvent conditions or adsorption to the surface 
of the stationary phase particles [210]. In addition, Aβ collected after SEC can 
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be prone to aggregate at high concentrations. Another possibility is that Aβ 
might stick to tube walls during storage, which is especially a problem for Aβ 
samples with low concentration. It has already been shown that different tube 
materials can bind Aβ in cerebrospinal fluid (CSF) samples, thereby lowering 
the measurable concentration [211]. Another disadvantage of the method 
is the relatively low sample recovery, due to dilution effects inherent to the 
procedure and proteins sticking to the stationary phase [210]. Furthermore, 
interactions between proteins and the column material will result in inaccurate 
molar mass calculations [212]. In addition, molecular mass determination in 
SEC may be inaccurate since elution of proteins is not only dependent on 
molecular weight but also on protein conformation, and proteins are compared 
to molecular weight standards. 
Resolution of SEC is lower than that of SDS-PAGE, and usually not as optimal as 
desired for Aβ research [142], since small oligomers are not resolved. Therefore, 
SEC is particularly suitable for coarse separation of small oligomers from the 
larger oligomers or (proto)fibrils [142, 154, 213]. The problem of poor resolution 
may be partly solved by applying two columns with different particle sizes in 
tandem, resulting in a better resolution of small Aβ forms (mono- to hexamers) 
[190]. Also the use of a light scattering method in combination with SEC, offers 
an advantage in determining the molar mass of particles (see paragraph 2.3). 
In short, SEC can be successfully applied for analysis and fractionation of Aβ 
oligomers. There are however a few downsides, like low resolution of small 
oligomers, interactions of protein with the stationary phase and possible 
influence of the buffer on oligomer content.
Light Scattering
Light scattering techniques use laser light and a photodetector to measure the 
intensity of light reflected by particles in solution [214]. Multi Angle Laser Light 
Scattering (MALLS) is a form of static or classic light scattering that has been 
used to study Aβ aggregation. The scattering of the laser light is measured 
at multiple different angles and from this the average molecular weight of 
particles in suspension can be calculated.
An often used combination of techniques is SEC-MALLS: proteins are separated 
by SEC and subsequently the molecular mass is determined by MALLS, e.g to 
identify the different Aβ forms present in an ADDL solution, namely monomers 
and high molecular weight oligomers [186]. Another study investigated 
the potentials of a combination of MALLS with asymmetric flow field-flow 
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fractionation (a separation technique in which the sample flows between 
two plates and a perpendicular force is applied to elute proteins through a 
membrane in the bottom plate) to study Aβ aggregation [215]. Preliminary 
results showed that this combination provides clear insight into the time-
dependent aggregation process. Over 24 hours Aβ retention times increase, 
indicating a larger hydrodynamic radius (RH) – a computational parameter 
related to the size of a molecule – of eluting species. Furthermore, the peak 
broadens which indicates that a wider range of Aβ species is present. 
Another variant of the light scattering techniques is Dynamic Light Scattering 
(DLS), also called Quasielastic Light Scattering or Photon Correlation 
Spectroscopy [214, 216]. The difference between static light scattering and 
dynamic light scattering is that in the static version the average intensity 
over time is calculated, whereas in DLS the fluctuations in light intensity are 
detected. These fluctuations are caused by movement of the particles, and 
therefore regarded as diffusion coefficients [210, 217]. Usually DLS data are 
converted from the diffusion coefficient into the RH of the particles. Both 
MALLS and DLS have been combined to study the effect of low pH on Aβ40 
protofibril formation [218]. Furthermore, DLS has been used to study the 
interfering effect of Aβ42 C-terminal fragments on the oligomerization of full 
length Aβ [219]. However, DLS is more often used to gain kinetic information 
about the fibrillization process, for instance the growth rate of fibrils under 
various conditions [220, 221]. 
Even though light scattering techniques are quite sensitive [222], the resolution 
is rather poor and to differentiate between two particles, a difference in 
molecular weight of about a factor 8 is required [210]. Furthermore, small 
amounts of monomers and oligomers are difficult to detect among larger Aβ 
species [223], since light scattering detection provides an average picture of 
oligomers/aggregates present in the sample. To detect smaller oligomers, the 
technique can be combined with SEC [154]. Because this combination is often 
used in-line, the input for LS, in terms of sample volume and concentration,  is 
usually similar to the output of SEC.
Analytical Ultracentrifugation
In Sedimentation Velocity (SV) and Sedimentation equilibrium (SE) molecules 
are separated from each other by ultracentrifugation at very high speed up 
to 60,000 rpm. Movements of these molecules and sedimentation speed are 
analyzed. In SV, movements and sedimentation in the centrifuge are dependent 
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on the molecular weight and shape of a molecule, which is expressed as the 
sedimentation coefficient. For instance, molecules sediment faster, when 
they have a larger mass, whereas molecules with small masses will need more 
time to settle. The more conventional method SE is closely related to SV, but 
depends solely on the molecular weight of a molecule. The big advantage 
of SV compared to SE is, that performance time, which is needed to analyze 
molecules and their aggregation forms, is much faster in SV (mostly between 
1-24 hours) than in SE (several days).  
With respect to the different forms of Aβ, both techniques are useful in 
detecting and quantifying the amount of aggregates [224]. This was illustrated 
in a study in which a pharmacological inhibitor of Aβ aggregation was tested 
on Aβ42 labeled by a fluorophore [225]. Aggregation of Aβ42 was measured after 
5 hours, 1, 2 and 5 days by SV and the sedimentation coefficient increased over 
time, resembling the growth of Aβ aggregates. The added test compound was 
able to reduce the sedimentation coefficient and thus the size of aggregates. In 
a sample with mixed Aβ forms, rotor velocity can be used to separate different 
species. For instance, when 3 mg/ml of Aβ40 and Aβ42 was dissolved in PBS, it 
was possible to differentiate between three types of species [226]. At 3,000 rpm 
insoluble, large aggregates were measured with sedimentation coefficients of 
~50,000 S and molecular masses of ~1010 Da. After increasing rotor velocity to 
30,000 rpm, soluble aggregates with sedimentation coefficients of ~30 S and 
masses of ~106 Da sedimented. Remaining material, that did not sediment at 
this high speed, was identified as monomeric Aβ.
SV and SE are also able to analyze effects of different conditions like solvents 
and pH on the aggregation and hydrodynamic behavior of Aβ. SE was used 
to investigate the effect of pH on Aβ aggregation [212]. At pH 3, the average 
molecular mass of Aβ40 was 938,000 Da. At pH 5.0 no such Aβ40 aggregates 
could be detected and at pH 7, the average molecular mass was 12,100 Da. The 
results by SE could show, that aggregation of Aβ is pH-dependent. 
Recently, different fluorescent dyes were tested to measure amyloid oligomers 
by SV [227]. The dyes were attached in different ways to the amyloidogenic 
proteins apoC-II and huntingtin. These fluorescence-detection systems 
in general increased the sensitivity to subnanomolar concentrations. 
Furthermore, the range of concentrations could be extended spanning 10-10 
to 105 M.
Compared to other separation techniques such as SEC or SDS-PAGE, SE and 
SV are not prone to errors in molecular mass calculations since, for example, 
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no stationary phase or gel matrix is used, that could nonspecifically bind 
proteins [212]. Furthermore, higher resolutions can be achieved and a 
broad size range of molecules can be identified in one experiment. Also 
monomers and dimers are distinguished easily and with high accuracy [228]. 
The techniques enable the study of samples over a wide range of pH, ionic 
strength and temperatures. Therefore application of SE and SV is in particular 
useful for analysis of complex heterogeneous mixtures of molecules [229]. 
However, the techniques are limited by the absence of a direct relationship 
between sedimentation coefficient and the size of aggregates, in particular 
for fibrils [230]. Other disadvantages are the relatively long running time, 
in particular for SE and for small proteins like small Aβ aggregates, and the 
high concentrations that are needed (absorbance at OD280 in the range of 
0.1-1.5). Both factors might enable Aβ aggregation processes during the 
ultracentrifuge run. Usually the temperature during an SV or SE experiment 
is 20°C, but to slow down or prevent unwanted aggregation processes, the 
temperature could be decreased to 4°C [231]. It also should be noted that SE is 
not suited to analyze large amyloid fibrils, because they sediment too quickly 
and can therefore not form an equilibrium concentration gradient [231]. 
Both, SV and SE experiments require an expensive ultra-centrifuge (usually 
optimaTM XL-A or XL-I) and equipment to measure sedimentation speed.
Techniques to determine kinetic characteristics 
based on spectroscopy
Spectroscopic techniques are usually applied to gain information about the 
kinetics of Aβ aggregation. In real-time the fibrillization state of a sample can 
be investigated. Turbidity, Congo Red and Thioflavin T assays are unsuitable to 
detect small oligomers, but can be used to show the presence of protofibrils 
and fibrils. Techniques based on Fluorescence Microscopy are also able to detect 
LMW oligomers.
Turbidity
It is possible to study the kinetics of Aβ aggregation by the relatively simple 
technique of turbidity measurement, usually performed at 400-420 nm. The 
sample can be applied to a microplate well or a cuvette, depending on the type 
of spectrophotometer used. For the latter, a larger sample volume (up to 1 ml) 
is required. The technique is not very sensitive, concentrations of around 50 µM 
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are generally used [232, 233]. Also, the method is not optimally suited to study 
Aβ oligomerization [234]. Turbidity only detects fibrillary aggregates [154, 235], 
because protofibrils are too small to reflect light of 400 nm. This is also evident 
when the technique is compared to a Thioflavin T (ThT) assay which is believed to 
allow detection of both protofibrils and fibrils (see paragraph 3.2). It has previously 
been concluded that the curves generated in turbidity measurements display a 
significantly shorter lag time than those in ThT measurements, which indicates 
that turbidity can only be measured later in the aggregation cascade and therefore 
reflects larger species [196]. Differences in ThT and turbidity signals were also 
observed in aggregation studies with superoxide dismutase 1, an amyloidogenic 
protein that pathologically aggregates in amyotrophic lateral sclerosis. While 
Thioflavin T dye showed an increasing signal over time, no turbidity was measured, 
indicating that no insoluble particles (fibrils) were formed. 
Turbidimetric assays have especially been used to study the aggregation 
kinetics of Aβ [30, 235, 236]. In one study the aggregation of the highly toxic 
Aβ25-35 was investigated and  it was demonstrated that Aβ aggregates that 
were shifted in pH from 3 to 7.4 were significantly reduced in turbidity [237]. 
Also, this technique can be used in a simple way to take a rapid look at the 
effect of certain compounds on Aβ fibrillization [233]. It was for instance 
recently used to demonstrate that the addition of both Cu2+ and Zn2+ to Aβ 
increases turbidity and thus its aggregation [232]. 
Advantages of the technique are its simplicity and the requirement for a standard 
spectrophotometer. However, disadvantages of turbidity measurements are that 
protein concentrations need to be relatively high to be measured. Furthermore, 
it is not suitable to detect oligomers or even protofibrils and it is not applicable 
for quantification studies. The assay might however be more advantageous for 
analysis of non-amyloidogenic aggregating proteins (e.g. TDP-43), for which no 
alternatives, like the amyloid-staining compound ThT, are available.
Thioflavin T and Congo Red Assays
Many extrinsic fluorescent probes have been developed that bind amyloid 
proteins. Fluorescent dyes that bind non-covalently to amyloid proteins 
are known for more than 100 years [238]. Some other, newer dyes like 
tetramethylrhodamine, fluorescein or Cy3/Cy5 (different colours available) use 
covalent bond formation between the dye and a specific chemical group in 
the structure of Aβ, usually the ε-amino group of a lysine, the α-amino group 
of the N-terminus or the thiol group of cystein [239-241]. We will focus in this 
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paper on the two most important and widely used probes; Congo Red (CR) 
and Thioflavin T (ThT), which bind non-covalently to amyloid. Both undergo 
absorbance spectrum changes upon binding to amyloid proteins, for instance 
Aβ, huntingtin, α-synuclein and prion protein [242]. 
CR is mainly used as a histological staining dye to demonstrate the presence 
of amyloid aggregates in the brain [243]. Besides in histochemistry, CR is also 
applied in in vitro aggregation studies. In steady-state fluorescence assays, 
spectral data measured in a spectrophotometer can provide information about 
the aggregation state of amyloid proteins [239]. Upon binding to amyloid 
proteins, the absorption maximum of CR shifts under crossed polarization 
from a wavelength of 490 nm to 540 nm [242]. 
Binding of CR is mainly limited to fibrils, but it may also to a lesser degree 
bind oligomers and protofibrils [244]. A point of attention is the fact that CR 
has been shown to be able to inhibit Aβ aggregation, plaque formation and 
toxicity, e.g. towards cultures from rat hippocampal neurons [245, 246], human 
macrophages [247] and pericytes [248]. This might be caused by a stabilization 
of the monomeric species [249]. However, at low concentrations of CR, fibril 
formation has been shown to be enhanced [250].  
Another ubiquitously used fluorescent amyloid binding dye is Thioflavin T (ThT). 
This dye is, similar to CR, widely applied to identify amyloid deposits in post 
mortem brain tissue [251, 252] and as a probe to quantify protein aggregation 
in vitro [253, 254]. ThT also undergoes an absorbance spectrum shift. Free, 
unbound ThT has an excitation and emission maximum of respectively 385 and 
445 nm,  and these are elevated to respectively 450 and 482 nm upon amyloid 
binding [254]. It was first believed that ThT binds only β-sheets in protein 
structures [254], however recent evidence shows that ThT supposedly also 
binds similarly shaped, non β-sheet containing cavities inside molecules [255].
ThT assays can be used to study the influence of external factors on the 
fibrillization, for instance in the search for aggregation inhibitors. However, 
the technique should be used with caution in the presence of exogeneous 
polyphenols, because their intrinsic fluorescence can cause significant 
absorption in the spectral range of ThT, thereby significantly biasing the 
results [256]. 
It has been well established that ThT and CR both bind Aβ fibrils, but whether 
these dyes also bind smaller oligomeric Aβ is still under debate. By measuring 
fluorescence intensity, it has been shown that ThT is able to bind fibrils and 
protofibrils, but not monomeric and dimeric Aβ [223]. Another indication 
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that ThT is able to bind HMW oligomers and protofibrils was found when the 
aggregation of Aβ was reduced by the molecular chaperone prefoldin [257]. In 
this experiment, electron microscopy revealed the absence of mature fibrils in 
these samples, but both particles smaller than fibrils (that on SDS-PAGE were 
found to be high molecular weight oligomers) and protofibrils were visible 
that likely generated the ThT signal (Fig. 6). In addition, in other studies it was 
also found that CR and ThT may bind to oligomeric Aβ [258]. ThT however 
shows a relatively low binding affinity. In addition, the binding characteristics 
of ThT and CR to amyloid proteins and their specificity are not fully understood 
[242]. The current status of today’s research of their binding characteristics is 
extensively discussed in a recent review by Groenning (2009) [259]. 
In summary, extrinsic fluorophores have proven to be useful tools to 
investigate the molecular mechanisms involved in protein fibrillization in a 
high-throughput screening way and to quantify amyloid aggregation over 
time [260]. The methods are fast, since it is relatively simple to withdraw only 
a few microliters of sample from an incubation mixture of between 0,5 - 50 µM 
of Aβ and measure those at different time points [202, 257, 258]. Nevertheless, 
as mentioned above, the specificity of both CR and ThT and the protein 
structure they bind to are still relatively unclear, but in general the usefulness 
in studying smaller oligomers seems to be limited.
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Fig. 6) Application of thioflavin T to quantify formation of prefibrillar Aβ aggregates.  Aβ42 fibril 
formation (A) leads to a high Thioflavin T fluorescence (open circles in C). Fibrils are absent after 
Aβ42 preincubation with prefoldin (B); the corresponding Thioflavin T fluorescence is reduced 
compared to fibrillar Aβ but is still present and represents prefibrillar Aβ (closed circles in C). A.U. 
= Arbitrary Units. ([257] Copyright John Wiley and Sons.  Reproduced with permission.)
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Fluorescence Microscopy
By attaching a fluorescent label (such as Hilyte FluorTM or Alexa-fluor 488) 
to Aβ, aggregation of Aβ can be studied by fluorescence microscopy (FM). 
Diffusion of the fluorescent molecules in solution can be tracked and the RH, 
can be calculated [261]. 
An advanced application that uses a fluorescent label to study Aβ polymerization 
is fluorescence correlation spectroscopy (FCS). For an extensive description of the 
technique and its applications we refer to a review by Krichevsky and Bonnet (2002) 
[262]. In short, this technique is based on fluctuations of fluorescent intensity 
that are measured with a confocal laser microscope. These fluctuations can be 
detected in a confocal volume of only 1 femtoliter. Fluorescent particles in this 
volume are excited by the laser and every single photon is recorded. Furthermore, 
because the technique is based on single-molecule detection, the fluorophores 
are diluted to such an extent that only a few are present in the confocal volume at 
the same time. This enables the detector to measure between sub-nanomolar to 
micromolar concentrations of fluorophores, and only 20 µl of sample is required. 
Fluctuations in fluorescent signal, which are caused by diffusion of particles in and 
out of the confocal volume, can be quantified by the autocorrelation of time and 
fluorescent intensity [263]. The residence time (τD) of a molecule in the confocal 
volume is in proportion with its RH. FCS has been used to study the aggregation 
and the composition of samples of synthetic Aβ [240, 264-266]. Usually a very 
low concentration of labeled Aβ is co-incubated with a higher concentration 
of unlabeled Aβ and the peptide mixture is allowed to aggregate. Observed 
differences in diffusion time and fluorescence intensity allow estimation of the size 
of the oligomers. 
The effect of fluorophore conjugation on the morphology and function of 
Aβ oligomers has also been studied [241]. When labeled Aβ was incubated 
to aggregate, the N-terminally bound fluorophore was shown to cause 
atypical oligomer and fibril formation. Thus, in order to retain the oligomeric 
structure of unlabeled Aβ oligomers, it is advised to label the proteins after the 
aggregation process. Both strategies are described in figure 7. Another option 
is mixing a small amount of labeled Aβ with a large concentration of unlabeled 
protein, but this option was not investigated [241]. In one recent article, FCS 
was used in combination with EM and toxicity assays, to identify and investigate 
different pathways that lead to fibril formation and the formation of highly 
toxic, spherical Aβ oligomers, termed amylospheroids [146]. In this study, FCS 
provided information regarding the mass and distribution of aggregates in the 
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sample. Furthermore, EM gave insight into the morphology of the aggregates.
A relatively novel fluorescence-based technique, using fluorescent nanocrystals, 
also called quantum dots (QD), has been employed to image the aggregation 
of Aβ in time [196]. QDs consist of semiconductor material (cadmium mixed 
with selenium or tellurium) surrounded by a shell of zinc sulfide and belong to 
the category of fluorophores. Compared to conventional fluorophores they are 
very small, with sizes in the nanometer range (15-20 nm), which is close to the 
average protein size. QDs can fluoresce without the involvement of electronic 
transitions. To fluoresce, QDs make use of the formation of excitons that have 
much longer lifetimes than conventional fluorophores, which enables studies 
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Fig. 7) Two strategies to generate fluorescent labeled aggregates. In strategy A labeled monomeric 
Aβ is incubated during the oligomerisation and fibrillisation process. In strategy B the products 
after aggregation are subsequently fluorescently labeled. ([241] Copyright John Wiley and Sons. 
Reproduced with permission)
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over time. Furthermore, dependent on the size and the energy of the exciton, 
different colors are generated, a property useful in multiplex assays using different 
colors for visualization. QDs are functionalized with chemical groups, that can be 
activated and are able to bind to chemical groups of proteins. To couple Aβ, QDs 
Box 1) Atomic Force Microscopy: To visualize structures in the nanometer range, AFM uses a flexible 
scanning needle (cantilever)  with a very fine tip, whereby feature resolution is dependent on size and 
shape of the tip [299]. For soft sample surfaces, silicon cantilevers  with a sharp carbon nanotube tip 
attached, were developed. These probes access narrow and deep features [300], whereby differences in  
heights are depicted in the AFM image in different shades of gray: Dark color resembles features beneath 
the surface and white color represents structures lying above the surface. To visualize Aβ fibrils, multiwalled 
carbon nanotube (MWNT) probes were  successful  and can reach even higher resolution than silicon 
probes [299]. In order to measure biomolecules with AFM, the tapping mode is applied. Here the cantilever 
with the tip oscillates up and down with an amplitude of about 100-200 nm, making it possible for the 
loosely attached molecules to move and interact with each other. The surface to which biomolecules are 
attached, is most often hydrophilic mica [143, 159, 301-303], but also hydrophobic, highly ordered pyrolytic 
graphite (HOPG) [159, 301, 304]  is used. Dependent on the properties of these substrates, information 
about behavior of molecules in such environments can be obtained. The substrates  are mounted on a 
hydrophobic teflon disk and both are submerged in a fluidic chamber filled with a buffer solution. The 
electrolyte concentration and pH of  this buffer solution can be adjusted according to the sample, to rule 
out unwanted electrostatic interactions between the AFM tip and the sample, that could cause incorrect 
measurements of the heights of the imaged biomolecule [305, 306]. Nevetheless, correct determination of 
the X-Y axis can be diffcult with measurements is solution.
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functionalized with polyethylene glycol and amine groups were used [267]. By 
using a fluorescence microscope, tiny spots were observed of which the relative 
fluorescence could be measured, with the ability to discriminate even between 
Aβ dimers, trimers and tetramers. Only 1-10 nM protein in a a volume of 2 μl was 
needed. After prolonged incubation of a sample with QDs, oligomer formation 
could be observed under the microscope in real-time. 
The most important advantage of using this technique for imaging Aβ is that the 
small, but very stable QDs enable visualization of a single molecule over longer 
time intervals in an intact cell system. Fixation or immobilization procedures, which 
are necessary in AFM and EM studies, are not required. Furthermore, the technique 
is relatively easy to perform. Only a fluorescence microscope is required and the 
QDs themselves, which are commercially available. A major disadvantage is that, 
although QDs are in the nanometer size range, this is still significantly larger than 
an Aβ molecule. This most likely interferes with oligomerization processes and one 
could argue that the observed aggregation is not comparable to in vivo events. 
This problem was attempted to circumvent by incorporating only a few QDs with 
Aβ40 into emerging fibrils of Aβ42. 
Fluorescence microscopy can be used either by labeling Aβ directly with a 
fluorescent dye or by using quantum dots. The huge advantage of FM is the ability 
of imaging in a relatively intact sample, which is not the case for e.g. electron 
microscopy, and imaging in real-time. A draw-back for FM is, that labels (dye or QDs) 
have to be attached, which possibly influence aggregation and fibrillogenesis. Also 
the issue of auto-fluorescence might play a role. Proteins with tryptophan, tyrosine 
or phenylalanine can show some intrinsic fluorescence and thereby interfere with 
the analysis [268].
Techniques for quantification based on 
immunology
Immunodetection is based on the availability of specific antibodies. Currently, a 
large number of different antibodies is available, specific for an Aβ-isoform, a 
conformational epitope within Aβ or even an isoform in a specific conformation 
[269]. The most-common technique for immunodetection of oligomeric Aβ is the 
enzyme-linked immunosorbent assay (ELISA). Novel variants on this classic design, 
such as the Bio-Barcode Assay (BCA) and immunofluorescent assays have been 
developed, which are more sensitive in detection with detection limits into the 
attomolar range. 
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Sandwich ELISAs
ELISAs [270] are commonly used for detection of Aβ monomers and usually reach 
a detection limit of 1-10 pM in about 100 μl of sample [271]. Running an ELISA 
takes between a few hours and a day, depending on the number of incubation 
steps (also usually one overnight incubation). Given its relative simplicity, ELISA 
is also an attractive platform to measure oligomeric Aβ and the availability of 
an ELISA that may quantify Aβ oligomers, but not monomers, would be of great 
interest in biomarker research, studies of the Aβ aggregation process in general, 
or studies aimed at determining the neurotoxicity of Aβ species. Two strategies 
have been used to develop a specific quantification method for oligomers: (A) 
the use of the same capture and detection antibody (the latter labeled with e.g. 
biotin or horseradish peroxidase) or (B) the application of an oligomer-specific 
antibody in the ELISA (Box 2). 
An Aβ oligomer-specific ELISA according to strategy A has already been 
described in 1999 [272]. Several monoclonal antibodies directed against Aβ have 
been applied in this technique. This type of ELISA has been used to study the 
time-dependent oligomerization of Aβ [272, 273], which resulted in a temporal 
increase in signal suggesting an increased abundance of oligomers. Recently, it 
was described that, by using this approach, concentrations of high molecular 
weight oligomers were significantly elevated (p < 0.0001) in CSF of Alzheimer 
patients [190]. Using Aβ fractionation by SEC it was concluded that only HMW 
oligomers (mainly 10-20mers of synthetic Aβ) could be detected by this assay. 
The authors hypothesized that the epitopes for the detection antibody, located 
on residues 1-16, might have been hidden inside the 3D-structure of the 
relatively small oligomers, and were only accessible in the larger oligomers due 
to structural differences. 
Several different antibodies specifically directed against oligomeric Aβ have 
been developed and their specificity is usually shown in dot blots [274-276]. 
Although using these antibodies in an oligomer specific ELISA (strategy B) seems 
rather straightforward, not many attempts have been reported yet. Recently, 
the monoclonal antibody OMAB was tested for its specificity by applying it as 
a capture antibody in a sandwich ELISA [277]. Results showed that it is highly 
specific for oligomers, and does not detect monomers or dimers, because it 
displays very fast dissociation kinetics for these molecules. In another study 
an oligomer specific ELISA was designed to measure Aβ oligomers in brain 
homogenates [278]. First, a well studied antibody (designated as A11) was used, 
that detects high molecular weight Aβ oligomers (from approximately 40 kDa 
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and up), but not low molecular weight Aβ or, on the other hand, fibrils [276]. 
A11 is, however, not specific for Aβ, but also recognizes oligomer preparations 
of other proteins, for instance multimers of α-synuclein, polyglutamate, prion 
protein and several heat shock proteins [276, 279]. However, this attempt 
was unsuccessful, and subsequently the authors succeeded in designing an 
oligomeric Aβ ELISA using two other oligomer-specific antibodies, 7A1a and 
1G5. These studies showed the feasibility of detecting specific forms of Aβ 
by ELISA with the use of antibodies, but also showed that not every oligomer 
specific antibody might be suitable to use in ELISA. In another study, oligomer-
specific antibodies were generated by immunization with a specific oligomeric 
Aβ isoform, designated globulomers [280]. These antibodies recognized 
oligomers, but not monomers or fibrils. Using an oligomer-specific polyclonal 
antibody for capture and a generic Aβ antibody for detection, higher signals 
were obtained in AD patient’s and transgenic mice’s soluble brain extracts 
compared to controls. The same test failed to demonstrate detectable levels in 
Amyloid-β oligomer detection by ELISA
Box 2) Oligomer specific ELISAs: Two strategies to specifically measure oligomers in a sandwich ELISA have 
been described. In a monomer Aβ ELISA, the antigen is captured by a capture antibody and subsequently 
detected by another detecting antibody. In an oligomer ELISA according to strategy A the characteristic 
feature of monoclonal antibodies, i.e. the ability to specifically bind only one epitope in a molecule, is used. 
In this design, the same antibody is used for capture and detection of the target protein. The detection 
antibody is biotinylated in order to discriminate it from the capture antibody. In a monomeric protein, only 
one copy of the target epitope is present, and when this epitope is occupied by the capture antibody, the 
detection antibody will not be able to bind. In an oligomeric protein on the other hand, two or more copies 
of the specific epitope are available and, as a result, both the capture and detection antibody can bind and 
this will result in an ELISA signal. In contrast, in strategy B a capture antibody directed against Aβ is used in 
combination with an oligomer-specific detection antibody.
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CSF. Finally, a combination of both strategy A and B has also been described 
[281]. In this study a monoclonal antibody directed against protofibrillar Aβ was 
used both as capture and detection antibody. Results demonstrated that this 
ELISA detects protofibrillar Aβ levels in cell culture media and in homogenized 
mice brains. 
Thus, ELISA techniques may be good tools for specific measurement of some 
forms of Aβ oligomers. However, the functionality of the ELISA is highly 
dependent on the quality of the components used. With good quality antibodies, 
substrates with higher sensitivity, such as chemiluminescent or fluorescent, 
instead of chromogenic substrates such as TMB, can be used. However, both 
background levels and inter-assay variation may also increase. Background 
levels of non-specific binding to the Fc region can be eliminated by using only 
the Fab’ fragment of the detection antibody (conjugated with its detection label) 
[190]. Furthermore, the detection limit of the assay is highly dependent on the 
ability of the antibody to bind different types of oligomers, and application of 
these oligomer ELISAs may be hindered by the expected low concentrations of 
oligomers in e.g. body fluids. This is illustrated by a study in which oligomers 
were quantified in plasma samples. Plasma from 7 out of 10 control subjects and 
17 out of 36 AD patients contained oligomeric Aβ levels below the detection 
limit [282]. Detection limits of oligomer ELISA described are in the nM and pM 
ranges [281, 283]. In addition, oligomers are possibly ineffectively measured by 
ELISA methods, as not all epitopes may become occupied by antibodies or be 
available. Furthermore, the magnitude of this effect may depend on the size of 
the oligomers. This leads to an underestimation of their actual concentration 
[121], since the quaternary structure of oligomeric proteins may hinder its 
proper detection. 
Recently it was described that false-positive results in human body fluids could 
be obtained with the type B oligomer ELISA, caused by heterophilic antibodies 
[284, 285]. These antibodies, present in human plasma, serum and CSF, are 
polyreactive and directed against antibodies from other species. An estimated 
10-40% of patients are believed to have non-specific antibodies directed against 
murine antibodies (human-anti-mouse-antibodies, HAMAs) and how these arise 
is still not completely clear [286]. Since the same capture and detection antibody 
are used in this assay, these can be cross-linked by heterophilic antibodies, 
leading to false-positive results in the absence of antigen as demonstrated for 
the previously described Aβ protofibril specific ELISA [281]. These results point 
to the importance of ELISA specificity tests and lead to the conclusion that body 
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fluids might need pre-treatment to remove heterophilic antibodies, before Aβ 
oligomers can be reliably measured. 
In short, an ELISA has potential as a robust and quantitative method of Aβ 
oligomer quantification, since it can be designed to detect solely oligomeric 
species with the exclusion of monomeric species. In this way, ELISA offers 
many advantages over other techniques, since it is simple, high-throughput, 
possibly very specific and quantitative. Disadvantages may include the need 
for additional techniques (e.g. SEC) to establish which oligomeric species are 
detected and which are not, and the necessity to exclude confounding factors 
such as the detection of heterophilic antibodies. Furthermore, the sensitivity of 
the ELISA technique might not be sufficient to measure oligomeric Aβ in human 
body fluids.
Bio-Barcode Assay
In 2003 a highly sensitive method for detection of molecules in body fluids was 
introduced: The Bio-Barcode Assay (BCA) [287] (Box 3). This novel technique is 
based on sandwich methodology using magnetic microparticles (MMPs) and 
nanoparticles (NPs), and allows, due to an extra amplification step, measurement 
of protein targets at concentrations in the attomolar range. The BCA therefore 
offers a much lower detection limit than conventional ELISA techniques (see 
chapter 4.1).
Previously, the BCA assay has been used for detection of Aβ-derived diffusible 
ligands (ADDLs) in CSF, showing that it is possible to measure oligomers that 
were otherwise not detectable. In addition, AD patients and non-demented 
age-matched controls could be differentiated using this technique [288]. The 
ADDL concentration was 1.7 fM in the AD group and ~200 aM for the control 
group. Concentrations of more than 500 fM were too high to measure with the 
BCA. The assay could be completed in less than three hours. The main advantage 
of the BCA is the sensitivity provided for detecting proteins in body fluids. Only 
few ELISA-based techniques (e.g. immuno-PCR [289], single-molecule ELISA 
[290]) can compete with the BCA if compared in terms of limit of detection. 
However, sensitivity is also dependent on the specificity and binding efficiency 
of the antibodies used and on the size of the NPs and their loading capacity with 
oligonucleotides. Furthermore, the BCA offers the possibility for multiplexing. 
By using different antibodies against different targets with corresponding 
specific oligonucleotide tags, many analytes can be measured simultaneously 
in one sample. 
Amyloid-β oligomer detection by ELISA
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In its first design the BCA had a very limited dose-response curve. The assay 
was only applicable for antigens at very low concentrations and could only 
come into consideration after a conventional ELISA assay failed to detect the 
target. In addition, different concentrations of the antigen produced only small 
differences in detectable signal. The dose-response curve could be broadened 
to a range of about 4 logs by improving the light-scattering abilities of the gold 
NPs that were used for detection [289]. Yet the BCA is a complex method with 
several incubation and washing steps. Increase in speed and simplicity are 
achieved with bio-barcodes, containing a fluorophore label, that is attached to 
polystyrene microparticles. These particles are larger than NPs and therefore can 
bind a much larger amount of bio-barcodes. After release, the bio-barcodes are 
not amplified before detection, but are detected directly by fluorescence analysis 
[291]. Although more bio-barcodes can be attached and measured directly, the 
sensitivity of this approach is slightly decreased and multiplexing possibilities 
are greatly reduced, limited by the amount of available fluorophores. In terms 
of specificity and quality of the used antibody as well as the risk in detecting 
HAMAs, the same considerations apply for the BCA as for the conventional ELISA 
(see chapter 4.1).
Recently a chip-based BCA has been developed, also called surface-immobilized 
Bio-Barcode Assay (SI-BCA) [292]. Here, MMPs are not needed anymore. Instead 
the capture-antibody is attached to the inner surface of a microfluidic channel 
and the sandwich is formed on the modified surface. This SI-BCA is faster (only 
80 min) than the MMP-based BCA and also requires less reagent volumes (5 μl 
per wash step), but at the same time the SI-BCA is more sophisticated in its set-
up and obtaining the required material can be difficult as it is not commercially 
available yet. 
In conclusion both, the BCA and the SI-BCA, have been proven to push the limit 
of detection of molecules into the attomolar range and therefore could be very 
useful techniques in detecting low-abundant Aβ oligomers/ADDLs in body 
fluids. However, to our knowledge only two groups  have successfully set up a 
BCA [287, 293] and only one group did apply the assay to measure Aβ [288]. The 
need for expertise, specific equipment and time, that is necessary to invest in 
the development of such a complex assay, might hamper other groups. Future 
studies will have to show, whether BCA-based methods may become available 
for routine diagnostic measurements.
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Immunofluorescence Assays
A few approaches that use fluorescently labeled antibodies to detect aggregates 
of Aβ have been described. For instance in one study flow cytometry and 
fluorescence resonance energy transfer (FRET) have been combined to 
demonstrate the presence of Aβ oligomers in CSF [294]. Two antibodies that bind 
different epitopes, one labeled with Alexa Fluor 488, the other with Alexa Fluor 
594, were allowed to bind Aβ molecules. Next, a FRET signal is generated if both 
antibodies are located closer than 10 nm from each other. In this experiment 
monomers are not detected because these can only be bound by one antibody 
per antibody type, which will only generate a low intensity fluorescent signal. 
Binding of multiple antibodies to oligomers however, can cause a more intense 
signal that can be measured by flow cytometry. Using this technique, the authors 
succeeded in quantitatively measuring Aβ oligomers in CSF from control patients 
with neurological diseases other than AD. The detection range of the technique 
Amyloid-β oligomer detection by ELISA
Box 3) Bio-Barcode Assay: The principle of the Bio-Barcode Assay is, like in conventional ELISA methods, a 
sandwich design in which the target protein is sandwiched between a capture and a detection antibody (see 
Box 2). The capture antibody is attached to magnetic microparticles (MMPs), while the detection antibody 
is coupled to nanoparticles (NPs) that, in addition, are loaded with doublestranded oligonucleotides. Here, 
one oligonucleotide strand is covalently attached to the NPs, whereas its complementary sequence (also 
called bio-barcode) is hybridized to the nanoparticle-bound oligonucleotide and later can be dehybridized 
again. The amplification signal is generated at this step due to the presence of multiple oligonucleotides per 
antibody bound to these NPs. Both modified particles should be abundantly present to effectively capture 
and detect the target antigen and for effective isolation of the MMP-antigen-NP complexes by magnetic 
separation. Dehybridization of the doublestranded oligonucleotide sequences results in release of a large 
amount of biobarcodes that can be analyzed by gel electrophoresis, fluorophore-labeling or scanometric 
detection, with the possibility of increasing the signal by a PCR-amplification step. In this design, many bio-
barcodes are released per target molecule, resulting in a more sensitive
assay than conventional ELISAs.
Source : [288] Copyright 2011 National Academy of Sciences, U.S.A. Reproduced with permission.
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was determined to be accurate from low nM down to low pM concentrations. 
Later, the same group used an adapted version of this assay to measure Aβ 
oligomers in plasma samples, for which the sensitivity and specificity were about 
the same as in the previous technique [295]. Aβ was first immunoprecipitated 
and immobilized to magnetic beads. Subsequently a rabbit Aβ oligomer-
specific antibody and a fluorescently labeled anti-rabbit antibody were added 
and measurements in human plasma were conducted, using flow cytometry for 
detection. For this 2.5 ml of lithium heparin plasma was used per sample. Since 
flow cytometry is widely available and a relatively high throughput method, this 
technique can be widely applicable. Results of the study showed that oligomer 
levels were increased in AD patients compared to controls. Discrimination could 
be made with a specificity of 81.2% and a sensitivity of 70.6%. 
In another study, a variant of a sandwich ELISA was used, in combination 
with 2D-fluorescence intensity distribution analysis (2D-FIDA). Here, an anti-
Aβ antibody was coated on a glass surface and Aβ molecules were captured 
[296]. Subsequently, two different fluorescently labeled detection antibodies, 
with different fluorescent labels but overlapping epitopes, were applied. In this 
way only oligomers and not monomers can be detected with both detection 
antibodies at the same time. Next, fluorescence of both fluorescent labels is 
measured by a confocal laser scanner and 2D-FIDA was applied. Binding of both 
detection antibodies at the same time indicated the presence of Aβ oligomers. 
The benefit of the capturing step is that the technique becomes more specific 
for Aβ and with additional washing the background signal can be reduced. This 
makes the method sensitive enough to detect and quantify single molecules, and 
concentrations in the nM range could be measured in 20 µl of sample. However, 
the use of the confocal microscope makes the technique very expensive and not 
high throughput. The first part of the procedure takes as long as a normal ELISA, 
however the measurement and analysis of 2D-FIDA take much longer than a 
spectrometric readout.
Conclusion
The plaque-forming protein Aβ is a key player in the pathology of AD and its 
propensity to aggregate is an important aspect of the AD pathophysiology. 
It is generally assumed that oligomeric Aβ is the most toxic species in the 
amyloidogenic cascade. Therefore, there is a great need for techniques to identify, 
characterize, quantify and visualize the different Aβ species. In this review we have 
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listed and described all major techniques to achieve these goals and pointed out 
their advantages and disadvantages (see table 1 for an overview). Here, we did 
not aim to list all the available techniques that were used in the past to study 
amyloidogenic proteins, but to give an overview of the most useful and most 
often applied techniques in analyzing full length Aβ40 and Aβ42 in their different 
aggregation stages. Nonetheless, this paper can serve as a compass in directing 
the researcher to choose the methods best suited for his or her intentions. Since 
the various techniques each have their pros and cons, the use of a combination 
of different techniques to study Aβ oligomers will reveal the most optimal set of 
information. Many different combinations have been used in the past. A number 
of different research aims can be defined that require different experimental 
approaches and we have listed here the most often used and most successfully 
applied combinations of techniques. 
1)  Investigation of aggregation pathways in vitro. For such studies a combination 
of techniques to determine size, kinetics and morphology are important. An 
elegant recent example of this was a combination of FCS (in which factors 
like concentration and time can be manipulated and arising oligomers can 
be sensitively measured) and transmission EM (which gave insight into the 
spherical morphology of certain HMW oligomers  that were formed during 
aggregation) [146]. 
2)  Characterization of a particular type or range of oligomers, either brain derived 
or formed in vitro. A combination of the techniques PAGE, SEC-MALLS, analytical 
ultracentrifugation and AFM will provide a good overview of the composition 
of a synthetic, often heterogeneous Aβ-oligomer population, both in terms of 
size and morphology [186]. Also, SEC combined with Western blotting using 
an oligomer-specific antibody, was successfully used to identify a highly toxic 
brain derived oligomer species [149]. 
3)  Identification of a specific Aβ form requires its morphological and structural 
characterization. This can be done by using PAGE in combination with SV, 
providing information about size and shape of the molecule, and CD, for 
structural information [297]. 
4)  Identification of potential therapeutic agents, e.g. aggregation inhibitors. For 
these studies ThT fluorescence experiments may be suitable, because of its 
relative quick estimation of effects on protein aggregation. A combination 
with AFM, or alternatively EM, may deliver validation of ThT results and provide 
morphological information [298]. 
58
5)  Analysis of oligomers in biological samples. Because of the supposed low levels 
of oligomers in brain tissue, plasma and CSF, high sensitivity is essential. ELISA 
methods (possibly in combination with an amplification method such as BCA), 
FCS or immunofluorescence assays seem most suitable for this. Information on 
oligomer size may then be derived from SEC or SDS PAGE analysis [190].
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Techniques Advantages Disadvantages
Morphology
and structural 
conformation
Electron
Microscopy (EM)
- High resolution (visualizes fibrils, 
but LMW molecules are more 
difficult)
- Prone to artefacts
- Only a small part of the sample is   
visualized
- No real-time imaging
Atomic Force
Microscopy (AFM)
- High resolution (distinguishes 
also between ADDLs, protofibrils 
and fibrils)
- Real-time imaging possible
- Coiled structures are not always 
visualized properly 
- Determination of height in solution 
AFM is difficult
- Not all aggregates are absorbed to 
a mica surface
- limited availability of equipment
Circular Dichroism (CD) - Real-time measurements in 
aqueous solutions
- In heterogenous samples only the 
cross structural components are 
depicted
- Limited availability of equipment
- High concentration needed
Determination
of molecular
weight
Polyacrylamide Gel 
Electrophoresis (PAGE)
- Simple
- Inexpensive
- Good resolution possible, 
dependent on conditions used
- Disassembly of aggregates due 
to heat treatment, reducing or 
denaturing conditions
- Protein is lost after experiment
Size Exclusion 
Chromatography (SEC)
- Non-denaturing conditions
- Buffers with physiological 
composition can be used
- Protein fractionation for further 
testing is possible
- Procedure can cause disassembly 
of aggregates, dependent on 
conditions
- Low sample recovery
- Relatively low resolution
- Elution characteristics of molecular 
weight standards are not always 
comparable to those of protein in 
the sample
Light Scattering (LS) - Sensitive - Low resolution
- Computational model required for 
indication of molecular weight
- Limited availability of equipment
Analytical 
Ultracentrifugation (AUC)
- Sensitive (differentiates even 
between monomers, dimers e.g.)
- Broad range of samples
- pH, ionic strength or temperature 
are no problem
- In measuring fibrils, there is 
no direct correlation between 
sedimentation coefficient and 
their size
- Limited availability of equipment
- Long running time, especially 
for SE
- High concentrations needed
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Methods for analysis of Amyloid-β aggregates
Kinetic
charactistics 
Turbidity - Simple
- Equipment omnipresent
- Only fibrils can be detected
- Relatively insensitive, rather 
high concentrations necessary
Thioflavin T and
Congo Red Assays
- Simple
- Fast
- Only protofibrils and fibrils 
can be detected
- Congo Red might influence 
aggregation
Fluorescence Microscopy (FM) - Sensitive
- Small sample volumes 
sufficient
- (Limited) multiplexing 
possible when using 
differently coloured 
fluorophores
- Aβ labelling with fluorophore 
might influence aggregation 
process
- Auto-fluorescence might 
interfere with the analysis
Quantification
Sandwich ELISAs - Sensitive
- High specificity for target can 
be achieved
- High throughput
- Antibodies that recognize 
Aβ oligomers might also 
recognice other amyloidogenic 
proteins
- No information about the 
size of aggregates measured 
is acquired
- Oligomers are ineffectively 
measured compared to 
monomers
Bio-Barcode Assay (BCA) - Highly sensitive
- Multiplexing possible 
- Quick
- Complex
- Not well established yet
Immunofluorescent Assays See fluorescence microscopy  
- Use of antibodies adds to 
specificity
See fluorescence microscopy
table 1 : Schematic overview of techniques to analyze Aβ aggregates.
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Abstract
Amyloid-β (Aβ) deposits are important pathological hallmarks of Alzheimer’s 
disease (AD). Aβ aggregates into fibrils, however the intermediate oligomers 
are believed to be the most neurotoxic species and therefore of great interest 
as potential biomarkers. Here, we have developed an ELISA specific for Aβ 
oligomers, by using the same capture and (labeled) detection antibody. The 
ELISA predominantly recognizes relatively small oligomers (10-25 kD), and 
not monomers. In brain tissue of APP/PS1 transgenic mice, we found that 
Aβ oligomer levels increase with age. However, for measurements in human 
samples, pretreatment to remove human-anti-mouse-antibodies (HAMAs) was 
required. In HAMA-depleted human hippocampal extracts, the Aβ oligomer 
concentration was significantly increased in AD compared to non-demented 
controls. Aβ oligomer levels could also be quantified in pretreated cerebrospinal 
fluid (CSF) samples, however no difference was detected between AD and control 
groups. Our data suggest that levels of small oligomers may not be suitable as 
biomarker for AD. In addition, we demonstrate the importance of avoiding HAMA 
interference in assays to quantify Aβ oligomers in human body fluids.
Introduction
Alzheimer’s disease (AD) is the most common cause of dementia worldwide 
with an increasing incidence due to the growing elderly population. Still, the 
diagnosis AD can only be made definitively by post-mortem examination of the 
brain. In addition to neurological examination, several ancillary investigations 
have been advocated to support the clinical diagnosis. One of these presently 
used biomarkers include the analysis of specific proteins in cerebrospinal fluid 
(CSF), in particular the concentrations of total and phosphorylated tau proteins, 
which are both increased in AD, and the 42 amino acid form of the amyloid β 
protein (Aβ42), which is decreased in AD. These provide both a specificity and 
a sensitivity of over 80% to discriminate AD from healthy controls, but are less 
suitable in the discrimination with other forms of dementia [307]. For instance 
an increase in total tau is not only seen in AD, but can also be observed in 
vascular or frontotemporal dementia and in Creutzfeldt-Jakob disease [308] 
and decreased concentrations of Aβ42 are frequently observed in dementia 
with Lewy bodies [309]. Moreover, biomarkers that aid in diagnosing AD at 
an early stage, with a high predictive value for conversion from mild cognitive 
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impairment (MCI) to AD, are desired. Although there is no cure for AD yet, at 
present many different therapeutic strategies are being developed, stressing 
the need for biomarkers for early and specific detection of AD.
The Aβ protein plays a central role in AD pathology and is typically deposited 
as senile plaques in the AD brain. Monomers of this peptide have the 
propensity to aggregate into larger multimeric protein assemblies ranging 
from low molecular weight oligomers, high molecular weight oligomers, 
to protofibrils and mature fibrils. There is ample evidence to suggest that 
the oligomeric species of Aβ are the most toxic. Presence of Aβ oligomers 
correlates better than the extent of fibril formation with neurotoxicity, memory 
loss in transgenic (Tg) mice, disease occurrence and disease severity [310-
313]. Several mechanisms have been described by which oligomers might 
exert their toxicity, among others pore formation in cell surfaces and binding 
to several receptors, thereby disrupting homeostasis and cell signaling. These 
mechanisms lead to inhibition of long-term potentiation, facilitation of long-
term depression, alterations in the dendritic density and the synaptic plasticity 
of neurons in the hippocampus (for an overview see [39]). Given its proposed 
central role in the pathophysiology of AD, Aβ oligomers may serve as a more 
specific diagnostic biomarker than the currently used Aβ42 and tau proteins.
The detection of Aβ oligomers can be troublesome, because they are 
unstable and may disassemble or assemble during analysis. Sensitive and 
high throughput ELISA methods to measure oligomers have been described 
and generally comprise two approaches: 1) using conformation-specific 
antibodies; 2) using a capture and (labeled) detection antibody that recognize 
the same epitope.
Application of the first strategy for the quantification of Aβ oligomers in body 
fluids has been limited, although several different antibodies directed against 
(a subset of ) Aβ oligomers have been developed in the recent past [314-319]. 
One study reports the use of an antibody raised against a specific globular Aβ 
oligomer (termed globulomer) by ELISA, however no globulomers could be 
detected in CSF [314]. In another study an immunoassay using an antibody 
directed against protofibrils, has been described. Protofibrils were detected 
in only 34% of the plasma samples that were analyzed [320]. These examples 
suggest that ELISAs based on antibodies specifically directed against Aβ 
oligomers may not be sufficiently sensitive to quantify Aβ oligomers in 
body fluids. In addition, not each antibody reactive with Aβ oligomers may 
be specific for Aβ oligomers. For instance, one antibody recognizes also 
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oligomeric samples of other proteins like α-synuclein, polyglutamate and 
several heat shock proteins [321, 322].
The second, more frequently used ELISA design to measure Aβ oligomers, 
utilizes the same capture and (labeled) detection antibody in a single assay. 
This ensures that only oligomers, that possess two or more copies of the same 
epitope, can be simultaneously captured and detected. An ELISA according to 
this design has already been described in 1997 [323]. This technique has been 
used to study the time-dependent oligomerization of synthetic Aβ in vitro 
[324-327]. Furthermore, oligomer ELISAs with the same capture and detection 
antibody have been used for measurements in body fluids. One group detected 
higher levels of Aβ oligomers in plasma samples from AD patients versus 
controls, however levels in about half of the plasma samples were below the 
detection limit [328]. In addition, it was found that Aβ oligomer levels in these 
samples was closely related to the levels of total Aβ42. Another study described 
that concentrations of high molecular weight oligomers were significantly 
elevated (p < 0.0001) in CSF of AD and MCI patients [329] compared to non-
demented controls. Also, a trend towards a negative correlation of Aβ oligomer 
level with MMSE score was found, indicating a higher Aβ oligomer level in 
patients with a lower cognitive functioning.
The two above-mentioned strategies may also be combined into an assay in 
which an oligomer-specific antibody was used both as capture and detection 
antibody [315]. By using such a design, it was demonstrated that total Aβ42 is 
less efficiently measured in vitro when a greater portion of the Aβ molecules 
are in an aggregated form.
To demonstrate the specificity of ELISAs designed to quantify Aβ oligomers 
has been challenging, since the generation of a completely monomeric sample 
has proven to be difficult [315, 327, 330]. Also, interference of heterophilic 
antibodies (human antibodies that bind to antibodies of another species) in 
the second type of ELISA strategy is of concern [331]. These antibodies may 
be present in body fluids in a subset of the population and can cross-link the 
capture and detection antibody. In this study we developed an Aβ oligomer 
specific ELISA. We validated the specificity of our assay by using a mutant 
Aβ42 protein that shows significantly reduced aggregation characteristics. 
Furthermore, we applied methods to deplete heterophilic antibodies from 
biological samples and subsequently verified the success of this approach. 
Finally, results from Aβ oligomer measurements in human CSF and both 
human and murine brain tissue extracts are reported.
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Materials & methods
Antibodies and synthetic peptides
The following antibodies were used in this study: mouse monoclonal NAB 
228 [332], directed against Aβ 1-11 (Sigma, St. Louis, MO, USA), which we 
also biotinylated using the Biotin label kit-NH2 (Abnova, Taipei City, Taiwan), 
mouse monoclonal anti-Aβ 6E10, epitope within amino acids 4-9 (Signet 
Laboratories, Dedham, MA, USA), rabbit polyclonal anti-Aβ 40-4 (gift from Dr. 
W.E. van Nostrand), HRP-conjugated goat-anti-human IgG H&L, pre-absorbed 
(Abcam, Cambridge, UK), HRP-conjugated goat anti-mouse Ig (DAKO, Glostrup, 
Denmark) and goat-anti-mouse Alexa 680 (Invitrogen, Grand Island, NY, USA).
Synthetic Aβ42 was obtained from Quality Controled Biochemicals (QCB; 
Hopkinton, MA, USA) and Bachem (Bubendorf, Switserland). All experiments 
were performed with Aβ from QCB, except for the SEC experiment which was 
conducted with Aβ from Bachem. The double mutant F19S/L34P Aβ42 (mutAβ42) 
[333, 334] was obtained from 21th Century Biochemicals (Marlboro, MA, USA). 
Preparation of synthetic Aβ oligomers
All Aβ peptides were dissolved in HFIP (Sigma), air-dried overnight and prior 
to use dissolved in DMSO at a concentration of 5 mM. Then the peptide was 
further diluted in phosphate-buffered saline (PBS) to the desired concentration. 
To obtain oligomer enriched samples, Aβ42 was incubated at a concentration 
of 50 µM at 4 °C for 24 hours. Oligomer samples were aliquoted and kept at 
-80 °C until further use.
CSF samples
For this study, CSF of 25 AD patients and 25 non-demented controls was selected. 
AD cases were diagnosed based on accepted clinical criteria (NINCDS-ADRDA) 
[106] and standard biomarker measurements. Controls were patients examined 
for a neurological disorder, but diagnosed with either a systemic disease without 
neurological manifestations or e.g. with tension-type headache or depression. 
Patient characteristic are described in Table 1. As expected Aβ42 levels were 
significantly decreased in AD and both total tau (t-tau) and phosphorylated tau 
(p-tau) were significantly increased compared to controls. CSF was obtained by 
our departments of Neurology and Geriatrics by lumbar puncture via standard 
procedures in polypropylene tubes, directly transported to our laboratory, 
centrifuged and stored at -80 °C until use for this study. All patient information was 
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decoded to maintain patient confidentiality. Informed consent was obtained 
from the patient or his legal representative. In the selection procedure, CSF 
samples with IgG levels > 45 mg/L were omitted, because occasionally these 
samples could not be completely depleted from IgG.
Tissue samples
Twelve female Tg APPswe/PS1dE9 (APP/PS1) mice [335] (founder animals obtained 
from John Hopkins University, Baltimore, MA, USA), were sacrificed by transcranial 
perfusion and were decapitated at 4, 7 or 10 months of age [336]. A non-Tg mouse 
was used to confirm the expected complete absence of Aβ oligomers in WT mice. 
Brains were collected and hemispheres were snap-frozen in liquid nitrogen and later 
dissected into cortex, hippocampus and cerebellum as previously described [336]. 
Brain regions were extracted at 100 µg/µl in carbonate buffer (0.1 M carbonate, 50 
mM NaCl, 0.5% sodium azide, pH 11.5) containing protease inhibitors (Complete, 
Roche, Woerden, The Netherlands) and homogenized as described before [337]. 
Total protein concentrations were determined using a bicinchoninic acid protein 
assay kit according to the manufacturer’s description (BCA protein assay, Thermo 
Scientific, Rockford, IL, USA).
Human hippocampal tissue was obtained by our Pathology department 
after autopsy and rapidly frozen in liquid nitrogen. Informed consent was 
obtained according to European guidelines. Post-mortem diagnosis and 
grading of AD patients and control cases was based on immunohistochemistry 
staining using antibodies directed against Aβ (4G8; Covance, Princetown, NJ, 
USA) and p-tau (AT8; Innogenetics, Gent, Belgium), and was performed and 
judged by a neuropathologist, according to the criteria established by Braak 
& Braak and CERAD [338, 339]. In addition, cerebral amyloid angiopathy 
(CAA) grading was determined as described previously [340]. By random 
selection, ten AD patients and six cases without AD pathology were chosen. 
Patient characteristics are described in Table 2. For tissue extraction, serial 10 
µm cryosections were extracted at 100 µg/µl in carbonate buffer containing 
protease inhibitors, followed by centrifugation for 20 minutes at 16,000 x g at 
4 °C. After this extraction monomers and low molecular weight oligomers are 
expected. Supernatant was stored at -80 °C for later analysis.
Thioflavin T and Western blot analysis
Aggregation over time of both mutAβ42 and wildtype Aβ42, was assessed in a 
Thioflavin T assay as previously described [341]. The aggregation state of Aβ 
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(directly after dissolving) was also analyzed by SDS-PAGE followed by Western 
blotting. Aggregated samples were diluted in non-reducing sample buffer and 
heated for 15 minutes to 37 °C. Subsequently, samples were run on a 4-20% 
gradient gel (Precise Protein Gel, Thermo Scientific). After electrophoresis, 
proteins were transferred to PVDF membranes by wet blotting. These 
membranes were blocked for 1 h at RT with Odyssey blocking buffer (LI-
COR, Lincoln, NE, USA) diluted 2 times in PBS and the membranes were then 
incubated overnight at 4 °C with antibody NAB 228 diluted in blocking buffer. 
After washing with PBST, membranes were further incubated for 1 h at RT with 
goat-anti-mouse Alexa 680 and proteins were visualized using the Odyssey 
infrared imaging system (LI-COR).
Size exclusion chromatography
For this, Aβ oligomers were prepared essentially as described before [342]. 
In short, a HFIP peptide film of 700 µg Aβ42 dissolved in 500 µl sodium 
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Males/
Females (n)
Age (y)
***
Disease 
duration 
(m)
MMSE Aβ42 (pg/ml) 
***
t-tau (pg/
ml)  ***
p-tau (pg/
ml) ***
Controls 17/8 62.8 ± 12.0 n.a. n.d. 826 ± 237 285 ± 97 58 ± 18
AD 8/17 74.7 ± 7.9 16.1 ± 23.6 20.2 ± 3.3 472 ± 127 733 ± 487 107 ± 52 
Values are expressed as mean ± SD.
AD, Alzheimer’s disease; t-tau, total tau; p-tau, phosphorylated tau; n.a. not applicable; n.d. not 
determined. ***, Value is significantly different from control value (P<0,001)
table 1 : Patient characteristics and CSF parameters.
table 2 : Patient characteristics and hippocampal tissue parameters.
Values are expressed as mean ± SD. 
AD, Alzheimer’s disease
***, Value is significantly different from control value (P<0,001)
Males/fe-
males (n)
Age (y) Post mortem 
delay (h)
Braak & Braak CERAD CAA
Controls 1/5 83.7 ± 8.0 4.2 ± 1.5 0-III -/+ -/+
AD 3/7 76.7 ± 12.2 3.7 ± 0.8 VI +++ -/+++
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phosphate buffer (50 mM phosphate, 0.15 M NaCl, at pH7.2) was sonicated 
for 5 minutes and incubated at 4 °C for 24 hours to allow oligomer formation. 
Next, the formed Aβ oligomers were stabilized by photo-induced crosslinking 
of unmodified proteins (PICUP) (Jongbloed et al., manuscript in preparation) 
[343, 344]. For this, the sample was mixed with 100 µl 3.1 mM Ruthenium 
(II) and 100 µl 62 mM ammonium persulphate (APS), immediately exposed 
to visible white light for 3-5 seconds, whereafter the crosslink reaction was 
quenched by addition of 10 µl of 1 M DTT and heating of the sample at 95 °C 
for 5 minutes. After centrifugation for 10 minutes at 10,000 x g, the precipitate, 
which contained the oligomers, was resuspended in 700 µl sodium phosphate 
buffer containing 0.2% SDS.
The sample was then added to a Superdex 75 column (GE Healthcare). 
Elution was performed with phosphate buffer containing 0.1% SDS and 
the optical density at 280 nm was continuously measured. Fractions of 250 
µl were collected, immediately snap-frozen in liquid nitrogen and stored 
at -80 °C. Before further analysis, SDS was removed from the samples with 
SDS-out Precipitation Reagent according to the manufacturer’s instructions 
(Thermo Scientific). Eluted fractions from the SEC were analyzed by SDS-
PAGE and Western blotting essentially as described above with the following 
modifications: Aβ proteins were heated for 5 minutes to 95 °C, run on a 
4-12% gradient gel (NUPAGE, Invitrogen), transferred by semi dry blotting, 
blocking was performed with PBS containing 5% milk and 0.05% Tween-20, 
the primary antibody 6E10 and the secondary peroxidase-labeled goat anti-
mouse Ig were used and proteins were visualized by chemiluminescence 
(ECL) (GE Healthcare). Because the Aβ protein concentration was too low to 
determine with conventional protein assays, the relative Aβ content of the 
SEC fractions was measured by dot blotting. 5 µl of each fraction in different 
dilutions were applied to a nitrocellulose membrane. Blots were blocked for 1 
hour in PBS/Odyssey block buffer and incubated with Aβ antibody 40-4 1:2000 
overnight at 4 °C. Dot densities were determined by densitometry and this 
information was used to apply equal amounts of Aβ from each SEC fraction to 
the ELISA. To check if indeed equal amounts had been applied, the adjusted 
Aβ concentrations were verified by a second dot blot.
Heterophilic antibody depletion
CSF or human hippocampal extracts were depleted from human anti mouse 
antibodies (HAMAs) as follows. Hippocampal extracts were diluted 50x in 
71
sample diluent (INNOTESTTM Amyloid-β42 diagnostic ELISA kit, Innogenetics, 
Gent, Belgium) to reduce background signals. Protein G resin (Thermo 
Scientific) was washed 3 times with PBS, mixed with either CSF or brain 
extracts in a ratio of resin:sample of 1:8 - 1:10 and incubated for 1 hour at RT 
on a rotator. It was verified that both synthetic Aβ and Aβ levels in CSF did 
not decrease due to incubation with protein G resin. Finally, all samples were 
centrifuged at 2,500 x g for 3 minutes and the supernatants were analyzed for 
Aß oligomer content and the residual amount of human IgG able to bind the 
NAB228 capture antibody by ELISA.
ELISAs
In order to measure Aβ oligomers, NAB 228 was coated overnight at 4°C on 
a 96-wells plate in a 2 µg/ml dilution in 0.1 M NaHCO3, pH 9.6. After this and 
each following incubation step, the plate was washed 3 times with PBST 
(0.05% Tween-20 in PBS). Wells were blocked for 1 hour with 250 µl of 1% BSA 
in PBS at RT. Next, 100 µl of antigen, CSF or brain tissue extract, was added and 
incubated for 2 hours at RT on a shaking device. CSF was diluted 1:1 and brain 
extract 1:20 (mice) or 1:50 (human) with INNOTEST sample diluent. Synthetic 
Aβ42, allowed to oligomerize as described above, was used as a standard at a 
concentration ranging from 9 to 300 ng/L, diluted in the INNOTEST sample 
diluent. Then 100 µl of biotinylated NAB 228 (diluted to 500 ng/ml in PBS 
containing 0.1% BSA and 0.05% Tween-20 (PBST-BSA) was added for 1 hour 
at RT while shaking. Finally the plate was incubated with streptavidin-HRP in 
PBST-BSA for 30 min at RT while shaking. 100 µl of TMB solution was added 
as a substrate and the reaction was stopped with 50 µl of 1M H2SO4. OD 
values were measured at 450 nm using a Sunrise ELISA plate reader (Tecan, 
Männedorf, Switserland). In the case of CSF measurements, instead of TMB 
SuperSignal ELISA Femto Maximum Sensitivity Substrate (Thermo Scientific) 
was used as a chemiluminescent substrate, according to the manufacturer’s 
instructions. Luminescence (relative light units, RLU) was measured using a 
LUMIstar Optima device (BMG Labtech, Ortenberg, Germany).  
It has proven to be difficult to determine a precise concentration of oligomers 
in a sample, because these are ineffectively measured [121]. The concentrations 
mentioned in this study are therefore calculated as equivalent concentrations 
to monomers. The detection limit of this test was calculated to be 2.2 ng/L, 
determined on the average OD value of 21 blank values + 3 times the standard 
deviation. The assay was linear from 2.2 ng/L until at least 1 µg/L. The inter- 
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and intra-assay coefficient of variation of the standard curve were below 18%. 
Omission of capture or detection antibody completely abolished the signal.
To quantify HAMAs present in human samples that may interfere with Aβ oligomer 
detection, we used the above-described design, but incubation of antigen was 
followed by detection with the HRP-conjugated goat-anti-human IgG, diluted 
1:10,000 times in PBST-BSA, and TMB as substrate.
To investigate the potential of NAB 228 to detect mutAβ42, this peptide and Aβ42 as a 
positive control were coated at a 5 µg/L dilution on the plate and detected with NAB 
228-biotin, streptavidin and TMB substrate according to the method described above.
Results
Characterization of specificity of the Aβ oligomer ELISA
Analysis of WT Aβ by Western blot, directly after dissolving the peptides, 
showed a wide range of oligomers next to a strong 4.5 kDa band, whereas 
mutAβ42 appeared solely as a monomeric band of 4.5 kDa (Fig. 1A). Furthermore, 
Thioflavin T analysis demonstrated that WT Aβ42 follows a time-dependent 
aggregation course, whereas mutAβ42 does not demonstrate a detectable 
degree of aggregation (Fig. 1B). In an ELISA mouse monoclonal NAB 228 was 
found to detect both WT Aβ42 and mutAβ42 (data not shown), which enabled 
us to use mutAβ42 as a monomeric Aβ control for the development of the Aβ 
oligomer ELISA. In this ELISA, as expected, no signal was observed for mutAβ42, 
while a concentration dependent signal was observed for synthetic oligomeric 
Aβ42 (Fig.2 ). These results show that the ELISA is specific for oligomers, and 
does not detect monomeric Aβ.
Aβ oligomer quantification in transgenic mouse brain
We subsequently applied the oligomer ELISA to quantify Aβ oligomers in 
Tg mouse tissue extracts. In brain extracts of a non-Tg mouse Aβ oligomers 
could not be detected as expected (data not shown). In APP/PS1 mice, an 
age-dependent increase in the concentrations of Aβ oligomers was found, in 
particular in the cerebral cortex (Fig. 3). Levels in the hippocampus showed 
the same age-dependent increase, however levels were very low and no Aβ 
oligomers were measured in the cerebellum (data not shown). 
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Fig. 1) Mutant Aβ42 F19S/L34P shows a significantly reduced aggregation propensity.
A) Western blot analysis of freshly dissolved Aβ42. Wildtype Aβ42 appears as a wide range of 
oligomers, mutant Aβ42 of solely a monomeric band. Lane 1: Protein marker, lane 2: Wildtype Aβ42 
and lane 3: Mutant Aβ42
B) β-Sheet formation overtime, measured by a Thioflavin T assay, is strongly reduced in the 
mutant form of Aβ42 (▲) compared to wildtype Aβ42 (■). A.u., Arbitrary units. N=2.
Fig. 2) Validation of the oligomer ELISA.
Determination of the specificity for oligomers. The mutAβ42 in monomeric form is not detected, 
even at concentrations as high as 5 µg/L Aβ. In contrast, Aβ42 oligomers generate a concentration 
dependent signal (R2=0.9985). The limit of detection for oligomers was calculated to be 2.2 ng/L. N=2.
Amyloid-β oligomer detection in CSF and brain tissue
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Fig. 3) Aβ oligomers in the cortex of APP/PS1 transgenic mice.
Levels of Aβ oligomers were quantified by the oligomer ELISA. The amount of oligomers increases 
with age. N = 5 (4 mths), N = 4 (7 mths) and N = 3 (10 mths).
Fig. 4)  Heterophilic antibody depletion from CSF.
A) Design of ELISA to quantify HAMAs binding to the NAB 228 antibody.
B) Effects of IgG depletion from human CSF (left) and hippocampal tissue (right) on the 
quantification of HAMAs binding to NAB 228. Before depletion, IgG binding to NAB 228 was 
measured in almost all samples, after depletion bound IgG levels could not be detected.
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Fig. 5) Aβ oligomer levels in hippocampus and CSF samples of AD patients and controls.
A) After IgG depletion, oligomers were measured by ELISA in 10 AD and 6 control hippocampus 
extracts. The concentration of Aβ oligomers was significantly higher in AD than in control cases (P 
< 0.05).
B) Aβ oligomers were measured by ELISA in IgG depleted CSF samples of 25 AD and 25 control 
cases. No difference was detected.
Fig. 6) Specificity of Aβ oligomer ELISA for LMW oligomers.
A) Preformed, cross-linked, oligomers of synthetic Aβ were separated by SEC on a Sephadex 75 
column and analyzed by Western blotting (using  antibody 6E10). Different fractions contain 
enrichments for differently sized oligomers.
B) Fractions collected by SEC were tested at equal protein concentrations in the oligomer ELISA. 
Fractions 4 to 6 generated the highest signal, while in these fractions low molecular weight 
oligomers (from dimers up to pentamers) were relatively most abundant. Fraction 2 consists 
almost solely of large oligomers that are hardly detected. N=2.
Amyloid-β oligomer detection in CSF and brain tissue
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Aβ oligomers and HAMA interference in human CSF and hippocampal tissue 
samples
Since the design of our Aβ oligomer ELISA may generate false-positive results 
due to interference of HAMAs [331], we depleted human CSF samples and 
brain extracts from IgG and checked the success of this approach by ELISA (Fig. 
4A). Indeed we could demonstrate that preclearance of CSF samples led to a 
successful depletion of IgG (Fig. 4B). Similar results were obtained for human 
brain tissue (data not shown).
Subsequently, oligomers were quantified in human brain tissue and CSF after 
IgG preclearance. Aβ oligomer levels in extracts of human hippocampal tissue 
were significantly higher in AD patients compared to controls (Fig. 5A). In 3 
out of 6 control samples, Aβ oligomer levels were below the detection limit, 
while in contrast, Aβ oligomer concentrations could be quantified in all AD 
tissue extracts tested. In CSF, Aβ oligomer levels did not significantly differ 
between AD cases (300 ± 26.0 ng/L) and controls (264 ± 27.4 ng/L) (Fig. 5B). No 
significant correlations were detected between Aβ oligomers and Aβ42, t-tau 
or p-tau levels.
Since we did not expect equal Aβ oligomer levels in control and AD CSF samples, 
we analyzed the specificity of the Aβ oligomer ELISA for specific subspecies of 
Aβ oligomers. Cross-linked oligomers of Aβ42 were separated according to size 
by SEC and analyzed by Western blot and ELISA. SEC did not result in a perfect 
separation of differently sized oligomers, however enrichment of subspecies 
in subsequent fractions was achieved (Fig. 6A). ELISA measurements revealed 
that highest signals were obtained in those fractions that contained Aβ 
oligomers between ± 10 and 25 kDa, with lower signals in those fractions that 
were enriched in Aβ species of < 10 or > 200 kDa (Fig. 6B).
Discussion
In this report we demonstrated the successful development of an ELISA 
method for specifically detecting Aβ oligomers, and not monomers, in 
biological samples. This ELISA detects a wide range of oligomers, but LMW 
oligomers (between 10 and 25 kDa) generate the highest signal. We also 
demonstrate that HAMAs may interfere with the Aβ oligomer assay, as CSF 
samples appeared to contain Ig able to bind to the NAB 228 antibody used 
for capturing the oligomers. We demonstrated that, after removal of HAMAs, 
Aβ oligomer levels in AD hippocampal tissue were significantly increased 
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compared to controls, but Aβ oligomer concentrations were similar in AD and 
control CSF.
Because of the important role that has been assigned to oligomeric Aβ in AD 
pathology, the possibilities for specific detection of oligomers have gained 
much attention recently [345]. Validation of the specificity and sensitivity of 
ELISAs to quantify Aβ oligomers has proven to be difficult, as was elaborately 
discussed in a previous study [330]. It was questioned whether the various 
ELISAs are completely oligomer specific, since for instance, often a low signal for 
‘monomeric samples’ is measured. Indeed, it might be problematic to generate 
an Aβ sample that solely consists of monomers without evidence of the presence 
of oligomeric species on Western blot. Low amounts of Aβ oligomers may be 
present in monomeric preparations of Aβ that can be detected in ELISA, which 
is a more sensitive technique than Western blotting [330]. Addition of Tween-20 
to the Aβ samples [327], the degradation of oligomers by β-mercaptoethanol 
[328] and the use of Aβ1-10,  that does not show aggregation [324] may be 
used to obtain pure monomeric Aβ samples. Only the latter sample was not 
detected in an oligomer ELISA, suggesting that the use of a non-aggregating 
form of Aβ might be the best strategy. In this study, we used a double mutant 
form of Aβ42 (F19S/L34P, mutAβ42) that has a significantly reduced aggregation 
potential [333, 334] (see Fig. 1). We demonstrated that mutAβ42 is recognized 
by NAB 228, but does not aggregate and, consequently, did not generate a 
signal in the Aβ oligomer ELISA. Therefore, this mutAβ42 peptide seems to 
be a very useful tool to validate the specificity of these type of Aβ oligomer 
assays. The lack of aggregation of mutAβ42 can be explained by the fact that 
the amino acids that are mutated in mutAβ42 are essential for formation of the 
typical hairpin structure in the oligomerization process of Aβ, and are therefore 
important for aggregation [346]. 
Another important aspect in the characterization of Aβ oligomer ELISAs is 
the size of oligomers that are detected. The use of a particular antibody and 
the specific conditions chosen for the ELISA setup can result in preferential 
detection of a specific size range of oligomers. One study reported that only 
oligomers ≥ 40 kDa were measured [327], while in another study smaller 
species such as dimers could be detected [328]. Recently, in yet another assay 
it was concluded that only HMW oligomers (mainly 10-20 mers of synthetic 
Aβ) could be detected [329]. The authors hypothesized that the epitopes for 
the detection antibody, located on residues 1-16, might have been hidden 
inside the structural conformation of the relatively small oligomers, and were 
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only accessible in the larger oligomers. In contrast, although we also used an 
antibody directed against the N-terminus of Aβ, our SEC results suggested that 
HMW oligomers were less efficiently measured than the smaller oligomers (10-
25 kDa). However, SEC does not provide a perfect resolution of Aβ oligomer 
separation, which may limit our conclusions of the preferential recognition of 
specific Aβ oligomers by our ELISA [347, 348]. The resolution of small oligomers 
might be enhanced by the use of two SEC columns with different particle sizes 
in tandem, by the use of a long thin column, or by the combination of SEC with 
a light scattering method [329, 345, 348].
 By using the oligomer ELISA reported in this article, we were able to detect 
age dependent levels of Aβ oligomers in Tg mouse cortex and hippocampus, 
but not cerebellum, in line with the plaque formation in these AAP/PS1 
double mutant mice [31, 45, 46]. Aβ oligomers of different sizes were shown 
to be present in APP/PS1 mice hippocampi, ranging from 6- to 16-mers and 
increasing with age [349]. Also, it has been demonstrated that Aβ oligomers 
in APP/PS1 Tg mice co-localize with postsynaptic densities and are associated 
with spine collapse [350].
We found elevated levels of soluble Aβ oligomers in human AD brain tissue as 
compared to controls. This is in line with studies showing that both soluble, 
and to an even larger extent, insoluble oligomers were more abundant in 
AD brains than in controls [328]. Another study demonstrated that levels of 
Aβ40 oligomers were not different between AD patient and control samples, 
while, in contrast, Aβ42 specific oligomers were significantly increased in AD 
samples [351]. However, yet another study investigating soluble brain extracts 
showed increased levels of particularly Aβ40 oligomers in AD samples [313]. 
These different results might be caused by different assay sensitivities or 
different extraction methods. In conclusion, our and previously published 
data show that Aβ oligomers are present and can be quantitatively measured 
in brain tissue extracts. Variable outcomes in comparisons of AD versus control 
tissues, might be caused by the measurement of differently sized oligomers or 
oligomers of different Aβ isoforms.
We also demonstrated that HAMAs can interfere with Aβ oligomer detection in 
human biological samples by using our ELISA design. This confirms the results 
of a previous study demonstrating that levels of oligomeric Aβ in human body 
fluids might be unreliable when HAMAs were not removed from the samples 
[331]. An estimated 10-40% of patients may contain non-specific antibodies 
directed against murine antibodies; how these arise is still not completely clear 
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[352]. In our ELISA, HAMA interference might not be completely prevented, 
since only the IgG type was depleted here, and HAMAs can also be of the IgA, 
IgM or sometimes the IgE type [353]. Still, both previous reports and our results 
point to the importance of testing the specificity of ELISAs and we propose 
that HAMA depletion or blocking might be important when assays like ours 
are used for the quantification of Aβ oligomers in human body fluids. 
We were able to detect Aβ oligomers in human CSF and we found similar 
concentrations in AD and control samples. To our knowledge, only one ELISA 
method has been reported that successfully measured Aβ oligomers in CSF 
[329]. In that study, in contrast with ours, an increased level of Aβ oligomers 
was found in a group of AD patients and MCI-converters compared to 
controls. Other methods have also been used to demonstrate the presence 
of oligomers in CSF. One group used an antibody directed against oligomers 
in a novel technique based on a conventional sandwich ELISA, but with the 
implementation of magnetic microparticles and nanoparticles for extra 
amplification [354]. With this so-called Bio-Barcode Assay, CSF from AD 
patients and controls were compared and Aβ oligomer levels were higher 
in the AD group [355]. Characterization of the oligomeric species detected 
by this method was not described. Also, by using fluorescence correlation 
spectroscopy [356] or confocal laser scanning microscopy in combination 
with dual color surface fluorescence intensity distribution analysis [357, 
358], multimers of Aβ were found at higher concentrations in AD CSF than in 
controls. By using flow cytometry and fluorescence resonance energy transfer, 
a weak correlation between age and Aβ oligomer level was found [359]. Thus, 
several studies have demonstrated increased levels of Aβ oligomers in AD CSF 
compared to controls. In the present study we did not find any difference. 
These contrasts in results might be explained by the specificity of the methods 
for certain oligomers. For instance in one previous study it was demonstrated 
that mainly HMW oligomers were measured, whereas our results suggest that 
these larger Aβ oligomers are less efficiently measured than the smaller ones. 
Another explanation for this discrepancy may be that in previous studies using 
the same ELISA design as ours [328, 329], CSF samples were not depleted 
from HAMAs. Although in one case an HRP-conjugated Fab’ fragment of the 
detection antibody was used, this may not fully prevent detection of HAMAs 
[353]. However, neither in every oligomer ELISA the interference of HAMAs 
may be present nor may be as strong as in this assay. Also, it should be noted 
that some studies used very small sample groups [357, 358]. Disease state of 
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the patients might play a role; patients in early stages of AD may have altered 
levels of small oligomers in their CSF compared to patients at later stages. 
In this study, CSF samples of AD patients with a disease duration of 17.6 ± 
24.6 months were used. The measurement of samples from patients in the 
beginning of their disease or even from patients suffering from MCI might 
yield different results. Finally, a publication bias towards positive results, and 
negation or lack of interest in negative results like ours, might result in positive 
findings becoming overrepresented in the literature. Unexpectedly, the 
outcome of our results in CSF were also different from our results on human 
brain tissue. A possible reason for this discrepancy may be that the stronger 
oligomerisation in AD patients is compensated by the deposition of Aβ, and 
thus no net increase in free Aβ oligomers occurs; while in the brain some 
oligomers might be released from the plaques during extraction, resulting 
in an increased level in brain tissue extracts, this effect may not be seen in 
CSF. Furthermore, we can not exclude that oligomer levels in the CSF do not 
reflect AD pathology because Aβ oligomers present in CSF might be formed 
by spontaneous oligomerisation. In contrast, in the brain tissue, aggregation 
stimulating factors may be present that induce oligomerisation in AD brain, 
but not or less so in control brain. Finally, the ELISA described here measures 
LMW oligomers most optimally, this might cause a bias in the oligomer levels 
detected in both brain tissue and CSF and thus not accurately reflect brain 
pathology.
In conclusion, we reported the development of an Aβ oligomer ELISA that 
preferentially detects LMW oligomers. With this method we showed that the 
presence of Aβ oligomers is significantly increased in brain tissue of AD patients 
compared to controls and in Tg mouse brain tissue. In contrast, however, such a 
difference was not demonstrated in CSF samples. Finally, we demonstrated the 
potential interference of heterophilic antibodies in assays that aim to quantify 
Aβ oligomers in human biological samples. For future research, assays should 
be designed in such way that this interference is avoided. Also, thorough 
characterization and description of the sizes and types of oligomers that are 
detected are advisable, to allow better interpretation of the data.
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Abstract
 
Objectives. 1) Analyze the potential of amyloid beta (Aβ)-oligomer concentrations in 
cerebrospinal fluid (CSF) to diagnose and predict progression to Alzheimer’s disease 
(AD) in a large clinical study sample. 2) Monitor Aβ-oligomer concentrations over-
time, both in early and advanced stages of AD. 3) Examine the relation between Aβ-
oligomer levels in CSF and cognitive functioning.
Methods. 24 Non-demented, 61 mild cognitive impairment and 64 AD-patients who 
underwent lumbar puncture and cognitive testing at baseline and follow-up were 
selected from the memory clinic based Amsterdam Dementia Cohort. CSF samples 
were analyzed for standard AD-biomarkers and Aβ-oligomer levels using a validated 
in-house Aβ-oligomer specific enzyme-linked immunosorbent assay. Aβ-oligomer 
levels were analyzed as indicators of disease progression (follow-up AD diagnosis) 
and cognitive decline, respectively.
Results. Patient groups did not differ in Aβ-oligomer concentrations at baseline or 
follow-up. Baseline CSF Aβ-oligomer levels were similar in MCI patients that develop 
AD as in stable MCI patients. Interestingly, both MCI and AD patients showed an 
annual decrease in Aβ-oligomer levels of 9.4% and 6.8%, respectively. A decrease 
in Aβ-oligomer levels over time was strongly associated with more severe cognitive 
decline in AD patients.
Conclusion. Despite the limited diagnostic potential of Aβ-oligomer levels in CSF to 
differentiate between patient groups, and between MCI-AD and MCI-stable patients, 
changes in CSF Aβ-oligomer levels were related to cognitive decline. Therefore, CSF 
Aβ-oligomers may aid in the selection of patients with a more aggressive disease 
course.
Introduction
An imbalance in the production and removal of the Aβ peptide can cause direct 
and indirect, through accumulation of Aβ into senile plaques and subsequent 
glial activation, neurodegenerative changes which ultimately lead to AD [360, 
361]. Small, soluble aggregates of the Aβ peptide, called Aβ-oligomers, have 
gained substantial scientific interest due to the in vivo findings on their direct 
toxic effects at the synapse level [36, 37, 362], and their early involvement in 
AD pathogenesis. Interestingly, Aβ-oligomers have been detected in CSF and 
levels were suggested to reflect the AD-related pathological event in the brain 
parenchyma [359]. 
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Publications in which Aβ-oligomer levels in CSF were examined as a potential 
- and much needed - biomarker for AD have reported promising findings [329, 
363]. Although these cross-sectional studies focus on the direct diagnostic 
importance of Aβ-oligomers, longitudinal changes in Aβ-oligomer levels may 
herald additional personalized diagnostic or pathophysiological insight in AD. 
To the best of our knowledge, longitudinal studies of CSF Aβ-oligomer levels 
have not been reported yet.
In this study we aimed to 1) analyze the potential of Aβ-oligomer concentrations 
in CSF to diagnose and predict AD in a large clinical study sample, and 2) 
monitor Aβ-oligomer concentrations in time, both in early and advanced 
stages of AD 3) analyze the relation between Aβ-oligomer levels in CSF and 
cognitive functioning.
Methods
Participants
The clinical study sample (149 individuals) has been described in an earlier 
study [364], in which we measured specific and a-specific AD biomarkers at 
baseline and follow-up in patients that were selected from the memory clinic 
based Amsterdam Dementia Cohort. Diagnosis of Mild Cognitive Impairment 
(MCI) (n=61) was made according to the criteria set by Petersen et al. [365], 
and the diagnosis of AD (n=64) was made following the National Institute of 
Neurological and Communicative Disease and Stroke/AD and Related Disorders 
Association (NINCDS-ADRDA) guidelines [366]. When cognitive screening, 
physical and neurological examination, laboratory tests, electroencephalogram 
(EEG), and magnetic resonance imaging (MRI) were normal, subjects were 
considered to have subjective complaints. The group of non-demented 
individuals (n=24) consisted of 20 patients with subjective complaints, two 
patients with a psychiatric disorder and two patients with temporal epilepsy. 
Clinical diagnoses were made by consensus of a multidisciplinary team and 
were independent of the biomarker concentrations in CSF in all cases. Cognitive 
performance of all participants was assessed at baseline and follow-up through 
scores on the Mini-Mental State Examination [367]. 
At follow-up (on average 45 months, with minimum of 6 months), 34 of the 61 
MCI patients had progressed to AD, three to frontotemporal lobar degeneration 
[368], two to vascular dementia [369], one to dementia with Lewy bodies 
[370] and one subject was diagnosed with normal pressure hydrocephalus. 
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Six non-demented subjects had progressed to MCI, two progressed to AD and 
one was diagnosed with vascular dementia at follow-up. Demographic data 
of the cohort are depicted in Table 1. The VU University Medical Center ethics 
committee approved the study and all participants gave written informed 
consent.
Sample handling
CSF was obtained through lumbar puncture between the L3/L4 and L4/L5 
intervertebral space, collected in 12 mL polypropylene tubes. Samples were 
centrifuged at 1800 x g for 10 minutes at 4°C within two hours after lumbar 
puncture [371]. A fraction of the CSF was stored at -20°C for ELISA and routine 
analysis including total cell-counts (for leucocytes and erythrocytes), total protein 
and glucose determination. CSF was aliquoted into 0.5 mL or 1.0 mL polypropylene 
Characteristics Non-demented MCI AD
n (male/female) 24 (17/7) 61 (38/23) 64 (36/28)
Age - years 64 (10) 68 (8) a 65 (7)
Time to follow-up - months 48 (32) 45 (25) 38 (24)
Baseline cognition - MMSE 1  28.3 (1.8) 26.5 (2.5) a 21.7 (5.3) b
Follow-up cognition - MMSE 2  27.3 (2.8)   21.9 (5.5) a, b  16.9 (6.6) b
Aβ40 - pg/L 9.7 (3.0) 9.5 (3.2) 8.5 (2.8)
Follow-up Aβ40 - pg/L 10.8 (3.2) 9.9 (3.1) 9.1 (3.4)
Aβ42  
- µg/L 711 (276) 530 (243) a, b 415 (141) b
Follow-up Aβ42  
- µg/L 721 (300) 560 (253) a, b 451 (174) b
Tau - µg/L 395 (258) 606 (495) 690 (360) b
Follow-up Tau - µg/L 443 (271) 649 (636) 678 (333) b
pTau - µg/L 58 (29) 78 (43) 87 (35) b
Follow-up pTau - µg/L 66 (33) 79 (42) 85 (36)
Aβ-oligomers - a.u. 1471 (574) 1651 (589) b 1581 (685)
Follow-up Aβ-oligomers - a.u. 1622 (555) 1427 (428) b 1520 (641)
Age, time, MMSE and AD-biomarkers are depicted as mean (standard deviation)
Compared to AD a P <0.05
Compared to non-demented b P <0.05 
1 Missing data on one AD and two MCI patients. 2 Missing data on one non-demented,
one AD and three MCI patients.
Table 1. Demographical data of study sample
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tubes and stored at -80°C for further analysis in this study. Aβ42, Tau and pTau (181) 
concentrations were determined using the Innotest sandwich ELISA (Innotest 
β-amyloid1-42, htau Ag and Phospo-tau (181P) Innogenetics, Ghent, Belgium). Aβ40 
levels were quantified using an in-house method [372]. Staff involved in CSF analyses 
was blinded for clinical diagnosis. 
Aβ-oligomer specific enzyme-linked immunosorbent assay (ELISA)
For the measurement of Aβ-oligomer levels in CSF we used an Aβ-specific 
sandwich ELISA (see Supplementary data for assay validation), in which a 
96-wells Costar 9018 plate (Corning Inc., New York, USA) was coated with 100 
µL/well of VU-17 antibody [373] at 1 µg/mL in 100 mM carbonate buffer at pH 
9.6, overnight at 4°C on a shaking platform (600rpm). After coating, the plate 
was washed once with PBS and block buffer (PBS with 1% BSA) was added for 
two hours at RT. The plate was washed three times with wash buffer (20mM Tris-
HCl, 0.05% Tween at pH 7.5). An aliquot of Aβ-oligomer enriched Aβ42, which 
contained a total of 500 ng/mL synthetic Aβ42 was diluted in assay buffer (20mM 
Tris-HCl, 50 mM NaCl, 0.1% BSA and 0.1% Tween20 at pH 7.5) to reference values 
of 15, 3, 1.5, 0.5, 0.25 and 0.125 ng/mL. CSF samples were added at four times 
dilution and incubated for two hours at RT at 600rpm. The plate was washed 
three times with wash buffer followed by detection with 100 µL/well biotinylated 
VU-17 (1 mg/mL) diluted 1:2500 in assay-buffer for one hour at RT at 600rpm. 
Next, the plate was washed three times with wash buffer followed by incubation 
with 100µL Streptavidin/poly-HRP conjugate (1 mg/mL) diluted 1:10.000 in PBS 
for 30 minutes at RT. The plate was washed four times with wash buffer. Then, 
100 µL/well of TMB in substrate buffer (100 µL of 10 mg/mL TMB was added to 
11 mL citric acid/acetate buffer at pH 4.0 with 10 µL 30% H2O2) was added and 
incubated at RT. After 10 minutes the reaction was stopped with 100 µL sulfuric 
acid at 1M, followed by detection at 530nm using a spectrophotometer (Bio-
Tek Synergy HT, Winooski, VT, U.S.A). Due to uncertainty concerning the exact 
size of the oligomers in the solution used to prepare the calibration curve, the 
concentration was based on the molecular size of a single Aβ42 peptide (molecular 
weight of 4514 dalton). The lower limit of detection of the Aβ-oligomer ELISA was 
9 pg/mL. See Supplementary data for additional assay characteristics.
We used an oligomer-enriched preparation with a known start concentration 
of amyloid beta as standard material, but did not verify the stringent levels of 
oligomers within this preparation. Therefore, we present our data as arbitrary 
units (a.u.) throughout the manuscript.
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Statistical analysesGroup comparisons were performed using one-way 
analysis of variance (ANOVA). Pearson’s correlation coefficient was used to 
assess the correlation between continuous variables. Age- and sex-adjusted 
linear mixed models were applied to assess baseline effects for diagnosis 
and changes over time in CSF Aβ-oligomer levels by diagnosis. In this model, 
Aβ-oligomer concentration was the dependent variable, while diagnosis and 
time (in years; treated as a continuous variable) and interaction between 
diagnosis and time were independent variables. Furthermore, we calculated 
the annualized changes of CSF biomarker level and MMSE, with the formula 
value of measurement at follow-up minus value of measurement at baseline, 
divided by follow-up period in years. Associations between annualized 
change in CSF biomarker levels and annualized change in MMSE-scores (data 
available for 130 patients) were assessed using multiple linear regression, 
stratified for diagnoses and adjusted for sex and age.  A priori power analysis, 
with power set at 0.8, showed that at least 15 patients were required per 
group to detect the expected differences between AD and controls. SPSS 
Statistics package 19.0 (IBM, New York, USA) for OS X Lion was used for the 
statistical analyses and the generation of graphs. P-values below 0.05 were 
considered significant.
Results
Group comparison
Levels of CSF Aβ-oligomers did not differ between the groups of non-
demented, MCI and AD neither at baseline (Fig 1A), nor at follow-up (Fig 1B). 
Aβ-oligomer levels decreased significantly at an annual rate of 9.4% (155 a.u., 
p-value < 0.05) in MCI and 6.8% (108 a.u., p-value < 0.05) in AD patients. The 
Aβ-oligomer levels in CSF of non-demented subjects did not change over time. 
Prediction of AD in MCI patients
Within the group of MCI patients (n = 61) a total of 34 patients had progressed 
to AD (MCI-AD) at follow-up clinical assessment. To examine the predictive 
value of Aβ-oligomers, we compared the baseline Aβ-oligomer concentrations 
in CSF of MCI-AD patients and those that did not progress to AD (MCI-stable). 
As shown in Figure 2, there was no difference in Aβ-oligomer levels between 
MCI-AD (1690 ± 571 a.u.) and MCI-stable patients (1571 ± 629 a.u.).
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Correlation of Aβ-oligomer levels with AD-biomarkers levels in CSF
Aβ-oligomers and pTau levels correlated in non-demented subjects, but not in 
MCI or AD patients, at baseline (r = 0.38, p-value = 0.07) and at follow-up (r = 
0.54, p-value = 0.01). Aβ-oligomer concentrations were unrelated to total Tau, 
Aβ40 or Aβ42 in any of the diagnostic groups. 
Longitudinal CSF Aβ-oligomer and AD-biomarkers levels
We assessed the relation between the annualized changes of Aβ-oligomer 
content in CSF with annualized changes in Aβ40, Aβ42, Tau and pTau levels. An 
increase in Aβ-oligomer levels was positively associated with Tau (r = 0.27, 
p-value < 0.05) and pTau levels (r = 0.31, p-value = 0.02) in AD patients. A 
positive relation was found in longitudinal CSF Aβ-oligomer levels and Tau 
levels in MCI patients (r = 0.37, p-value = 0.005). No relation was found between 
longitudinal changes in Aβ-oligomer concentration and the established AD-
biomarkers in non-demented subjects. 
Correlation with cognition
There was no association between Aβ-oligomer levels in CSF and cognitive 
performance at baseline in any of our patient groups. There was, however, 
a strong relation between the yearly decrease in Aβ-oligomer levels and 
cognitive decline, as reflected by yearly decrease in MMSE-scores, in subjects 
with AD (β = 1.42 · 10-3, p-value = 0.02, corrected for age and sex) and a trend 
in MCI patients (β = 2.27 · 10-3, p-value = 0.06, corrected for age and sex). 
As visualized in Figure 3, subjects with AD that had the sharpest decrease 
in Aβ-oligomer levels (at least 267 a.u.) had the most pronounced cognitive 
decline. Fluctuations in Aβ-oligomer levels over-time were not associated with 
cognitive decline in the non-demented subjects.
Discussion
The neurotoxic and synaptotoxic effects of Aβ-oligomers in in vitro and 
animal model studies [310, 374], point to a role for Aβ-oligomers in the 
neurodegenerative changes and associated cognitive decline in AD.  In the 
present longitudinal study, we have investigated if Aβ-oligomer levels in 
CSF are associated with AD clinical phenotype and with cognitive decline. 
No differences in CSF Aβ-oligomer concentrations were observed between 
non-demented, MCI patients and AD patients at baseline. Neither could we 
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distinguish MCI-AD from MCI-stable patients on the basis of the Aβ-oligomer 
content in CSF. Based on these findings we conclude that the Aβ-oligomer 
levels in CSF have limited use as a direct diagnostic tool. 
However, when baseline and follow-up (mean 43 months) concentrations 
were compared, a decrease was observed in MCI and AD cases and not in non-
Fig. 1) CSF Aβ-oligomer levels in non-demented, MCI and AD subjects.
A) Baseline and B) follow-up CSF Aβ-oligomer levels are not different between the groups of non-
demented, MCI and AD subjects.
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demented subjects (Fig 1). These longitudinal changes in CSF Aβ-oligomers in 
MCI and AD were associated with the rate of cognitive decline, independent 
from baseline cognition. Interestingly, others found specific isoforms of Aβ 
(Aβ*56) to be reduced in AD brain compared to controls, and the reduced 
levels were associated with neuronal loss [375]. Although our assay is unlikely 
to quantify Aβ*56 oligomers specifically, it is conceivable that decreased 
levels of Aβ-oligomers and consequent neurodegeneration are the underlying 
mechanisms for cognitive decline in AD patients. In contrast to Aβ-oligomers, 
the levels of established AD-biomarkers Aβ1-42, total Tau or p-Tau were not 
associated with cognitive decline in any subject group. These findings indicate 
that Aβ-oligomers are an independent entity, which is separate from Aβ1-42 
or Tau, which may be used to evaluate within-subject disease progression. 
Clinically useful diagnostic AD-biomarkers should be able to discriminate AD 
patients from subjects with minor cognitive complaints rather than healthy 
controls, since these subjects reflect the population that visits the memory 
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Fig. 2) CSF Aβ-oligomer levels at baseline of MCI-stable and MCI-AD patients.
CSF Aβ-oligomer levels in MCI patients that did not progressed to AD (MCI-stable, left) and those 
that did progress to AD (MCI-AD, right) are not different at baseline.
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clinic for medical diagnosis. Therefore, participants with subjective complaints 
were used as non-AD reference group in this study. A drawback of the use of 
SMC as a control group is that differences in biomarker levels compared to 
AD may be less obvious as with real controls, since SMC subjects are known 
to have an increased risk of developing AD [376]. Indeed, six non-demented 
subjects had progressed to MCI and two to AD at follow-up clinical assessment. 
Fig. 3) Longitudinal changes in Aβ-oligomer levels are related to cognitive decline in AD patients.
The group of AD patients has been divided into quartiles based on the difference between 
baseline and follow-up CSF Aβ-oligomer levels. 
Quartile 1: Cases with a decrease in Aβ-oligomer levels of at least 267 pg/mL Quartile 2: Cases with 
a decrease in Aβ-oligomer levels between 267 and 14 pg/mL Quartile 3: Cases with a difference 
in Aβ-oligomer levels between baseline and follow-up, ranging from a decrease of 14 pg/mL and 
an increase of 125 pg/mL Quartile 4: Cases with increase in Aβ-oligomer levels above 125 pg/mL. 
The Y-axis represents the change in cognitive performance, determined by MMSE-score (follow-
up – baseline). Cognitive performance was significantly decreased in AD patients with the highest 
reduction of Aβ-oligomer levels, compared to the other cases. * P ≤ 0.05  *** P ≤ 0.001
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On the other hand, studying SMC may give insight in the earliest events in AD 
pathology. Therefore, further studies aim to elucidate the role of low-molecular 
weight CSF Aβ-oligomers in the earliest stages of AD-pathology in SMC cases 
without detectable cognitive deficits.
Whereas we found no difference in Aβ-oligomer levels between AD, MCI 
and SMC cases, others have reported increased levels in AD [329, 359]. This 
discrepancy may be due to the use of different detection platforms [377, 378], 
and pre-analytical procedures that favor detection of distinct species of Aβ-
oligomers. Our assay is most sensitive to smaller aggregates (Supplementary 
Figure 1), while others almost exclusively quantified larger Aβ aggregates for 
example [329], or did not identify their molecular targets [379]. The dynamic 
nature of Aβ-aggregation limits the stringency with which the total level of 
Aβ-oligomers can be determined [380], and restricts the analysis to relative 
differences among subjects and groups. Because of the intrinsic unstable 
nature of the Aβ-oligomers, we used CSF that was acquired under uniform 
conditions, was processed within two hours and directly stored at -80°C 
until further analysis. Therefore, we are confident that our study describes 
biologically relevant differences in actual Aβ-oligomer content. With respect to 
multicenter and large-scale studies, implementation of strict and concordant 
(pre-) analytical protocols is pivotal for reliable assessments of Aβ-oligomer 
concentrations in CSF.
It important to realize that distinct biological effects have been described for 
Aβ aggregates of varying sizes [33]. Particularly the small and soluble amyloid 
aggregates have a profound impact on neuronal long-term potentiation [374], 
neuronal dystrophy and degeneration [381] as well as tau phosphorylation 
[381, 382]. In line with these studies, we found that the concentration of low-
molecular weight Aβ-oligomer species is related to cognitive deterioration. 
The mechanisms underlying the increased cognitive deficits remain to be 
investigated. Interestingly, the Aβ*56 oligomers have recently been proposed 
to play a pathogenic role very early in AD, and were found to be correlated 
with pathological forms of tau in healthy individuals [375, 383]. The authors 
speculate that the Aβ*56 oligomers may underlie subtle cognitive deficits and 
impaired brain metabolism in healthy individuals at risk for AD. Our data partly 
support their hypothesis, as we observed a relation between pTau and Aβ-
oligomers in individuals with subjective complaints, which was uncoupled in 
MCI and AD. 
Amyloid-β oligomers relate to cognitive decline
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In conclusion, our results indicate that quantification of CSF Aβ-oligomer does 
not provide additional diagnostic information over and above the established 
CSF AD-biomarkers in a cross-sectional setting. However, we did observe a 
decrease in CSF Aβ-oligomer concentrations over-time, which was strongly 
associated to cognitive decline in AD patients. The association with cognitive 
decline points to a role of Aβ-oligomers as a disease-stage marker, in contrast 
to CSF Aβz and Tau levels [364]. More specifically, assessment of fluctuations 
in Aβ-oligomer levels might aid in targeting patients with a more progressive 
disease course. 
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Supplemental data
Preparation and stabilization of Aβ-oligomers
Aβ1-42 (Bachem) was dissolved in hexafluoroisopropanol (Sigma), aliquoted, 
dried in a speed-vacuum and stored at -80°C until use. 700 µg of Aβ1-42 was 
dissolved in phosphate-buffered saline (0.01M phosphate buffered saline at pH 
7.2) and allowed to aggregate at room temperature for 24 hours. This sample 
was treated with photo-induced cross-linking of unmodified proteins (PICUP) 
to snap-freeze the current state of aggregation, essentially as described before.
[1,2] In short, we added 100µL 3.1mM ruthenium (II) (Sigma-Aldrich, St. Louis, 
USA) and 100µL 62mM ammonium persulfate to the Aβ-oligomer enriched 
sample in a darkroom. The sample was then illuminated for one second using 
a cold light fountain (Type 482, Karl Storz KG, Tuttlingen, Germany). The cross 
linking reaction was quenched by adding 10µL DTT (1M) followed immediately 
by vortexing. Following the PICUP reaction, Aβ-oligomers were heated at 95°C 
before centrifugation at 10.000 x g. Aβ was collected in the precipitate, which 
was dissolved in 700µL sodium phosphate buffer containing 0.2% SDS.
Size exclusion chromatography
To separate the Aβ monomers and oligomers according to molecular size, the 
Aβ-oligomer sample was applied to a Superdex 75 column (GE Healthcare 
Bio-Science AB, Uppsala, Sweden) for size-exclusion chromatography on an 
AKTA-purifier. The flow-through was collected in 250µL fractions, which were 
snap-frozen in liquid nitrogen immediately after collection and stored at -80°C 
for later analysis. The optical density of the flow-through was continuously 
monitored at 280nm (UNICORN 5.11 software, GE Healthcare), which was used 
to determine the total amount of peptides in each of the fractions (Figure 
e1b). Fractions 1-11 were analyzed using our Aβ-oligomer ELISA. 
SDS-PAGE and western blot
Aβ-oligomers in each of the SEC fractions were analyzed by sodium dodecyl 
sulfate polyacrylamide gelelectrophoresis, using a 4-12% Nu-PAGE pre-cast 
gel (Invitrogen, Carlsbad, CA, U.S.A). Next, the proteins were electro blotted 
onto 0.2µM PVDF membranes (Millipore Corp., Bedford, MA, U.S.A) in a Trans-
blot SD semi-dry transfer cell (Bio-Rad, U.S.A) at 0.11mA for 60 minutes. 
Immunodetection was performed with mouse monoclonal 6E10 antibody 
(Sigma-Aldrich, St. Louis, MO, U.S.A; at 200ng/mL), which recognizes the 
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Fig. e1A) Western blot, using 6E10 antibody, of stabilized Aβ-oligomers separated into fractions 
1-11 by size-exclusion chromatography on a Superdex 75 column. The fractions were enriched for 
different sizes of Aβ-aggregates, ranging from monomers to fibrillar Aβ. B) The Aβ-oligomer ELISA 
specifically recognizes Aβ-oligomer species present in fractions 2-6, but not fibrils (fraction 1) or 
monomers and dimers (fractions 7-11).
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Characteristics Low (1ng/mL) Medium (2ng/
mL)
High (3ng/mL)
Number of 
CSF (n) 
7 7 7
Expected 0.42 1.52 1.81
Observed (ng/
mL) 
0.32 0.85 1.35
Recovery 76.7% 49.1% 58.3%
Table e-1 shows the spike-recovery data from low, medium and high concentrations of
untreated A-oligomer preparations (as used in the standard material for the assay).
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n-terminal amino acids of the Aβ peptides and a secondary peroxidase-linked 
goat-anti-mouse antibody (Dako, Glostrup, Denmark; at 0.5µg/mL). Peptides 
were visualized through ECL+ chemiluminescence (GE Healthcare, Munich, 
Germany), and luminescence was detected using a Fujifilm LAS-3000 camera 
and Imagereader LAS-3000 Lite software (Fujifilm Holdings Corporation., 
Dusseldorf, Germany). The western blot of fractions 1-11 is shown in Figure e1a.
ELISA specificity
Fractions 1-11 were analyzed using our Aβ-oligomer ELISA. The ELISA signal is 
compared to the total amount of peptides present in each fraction. As shown 
in Supplementary Figure 1a, the ELISA signal is strongly increased in fractions 
2-6, which all contain mid-range oligomers, and not in fractions 1 (fibrils) or 
8-11 (dimers and monomers). (Fig e1b).
Spike-recovery of the Aβ-oligomer ELISA
To determine the spike-recovery percentage of the Aβ-oligomer ELISA, a total 
of seven human CSF samples were analyzed in the ELISA. To each of these 
CSF samples spikes of 1, 2 and 3 ng/mL of non-stabilized Aβ-oligomers were 
added, which reflect the low, but biologically relevant concentrations of Aβ-
oligomers in human CSF. The ELISA read-out of each of the spiked samples 
was corrected for their endogenous (non-spiked) Aβ-oligomer concentrations. 
Using this approach, the spike-recovery of our Aβ-oligomer ELISA was 
determined at 61.4% (See Table e1). The relatively low recovery percentages 
are possibly attributed to the dynamic nature of Aβ-oligomers and factors in 
CSF that can bind and/or dissociate the unstable oligomers used for spiking.
Supplementary Table e1: Spike-recovery of the Aβ-oligomer ELISA
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Abstract
Amyloid-β (Aβ) is known as the most prominent core protein in Alzheimer’s 
disease (AD) senile plaques. Although research has focused mainly on Aβ40 
and Aβ42 as potential cerebrospinal fluid (CSF) biomarkers, a range of Aβ 
peptides with variable lengths has been demonstrated in the brains and CSF 
of AD patients. Recently, it has been found that the Aβ43 peptide may be more 
abundant than previously thought, could therefore play an important role in 
AD pathophysiology, and hence also function as putative biomarker. In this 
study the value of CSF Aβ43 in AD diagnosis was investigated. Aβ43 levels in 
CSF were highly correlated with Aβ42 levels. Furthermore, in differentiation of 
AD with non-demented controls and from patients with Lewy body dementia 
and frontotemporal dementia, Aβ43 had an equal diagnostic value as Aβ42, 
both as a single biomarker and in combination with total and phosphorylated 
tau. In conclusion, quantification of Aβ43 in CSF does not add novel diagnostic 
information to the differential diagnosis of AD compared to existing biomarkers.
Introduction
The Amyloid-β (Aβ) peptide is formed after sequential cleaving of the Amyloid 
Precursor Protein (APP) by β- and γ-secretase. The latter produces peptides 
differing in length at the C-terminus of which Aβ40 and Aβ42 are the most 
frequently studied for their potential as biomarkers of Alzheimer’s disease (AD). 
Cerebrospinal fluid (CSF) concentrations of Aβ42, when used in combination 
with total tau (t-tau) and phosphorylated tau (p-tau), provide both a specificity 
and a sensitivity of over 80% to discriminate AD from healthy controls. However, 
the diagnostic accuracy of this combination is inferior in the discrimination of 
AD from other forms of dementia [124, 125, 384, 385], since, for example, Aβ42 
concentrations are also decreased in CSF from patients with dementia with 
Lewy bodies (DLB) [386]. In addition, patients with frontotemporal dementia 
(FTD) may have increased CSF levels of t-tau and p-tau, which complicate the 
differentiation from AD [387]. Therefore, more specific biomarkers are needed 
that provide better discrimination between dementia subtypes.
It has been suggested that Aβ peptides may result from sequential cleavage 
of longer precursor peptides. In this model, it was proposed that Aβ40 and 
Aβ42 are formed in different production lines. β-Secretase-cleaved C-terminal 
fragments of APP are cleaved by proteases at the ε-site to generate various Aβ 
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peptides by subsequent release of tripeptides. In this way, Aβ40 results from 
cleavage of Aβ49 first to Aβ46, then to Aβ43 and – in parallel - Aβ42 results from 
cleavage of Aβ48 first to Aβ45 and then to Aβ42 (Fig. 1) [388-390]. This has been 
referred to as the tripeptide hypothesis. The detection of released tripeptide 
fragments in the cleavage process, supports this hypothesis [390]. Recent 
studies have demonstrated that the Aβ43 peptide may be abundantly present 
in the brain, and, similar to Aβ42, is deposited in an early stage of the disease 
[391]. Furthermore, Aβ43 can be found in plaque core extracts of both sporadic 
and familial AD patients [391-393], even more frequently than Aβ40 [394, 395]. 
In addition, based on the generation of a mouse model that overproduces 
Aβ43, it was demonstrated that this peptide causes short-term memory loss 
and accelerated amyloid pathology. Finally, in vitro studies showed that Aβ43 
aggregates with kinetics similar to Aβ42 and may be equally or even more 
neurotoxic [395-397]. In previous studies it was demonstrated that CSF Aβ43 
concentrations are decreased in MCI/AD compared to controls [398]. However, 
its potential value as a biomarker to discriminate AD from other dementia 
syndromes has not yet been evaluated.
The diagnostic value of CSF Amyloid-β43
Fig. 1) Schematic overview of APP processing by γ-secretase, according to the tripeptide 
hypothesis.
APP is first cleaved by β-secretase  into C99 and the soluble sAPPβ. Next, the C99 fragment is 
cleaved at the ε-site, resulting in the generation of Aβ49 and Aβ48 and the APP intracellular 
domains. Subsequently, Aβ42 and Aβ40 are generated by two separate product lines, via 
successive tri- and tetrapeptide cleavages by γ-secretase.
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In this study, we quantified Aβ43 in CSF from AD, DLB and FTD patients and 
non-demented controls.  We determined whether Aβ43 can provide additional 
value in the diagnosis of AD, relative to CSF Aβ40, Aβ42, t-tau and p-tau, both in 
differentiation of AD patients from non-demented controls and in differentiation 
between dementia subtypes. Our study demonstrated that Aβ43 analysis in CSF 
has an equal diagnostic value as Aβ42 analysis in AD diagnosis.
Materials & Methods
Patients
CSF samples of 33 AD, 18 DLB and 18 FTD patients were included. Informed 
consent for lumbar puncture was obtained from the patient or his legal 
representative. Dementia diagnoses were based on accepted clinical criteria, 
i.e. the NINCDS-ADRDA criteria for probable AD, the 1996 consensus guidelines 
for the clinical and pathological diagnosis of DLB and the 1998 consensus on 
clinical diagnostic criteria for FTD [106, 368, 399].
Thirty-three non-demented control patients were selected for this study. All 
were initially examined for a neurological disorder, but diagnosed with either a 
systemic disease without neurological manifestations or e.g. with tension-type 
headache or depression. Routine CSF parameters such as cell count, protein and 
glucose, were assessed as normal. Patient characteristics are listed in table 1.
CSF samples and analysis
CSF was obtained by lumbar puncture at our departments of Neurology and 
Geriatrics via standard procedures and collected in polypropylene tubes, 
directly transported to our laboratory, centrifuged and stored at -80 °C until 
use for this study. All patient information was decoded to maintain patient 
confidentiality. CSF parameters were measured by ELISA methods according to 
manufacturers’ protocols; Aβ42, t-tau and p-tau levels were determined using 
assays from Innogenetics (NV, Ghent, Belgium); Aβ40 using an assay from Merck 
Millipore (Billerica, MA, USA) and Aβ43 using an assay from IBL International 
(Hamburg, Germany). For the Aβ43 measurements, CSF samples were tested 
undiluted and in duplicate. In all samples, Aβ43 levels fell within the range of 
the standard curve (2.34 – 150 pg/ml). Mean intra-assay coefficient of variation 
of this assay was 6.6% for duplicate CSF samples and mean inter-assay variation 
was 11.2%.
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Statistics
CSF parameters with non-Gaussian distribution were log transformed to 
meet assumptions of normality. Differences between CSF parameter levels 
were determined by one-way analysis of variance (ANOVA), with Bonferroni’s 
post-hoc test. We performed Pearson’s correlations to test for age dependent 
changes and t-tests to test for gender dependent changes in protein levels. 
Analysis of covariance (ANCOVA) was used to control for age as a potential 
confounder. Receiver operator characteristics (ROCs) were used to determine 
the diagnostic value of CSF parameters. The Youden index aids in identifying 
the optimal combination of specificity and sensitivity (Youden index = 
sensitivity + specificity – 1.0) of the diagnostic models as a function of 
different cut-off points. Likelihood ratios (LR) were determined as follows; 
LR=sensitivity/(1-specificity). A test with a LR > 4 is commonly accepted as a 
test with clinically useful characteristics, which is, for example, achieved when 
sensitivity and specificity both reach 80% or more. Binary logistic regression 
was used to identify parameters that contributed to differentiation between 
The diagnostic value of CSF Amyloid-β43
Fig. 2) Aβ43 levels in CSF of non-demented controls and AD, DLB and FTD patients. 
Data of Aβ43 measurements in CSF are plotted. Levels of Aβ43 were significantly lower in both AD 
and DLB compared to controls or FTD. Aβ43 levels in FTD patients are similar to controls.
*, P<0.05; ***, P<0.001
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groups. Statistical analyses were performed using GraphPad PRISM 5 software 
(San Diego, CA, USA), SPSS software version 18 (Chicago, IL, USA) and MedCalc 
software version 12.2.1.0 (Mariakerke, Belgium).
Results
Aβ peptides, t-tau and p-tau CSF levels
Aβ42 levels were decreased in AD (p<0.001) and DLB (p<0.01) and Aβ40 levels were 
increased in FTD (p<0.05), compared to non-demented controls. Both t-tau and p-tau 
levels were increased in AD compared to non-demented controls (p<0.001) (Table 1). 
Fig. 3) Correlations of Aβ peptide levels in CSF of controls and AD, DLB and FTD patients.
Straight line indicates the correlation between CSF Aβ42 and Aβ43 levels, in all samples combined 
(p<0.0001 and r=0.85). Correlations in each study group: AD (p<0.0001 and r=0.75), DLB (p<0.0001 
and r=0.78), FTD (p<0.0001 and r=0.88) and controls (p<0.0001 and r=0.79).
Straight line indicates the correlation between CSF Aβ40 and Aβ43 levels, in all samples combined 
(p<0.0001 and r=0.44). Correlations in each study group: AD (p<0.0001 and r=0.73), DLB (p<0.01 and 
r=0.61) and controls (p<0.0001 and r=0.63). In FTD no significant correlation was found.
Straight line indicates the correlation between CSF Aβ40 and Aβ42 levels, in all samples combined 
(p<0.01 and r=0.27). Correlations in each study group: DLB (p<0.05 and r=0.57) and controls (p<0.05 
r=0.38). In AD and FTD no significant correlation was found.
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CSF levels of Aβ43 showed the same pattern as Aβ42 in control, AD, DLB and 
FTD groups. In short, a significant decrease of Aβ43 in CSF of both AD (p<0.001) 
and DLB patients (p<0.01), but not FTD, compared to healthy controls was 
detected (Fig. 2 and Table 1).
Age varied significantly between disease groups (Table 1) and was weakly 
correlated with p-tau (Pearson’s r=0.37, p<0.05) in the control group and with 
Aβ42 (Pearson’s r=0.42, p<0.05) and Aβ43 (Pearson’s r=0.38, p<0.05) in the AD 
group. Most of the significant differences for CSF parameters between disease 
groups were maintained after adjustment for age; except for the decrease 
in Aβ42 in DLB compared to normal levels, which was less significant after 
adjustment (p<0.05 instead of p<0.01).  In addition, gender distribution also 
differed between disease groups (Table 1), but analysis showed that this did 
not affect biomarker outcomes (data not shown).
Correlation of Aβ peptide levels in CSF
Aβ42 and Aβ43 were positively correlated (all samples: r=0.85, p<0.0001) (Fig. 
3A) in all disease groups (r=0.75 – 0.88). Also, a significant correlation was 
found between levels of Aβ40 and Aβ43 (all samples: r=0.44, p<0.001) in AD, DLB 
and controls, (Fig. 3B), but not in FTD. Finally, Aβ40 and Aβ42 correlated weakly 
with each other when all samples were analysed together (all samples: r=0.27, 
p<0.01) (Fig. 3C), but not in the separate AD and FTD groups.
Discriminative value of Aβ43 in dementia diagnosis
Aβ43 discriminated between AD and controls with a sensitivity of 52% and a 
specificity of 97% (AUC = 0.77) (Fig. 4A). The diagnostic accuracy of Aβ42 in AD versus 
controls appeared better (AUC 0.83, sensitivity 61% and specificity 97%), but the 
differences in AUC did not reach statistical significance (p=0.11) (Fig. 4A and Table 2).
Next, we determined the value of Aβ43 in the differentiation of AD versus 
DLB and FTD, and compared these results with the ROC curves obtained by 
discrimination based on Aβ42 levels (Fig. 4B,C). Again, the AUC of the ROC 
was higher for Aβ42 than for Aβ43, but this difference did not reach statistical 
significance (AD vs. DLB, p=0.51; AD vs. FTD, p=0.10; Table 2).
Comparison of diagnostic models
Discrimination between AD patients and controls or other dementias was 
investigated by comparing two combinations of biomarkers, i.e. Aβ42, t-tau 
and p-tau versus the combination where Aβ42 was replaced by Aβ43. Models for 
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optimal diagnostic discrimination of AD versus each of the other groups were 
determined (Table 3 and supplementary Table S1). Generally, the models in 
which Aβ42 was used generated ROC curves with similar or slightly higher AUC 
than those with Aβ43, but these differences were not significant. This indicates 
that equal diagnostic accuracy was achieved for the discrimination of AD from 
either controls (Fig. 5A), DLB (Fig. 5B) or FTD (Fig. 5C) by using models containing 
either Aβ42 or Aβ43. Furthermore, models that combined Aβ42 with Aβ43, p-tau and 
t-tau did not improve discrimination in any of the groups (data not shown).
For the discrimination of AD versus DLB, we also investigated whether the 
addition of Aβ40 to the model of Aβ42, t-tau and p-tau increased the diagnostic 
accuracy, since Aβ40 levels were lower in DLB than in AD (Table 1). However, 
the AUC of the ROC curve was (non significantly, p=0.41) smaller when Aβ40 
was included into the model than that of the model in which Aβ40 was not 
included (AUC 0.91 vs. 0.93) (Fig. 5B). Also the Youden index is lower (0.68 
versus 0.75), indicating that including Aβ40 levels in diagnosis of AD versus 
DLB does not improve diagnostic sensitivity and specificity.
Discussion
In this study, we investigated the CSF levels of Aβ43 in AD, DLB and FTD 
patients and non-demented controls. We show that (I) Aβ43 is detectable in 
CSF, (II) Aβ43 is decreased in AD and DLB patients, (III) levels of Aβ43 in CSF are 
highly correlated to levels of Aβ42, but less to Aβ40, and (IV) Aβ43 and Aβ42 have 
equal diagnostic value in the differentiation of AD from controls, DLB and FTD 
patients, either alone or in combination with t-tau and p-tau.
We measured 5 CSF parameters (t-tau, p-tau, Aβ42, Aβ40 and Aβ43) in samples from 
non-demented controls and AD, DLB and FTD patients. The levels of the first 
three, the most commonly analyzed AD biomarker proteins, were as expected. 
In AD, we found a decrease of Aβ42, and an increase in both t-tau and p-tau 
levels, a typical pattern for AD dementia [384, 385]. CSF levels in DLB patients 
showed a decrease in Aβ42 but no differences in t-tau and p-tau levels, which is 
characteristic for DLB CSF [386]. CSF levels of FTD patients have previously been 
described to contain normal Aβ42 levels and normal or increased t-tau and p-tau 
levels compared to controls [387, 400-402]. Indeed, we found normal Aβ42 and 
non-significantly increased tau levels. Furthermore, Aβ40 levels were decreased 
in DLB compared to AD, which has been reported before [403] and increased in 
FTD compared to controls. Aβ43 levels were decreased both in AD and DLB, but 
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table 1 : Patient characteristics and CSF parameters.
Values are expressed as mean ± SD, except for gender distribution. # p-value by ANOVA, except 
for gender distribution, where the chi square test was used. Statistical significant differences are 
indicated.
MMSE: Mini mental state (not determined for all patients); AD: Alzheimer’s disease; DLB: 
Dementia with Lewy bodies; FTD: Frontotemporal dementia; con: Controls, t-tau: total tau; p-tau: 
phosphorylated tau; n.a.: not applicable.
A Likelihood ratio: (sensitity/(1-specificity) b Youden index : sensitivity + specificity – 1.0
ROC: receiver operating characteristics; AUC: area under the curve; AD: Alzheimer’s disease; DLB: 
Dementia with Lewy bodies; FTD: Frontotemporal dementia; Con: controls
Controls AD DLB FTD p-value#
Males/
females (n)
20/13 13/20 17/1 13/5 0.001
Age (y) 66 ± 12 74 ± 8 72 ± 9 66 ± 8 0.002
MMSE 26 ± 3
n=9
21 ± 3
n=28
22 ± 8
n=9
20 ± 7
n=13
0.023
Disease duration 
(mo)
n.a. 11 ± 20
n=23
29 ± 28
n=13
12 ± 18
n=12
0.068
Aβ40 (pg/ml) 4228 ± 1754 5316 ± 2040 3316 ± 1116
p vs. AD <0.001
5619 ± 1931
p vs. con <0.05
<0.0001
Aβ42 (pg/ml) 721 ± 238 470 ± 109
p vs. con <0.001
585 ± 120
p vs. con <0.01 
782 ± 224
p vs. AD <0.001
<0.0001
Aβ43 (pg/ml) 29 ± 15 16 ± 7
p vs. con <0.001
17 ± 10
p vs. con <0.01
36 ± 20
p vs. AD <0.001
<0.0001
T-tau (pg/ml) 286 ± 149 695 ± 469
p vs. con <0.001
266 ± 161
p vs. AD <0.001
445 ± 335
p vs. AD <0.05
<0.0001
P-tau (pg/ml) 55 ± 19 108 ± 43
p vs. con <0.001
52 ± 19
p vs. AD <0.001
74 ± 31
p vs. AD <0.01
<0.0001
AUC Sensitivity/
Specificity
Likelihood 
ratioa
Youden indexb Cut-off point
AD vs Con Aβ42 0.83 61%/ 97% 20.0 0.58 >646.5
Aβ43 0.77 52%/ 97% 17.00 0.48 >27.3
AD vs DLB Aβ42 0.64 67%/ 73% 2.44 0.39 >503.0
Aβ43 0.52 33%/ 94% 5.5 0.27 <9.0
AD vs FTD Aβ42 0.88 83%/ 82% 4.58 0.65 >553.5
Aβ43 0.82 56%/ 100% 0.56 >31.8
table 2 : ROC analysis of Aβ42 versus Aβ43 in AD diagnosis.
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Fig. 4) Comparison of ROC curves of AD diagnosis with Aβ42 or Aβ43. 
ROC curves for the analyses of Aβ43 and Aβ42 in CSF for AD versus A) controls, B) DLB, or C) FTD. 
The ROC curves for Aβ42 and Aβ43 are similar (p>0.05).
Fig. 5) Comparison of ROC curves of discrimination models for AD diagnosis including either Aβ42 or Aβ43.
ROC curves for the combination models of biomarkers. The models including Aβ43 yield a similar 
(p>0.05) AUC as the models including Aβ42 for AD versus A) controls, B) DLB, or C) FTD. For DLB, 
the model combining both Aβ42 and Aβ40 with t-tau and p-tau yields a similar (p>0.05) AUC as 
the models including only Aβ42 or Aβ43 with t-tau and p-tau (B).
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not FTD, patients compared to non-demented controls. A decrease in Aβ43 in 
AD and MCI CSF has been described before [398]. To our knowledge, Aβ43 levels 
in CSF have not been measured before in DLB and FTD patients.
Previously, Aβ43 and Aβ42 CSF levels have been described to show a strong 
correlation [398]. We also found Aβ43 to be strongly correlated to Aβ42 levels, 
which was observed in all disease groups. In addition, we found a correlation 
between Aβ40 and Aβ43 levels, which also confirmed previous findings [398]. 
These results are compatible with the tripeptide hypothesis in which Aβ40 
results from cleavage of Aβ43. Interestingly, in FTD patients we did not find a 
correlation between Aβ40 and Aβ43. Furthermore, Aβ40 and Aβ42, which would 
be the fourth and third products in separate cleavage pathways, showed no 
(AD and FTD) or only a weak correlation (controls and DLB), in line with the 
tripeptide hypothesis [398]. The lack of a correlation between Aβ40 and Aβ43 
in FTD, in contrast to the other disease groups, might point to underlying 
differences in disease pathology, and further research into these correlations 
may provide more insight in Aβ processing in specific dementia disorders.
Biomarkers for diagnostic differentiation of the various dementia syndromes 
are much desired. Determination of a dementia diagnosis in a very early 
stage might improve chances for effective intervention, and because clinical 
differences are often subtle in this stage, CSF biomarker analysis, which can 
reflect early and specific pathological changes in the brain, might provide a 
good tool for diagnosis. Aβ42 has been extensively studied and its CSF levels 
are now advocated as one of the AD biomarkers. The longer Aβ43 peptide, 
however, has hardly been studied.  In this study, for the first time the value of 
Aβ43 in dementia diagnosis was investigated, and we found that the diagnostic 
discriminative power of AD from non-demented controls, DLB patients and 
FTD patients is equal for Aβ42 and Aβ43. Importantly, a decrease in CSF Aβ43 
has also been reported in MCI patients [398]. Therefore, in the light of future 
research, studying the potentials of Aβ43 could be of interest to improve AD 
diagnosis in an early disease stage. Furthermore, since Aβ43 is present in 
senile plaques and possesses a great potential to aggregate, analysis of the 
oligomeric forms of Aβ43 in CSF is also suggested to be investigated as a new 
potential biomarker for AD.
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Parameters in 
model
AUC Sensitivity/ 
Specificity
Likelihood 
ratioa
Youden 
indexb
Cuf-off point
AD vs Con Aβ42, t-tau, 
p-tau
0.94 76%/ 97% 25.00 0.73 >0.61
Aβ43, t-tau, 
p-tau
0.94 73%/ 97% 24.00 0.70 >1.29
AD vs DLB Aβ42, t-tau, 
p-tau
0.93 78%/ 97% 25.67 0.75 >0.32
Aβ43, t-tau, 
p-tau
0.92 78%/ 97% 25.67 0.75 >0.28
AD vs FTD Aβ42, t-tau, 
p-tau
0.92 72%/ 97% 23.83 0.69 >0.27
Aβ43, t-tau, 
p-tau
0.88 78%/ 97% 25.67 0.75 >0.13
Parameters in model Formula
AD vs Con Aβ42, t-tau, p-tau y=-0,166 + 0,003t-tau - 0,076p-tau + 0,008Aβ42
Aβ43, t-tau, p-tau y=1,965 + 0,003t-tau - 0,082p-tau + 0,151Aβ43
AD vs DLB Aβ42, t-tau, p-tau y=4,493 + 0,004t-tau - 0,108p-tau + 0,002Aβ42
Aβ43, t-tau, p-tau y=4,870 + 0,004t-tau - 0,108p-tau + 0,038Aβ43
AD vs FTD Aβ42, t-tau, p-tau y=-3,766 + 0,005t-tau - 0,064p-tau + 0,011Aβ42
Aβ43, t-tau, p-tau y=-0,38 + 0,005t-tau - 0,072p-tau + 0,163Aβ43
table S1 : Prediction models for the discrimination between disease groups.
Supplementary data
table 3 : ROC analysis of combinations of CSF parameters in AD diagnosis.
a Likelihood ratio: (sensitity/(1-specificity) b Youden index : sensitivity + specificity – 1.0
ROC: receiver operating characteristics; AUC: area under the curve; AD: Alzheimer’s disease; DLB: 
Dementia with Lewy bodies; FT:, Frontotemporal dementia; t-tau: total tau; p-tau: phosphorylated tau
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table S1 : Prediction models for the discrimination between disease groups.
Supplementary data
The diagnostic value of CSF Amyloid-β43
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Abstract
Amyloid-β (Aβ) is the most prominent protein in Alzheimer’s disease (AD) senile 
plaques. In addition, Aβ interacts with a variety of Aβ-associated proteins, some 
of which can form complexes with Aβ and influence its clearance, aggregation 
or toxicity. Identification of novel Aβ-associated proteins may shed new light 
on the pathophysiology of AD and the metabolic fate of Aβ. In this study we 
aimed to identify new Aβ-associated proteins by searching for proteins that 
may form soluble complexes with Aβ in CSF, using a proteomics approach. 
We identified the secreted Wnt pathway protein Dickkopf-related protein 3 
(Dkk-3) as a potential Aβ-associated protein. Using immunohistochemistry on 
human AD brain tissue, we observed that Dkk-3 (1) co-localizes with Aβ in the 
brain, both in diffuse and classic plaques; (2) is expressed in neurons and in 
blood vessel walls in the brain and (3) is secreted by leptomeningeal smooth 
muscle cells in vitro. Finally, measurements using ELISA revealed that (4) Dkk-3 
protein is abundantly present in both cerebrospinal fluid and serum, but its 
levels are similar in non-demented controls and patients with AD, Lewy body 
dementia and frontotemporal dementia. Our study demonstrates that Dkk-3 is 
a hitherto unidentified Aβ-associated protein which, given its relatively high 
cerebral concentrations and co-localization with Aβ, is potentially involved in 
AD pathology.
Introduction
In Alzheimer’s disease (AD), deposition of extracellular amyloid-β (Aβ) protein 
and intraneuronal accumulation of hyperphosphorylated tau protein are the 
major pathological events in the brain. Aβ deposition occurs as a consequence 
of aggregation of the protein into fibrils. The 40 amino acid Aβ isoform (Aβ40) 
is the most abundantly produced species, but the slightly longer Aβ42 isoform 
is more prone to aggregation. Most senile plaques in AD contain Aβ42, whereas 
Aβ40 is observed in classic senile plaques and in cerebral amyloid angiopathy 
(CAA) [31, 404]. Many Aβ-associated proteins (AAPs) co-deposit with Aβ, such 
as apolipoproteins, heat shock proteins, alpha1-antichymotrypsin, heparan 
sulfate proteoglycans, and several complement factors [405-408], but Aβ 
may also form soluble complexes with several AAPs, as demonstrated by the 
presence of Aβ-ApoE complexes in cerebrospinal fluid (CSF) [99, 409, 410]. 
The importance of the identification of AAPs is twofold. On the one hand, 
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identification of these AAPs and their interaction with Aβ can provide insight 
in how AD pathology develops. For instance, several AAPs, such as alpha1-
antichymotrypsin and several heat shock proteins affect Aβ aggregation and 
fibril formation [80, 86, 411]. On the other hand, AAPs, either by themselves 
or in complex with Aβ, may function as biomarkers for AD. For example, 
concentrations in CSF of Aβ-ApoE complexes are decreased in AD compared 
to controls [99].
Diagnostic differentiation between AD and other dementia types can be 
challenging, because clinical symptoms can be alike and CSF biomarker 
profiles partly overlap. In AD, typically a decrease of Aβ42 and increases of total 
tau (t-tau) and phosphorylated tau (p-tau) in CSF are observed. However, Aβ42 
concentrations are also decreased in CSF from patients with dementia with 
Lewy bodies (DLB) [386] and patients with frontotemporal dementia (FTD) 
may have increased CSF levels of t-tau and p-tau [387], which complicates 
the differentiation from AD. Therefore, more specific biomarkers that provide 
better discrimination between dementia subtypes are needed, and possibly 
AAPs provide such a source of biomarkers.
In this study we aimed to identify novel, yet unexplored AAPs, to obtain more 
insight into the pathophysiology of Aβ accumulation in AD, and to study 
if these novel AAPs may serve as novel  biomarkers. In order to do so, we 
performed an identification study of AAPs that form soluble complexes with 
Aβ40, the most abundant Aβ peptide in CSF, by mass spectrometry (nanoLC-
MS/MS) analysis. From the identified potential AAPs we selected one protein, 
Dickkopf-related protein 3 (Dkk-3), for further analysis, which comprised 
immunohistochemical study of the expression of Dkk-3 protein, production of 
the protein by cerebrovascular cells, and the study of its concentrations in CSF 
from patients with different forms of dementia.
Materials & Methods
Tissue samples
Tissue from the hippocampus of 11 AD patients and 5 non-demented control 
cases and from the occipital cortex of 4 AD patients and 5 non-demented 
control cases was obtained after rapid autopsy and immediately frozen in 
liquid nitrogen. Informed consent was obtained according to national and 
local guidelines. For control tissue, anonymized material was used according 
to national and local guidelines. Grading of AD patients and controls was 
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116
performed according to criteria established by Braak & Braak [26] or Braak et 
al. [412] and CERAD [413]. Patient characteristics are provided in Table 1.
CSF and serum samples
CSF samples of 3 AD patients and 3 non-demented controls were selected 
for proteomics discovery experiments. CSF was selected from AD patients (2 
males, 1 female, 76 ± 4 years) and controls (2 males, 1 female, 70 ± 11 years), 
who were age- and gender-matched and from whom 4 ml CSF was available.
In addition, 30 patients with clinical AD, 17 with DLB, 18 with FTD and 30 non-
demented controls were selected for validation purposes. CSF was obtained by 
lumbar puncture at our departments of Neurology and Geriatrics via standard 
procedures and collected in polypropylene tubes, directly transported to our 
laboratory, centrifuged and stored at -80 °C until use for this study. 
Patients were informed that their data, including CSF, could be used for further 
scientific purposes and were given the option to object against this use, in 
which case their data were not used.
In addition, serum samples from 20 AD patients and 19 non-demented 
controls were selected. All patient information was decoded to maintain 
patient confidentiality. Dementia diagnoses were based on accepted clinical 
criteria, i.e. the NINCDS-ADRDA criteria for probable AD, the 1996 consensus 
guidelines for the clinical and pathological diagnosis of DLB and the 1998 
consensus on clinical diagnostic criteria for FTD [106, 368, 399]. More recent 
diagnostic criteria [106] were not applied, since the patients’ samples were 
collected prior to the introduction of these criteria. Control subjects were 
initially examined for a neurological disorder, but turned out not to have a 
neurological disorder.  In 8 subjects no abnormalities were found, 8 patients 
were diagnosed with tension-type headache, 6 patients with psychological 
complaints such as depression or psychosis and the remaining 8 patients were 
diagnosed with a systemic disease without neurological manifestations (e.g. 
visual problems or tremor). Routine parameters including cell count, total 
protein, glucose, lactate, blood pigments and oligoclonal IgG bands were also 
assessed as normal. We did not have mini-mental state examination (MMSE) 
scores for all subjects, because for control patients the MMSE is not routinely 
scored and for some demented patients we were unable to retrieve MMSE data 
from the patients files due to the retrospective nature of this study. Patient 
characteristics are listed in Table 2 (CSF) and Table 3 (serum).
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Amyloid-β peptides
Aβ40, Aβ42 and reversed-sequence Aβ40 (revAβ40) were obtained from QCB 
(Hopkinton, MA, USA). Aβ40, N-terminally labelled with biotin (Aβ40-biotin), 
was obtained from Innovagen (Lund, Sweden). All Aβ peptides were dissolved 
in hexafluoroisopropanol (HFIP; Sigma-Aldrich, St. Louis, USA) and air-dried 
overnight. Subsequently the resulting peptide films were dissolved in dimethyl 
sulfoxide (DMSO) at a concentration of 5 mM.
RevAβ40 was biotinylated using Biotin label kit-NH2 (Abnova, Taipei City, 
Taiwan). The success of biotinylation was confirmed by coating of the labeled 
Aβ on a 96-wells plate and detection with streptavidin-HRP.
Sample preparation for proteomics analysis
For use in the proteomics study, 4 ml CSF per patient was first depleted 
from albumin and IgG by BAC CaptureSelect affinity resin (Life Technologies, 
Bleiswijk, The Netherlands), followed by incubation of 1.7 ml CSF per patient 
with 500 ng Aβ40-biotin and another 1.7 ml with a comparable amount of 
revAβ40-biotin as a negative control, for 4 hours at 37 °C on a rotator, to allow 
complex formation of Aβ with associated proteins. CSF samples were then 
incubated with monomeric avidin agarose (Thermo Fisher Scientific, Rockford, 
IL, USA) to capture the biotinylated proteins in a ratio of 1:24 v/v for 1 hour at 
RT and subsequently O/N at 4 °C. Next, the CSF with agarose was centrifuged at 
5,000xg for 2 min and supernatant was removed. The agarose pellet was washed 
4 times with PBS and protein-protein bonds were disrupted by incubation with 
4 M KCl for a few minutes to allow elution of associated proteins from Aβ. Pilot 
experiments demonstrated that this elution with a high salt concentration is 
suitable to decompose protein-protein complexes and does not disturb the 
avidin-biotin bond. The supernatant containing AAPs was concentrated and 
the high salt levels were removed using Amicon 3 kDa cutoff spin filters (Merck 
Millipore, Billerica, MA, USA) and extensive washing with PBS.
To reduce possible interference of unspecific compounds (e.g. polymers) with 
nanoLC-MS/MS analysis, samples were subjected to SDS-PAGE. Subsequently, 
proteins were in-gel reduced (10 mM dithiotreitol), alkylated (50  mM 
chloroacetamide) and digested with trypsin (12.5 ng/µl sequencing grade 
modified trypsin (Promega) in 50 mM ammonium bicarbonate). After extraction 
of the peptides from the gel, samples were desalted and concentrated using 
Stage tips [414].
Dkk-3 is a potential Aβ-associated protein
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Values are expressed as mean ± standard deviation (SD), except for gender distribution. AD: 
Alzheimer’s disease; PMI: Post mortem interval. Grading of Braak and CERAD (not determined for 
all control cases) as described in Materials and Methods
Males/females (n) Age (y) PMI (h) Braak CERAD
Hippocampus
Controls 2/3 86 ± 6 4 ± 1 0-II
(n=4)
-/+
(n=2)
AD 2/9 76 ± 10 5 ± 2 VI ++/+++
Occipital cortex
Controls 1/4 87 ± 6 4 ± 2 0-III
(n=4)
-/++
(n=4)
AD 2/2 81 ± 13 5 ± 2 V/VI +++
table 1 : Characteristics of brain tissue samples
table 2 : Demographic and biochemical  characteristics of CSF samples for validation study
Controls AD DLB FTD
Males/Females (n) 19/11 10/20 17/0 13/5
Age (y) 68 ± 10 72 ± 9 72 ± 9 66 ± 8
MMSE 28 ± 2
(n=4)
21 ± 3
(n=26)
22 ± 8
(n=8)
20 ± 7
(n=13)
Aβ40 (pg/ml) 3905 ± 1348
(n=26)
5385 ± 2105*
(n=28)
3361 ± 1133 5619 ± 1931**
Aβ42 (pg/ml) 887 ± 332 505 ± 214*** 534 ± 205*** 763 ± 232
t-tau (pg/ml) 287 ± 107 732 ± 495*** 261 ± 141 438 ± 326
p-tau (pg/ml) 54 ± 18 110 ±  44*** 51 ± 19 74 ± 31
Dkk-3  (ng/ml) 1232 ± 477 1387 ± 722 1085 ± 369 1401 ± 825
Ratio Aβ42/Dkk-3 (pg/ng) 0.79 ± 0.30 0.44 ± 0.26*** 0.54 ± 0.26* 0.65 ± 0.29
Values are expressed as mean ± SD, except for gender distribution. MMSE: Mini mental state 
(not determined for all patients, as indicated); AD: Alzheimer’s disease; DLB: Dementia with 
Lewy bodies; FTD: Frontotemporal dementia; t-tau: total tau; p-tau: phosphorylated tau; n.a.: not 
applicable. Statistical significance versus controls was determined by ANOVA with Bonferroni’s 
post-hoc test; *p < 0.05, **p < 0.01, ***p < 0.001
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Mass spectrometry analysis of Aβ40-associated proteins
NanoLC-MS/MS analysis was performed using an EASY-nLC liquid 
chromatograph (Thermo Fisher Scientific) coupled online via a nano-
electrospray ion source (Thermo Fisher Scientific) to a 7T linear ion trap Fourier 
transform ion cyclotron resonance mass spectrometer (LTQ FT Ultra, Thermo 
Fisher Scientific). Instrument settings are further explained in Supplemental 
Experimental Procedures (Table S1). 
Mass spectrometric data files were searched using the database search 
program Mascot (Matrix Science Inc., USA, version 2.2). The database used 
for the searches consisted of the human RefSeq database (release 33) with 
addition of known contaminants such as trypsin. An in-house developed script 
was used to parse first-ranked peptides from the Mascot search HTML files and 
evaluate peptide and protein identifications. Validation criteria are described 
in Table S1.
Immunohistochemical staining
The following antibodies were used for immunohistochemistry; goat anti-
human Dkk-3 (R&D Systems, Minneapolis, USA), mouse monoclonal NAB 228, 
directed against Aβ (Sigma-Aldrich), rabbit polyclonal clone 40-4 anti-Aβ 
(gift from Dr. W.E. van Nostrand, Stony Brook, NY), mouse anti-Aβ40 clone G2-
10 (Merck Millipore) and either biotin-labeled horse anti-mouse antibodies 
or horse anti-goat antibodies (Vector Laboratories, Burlingame, CA, USA) 
or donkey anti-goat 488 Alexa, donkey anti-mouse 647 Alexa, donkey anti-
rabbit 594 Alexa or donkey anti-goat 594 (Life Technologies, Bleiswijk, the 
Netherlands) for secondary detection. All antibodies were diluted in PBS 
containing 1% bovine serum albumin (BSA), which also served as a negative 
control.
Cryosections (5 or 6 µm) were air-dried and fixed in acetone for 10 min. In 
the case of DAB staining, endogenous peroxidase activity was blocked using 
acetone containing 0.15% H2O2 for 5 min and sections were preincubated for 
30 min with 20% serum of the animal in which the secondary antibody was 
raised. Between incubation steps, sections were extensively washed using 
PBS. Subsequently, sections were incubated overnight at 4°C with primary 
antibodies and with secondary antibodies for 60 min at room temperature 
(RT). When DAB was used as a chromogen, sections were first incubated 
with an avidin-biotin complex solution for 45 min (Vector Laboratories) and 
subsequently staining was developed with DAB. Copper sulphate (0.5% in 
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saline) was used to intensify the DAB staining and haematoxylin to counterstain 
the surrounding tissue.
Antibody specificity controls were performed by pre-incubation of goat anti-
human Dkk-3 with a 10-fold excess of recombinant His-Dkk-3 (generous gift 
from R&D systems) for 1 hour at RT.
To detect fibrillar Aβ plaques, sections were stained with Thioflavin S (Sigma-
Aldrich) (1% w/v in distilled water) in the dark for 5 min. Subsequently, sections 
were incubated with 70% ethanol for another 5 min in the dark.
In the case of fluorescent staining sections were mounted with Dapi 
Fluoromount-G (SouthernBiotech, Birmingham, USA).
Cell culture
Human leptomeningeal smooth muscle cells (SMCs) were isolated from brain 
tissue obtained after autopsy as described previously [415, 416]. SMCs were 
cultured in Eagle’s modification of essential medium (EMEM), supplemented 
with 20% fetal calf serum (Lonza, Basel, Switserland), 10% human serum 
(Lonza), 1 ng/ml basic fibroblast growth factor and 2.5 μg/ml gentamycin at 
37°C in a humidified incubator under an atmosphere of 5% CO2. Cells were 
maintained in 75 cm2 culture flasks coated with fibronectin to support solid 
attachment of cells.
For cellular stimulation, SMCs were seeded on a 12-well plate in regular 
medium and cells were cultured until reaching confluence. Medium was 
replaced by serum-free EMEM containing 0.1% BSA for a minimum of 4 hours 
before stimulation with 12.5 µM Aβ40 or Aβ42 for 48 hours. After incubation, 
conditioned media were collected, centrifuged at 13,200 rpm for 10 min and 
resulting supernatants were stored at -20°C until ELISA analysis.
Controls AD
Males/Females (n) 9/11 10/10
Age (y) 65 ± 9 71 ± 6
MMSE 29 ± 1 (n=2) 19 ± 5 (n=14)
Dkk-3 80 ± 23 73 ± 16
table 3 : Demographic characteristics and Dkk-3 concentrations of serum samples
Values are expressed as mean ± SD, except for gender distribution. MMSE: Mini mental state 
(when available, as indicated); AD: Alzheimer’s disease
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ELISAs
Dkk-3 levels were measured using an assay from R&D Systems. CSF samples 
were diluted 5,000 times, serum samples 500 times and cell supernatants 10 
times in reagent diluent (R&D Systems). Samples were tested in duplicate. 
For all samples, Dkk-3 levels of diluted samples fell within the range of the 
standard curves (31.25 – 2000 pg/ml). For CSF measurements, mean intra-
assay coefficient of variation of 3 samples, all measured in eightfold, was 5.9% 
and mean inter-assay variation of 3 samples, all measured in duplicate in 4 
different assays, was 14.4%.
Additional CSF parameters were measured by ELISA methods according to 
manufacturers’ protocols; Aβ42, t-tau and p-tau levels were determined using 
assays from Fujirebio (Ghent, Belgium); Aβ40 was determined using an assay 
from Merck Millipore. 
SDS-PAGE and Western blotting
Hippocampus extracts of AD patients and control subjects (homogenized in 
carbonate buffer as described before [417]), containing 40 µg total protein 
or 2 µl of a pooled CSF sample, were separated on a 12% SDS-polyacrylamide 
Tris/Glycine gel. After electrophoresis, proteins were transferred to a PVDF 
membrane by western blotting. The membrane was blocked for 1 hour at RT 
with Odyssey blocking buffer (LI-COR, Lincoln, NE, USA) diluted 2 times in 
PBS and the membrane was then incubated overnight at 4 °C with goat anti-
human Dkk-3 antibody diluted 2,500x in blocking buffer. After washing with 
PBS/0.05% Tween-20, the membrane was subsequently incubated for 1 hour 
at RT with donkey anti-goat 680 Alexa antibodies (Life Technologies) and the 
labeled proteins were visualized using the Odyssey infrared imaging system 
(LI-COR).
Statistics
For ELISA results, CSF parameters with non-Gaussian distribution (Dkk-3, Aβ42 
and t-tau) were log-transformed to meet assumptions of normality. Differences 
between CSF parameter levels were determined by one-way analysis of 
variance (ANOVA) and by analysis of covariance (ANCOVA), with Bonferroni’s 
post-hoc test. Statistical analyses were performed using GraphPad PRISM 5 
software (San Diego, CA, USA) and SPSS software version 20 (Chicago, IL, USA).
Dkk-3 is a potential Aβ-associated protein
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Results
Identification of Aβ40-binding proteins by a proteomics approach
We conducted a discovery experiment with exogenous Aβ40 in CSF to detect novel 
AAPs. Since levels of Aβ in CSF are low, detection of proteins binding to endogenous 
Aβ was expected to be challenging. Therefore, we used synthetic Aβ40 in a quantity 
of approximately 50 times the endogenous levels as bait. We chose to use Aβ40 
because this is the most abundant Aβ peptide in CSF. In addition, we performed 
similar experiments with Aβ42, but these studies did not yield novel candidate Aβ-
binding proteins (data not shown).
Using LC-MS analysis, we identified 43 proteins that bound to Aβ40 in CSF. However, 
36 of these proteins were also detected after incubation with revAβ40, including 
the known AAPs clusterin and ApoE. We searched for proteins that were primarily 
detected with normal sequence Aβ40 and we selected the protein Dkk-3 for further 
analysis, which was the only protein detected in all 6 samples after baiting with 
Aβ40 but in only one sample as binding partner of revAβ40.
Dkk-3 expression in human hippocampus and cortex
To gain more insight into a putative role of Dkk-3 in AD, we investigated the 
expression and location of Dkk-3 in brain tissue. The Dkk-3 protein was detected 
in hippocampus extracts from AD and non-demented control patients using 
SDS-PAGE followed by western blotting (see Fig. 1a for a representative case 
on blot). In addition, both hippocampal and cortical tissue sections from AD 
patients and non-demented controls were stained for Dkk-3. Dkk-3 expression 
was mainly located in blood vessels (Fig. 1b, c), in the cytoplasm of neurons in 
the pyramidal cell layers (Fig. 1d) and occasionally in other neurons (Fig. 1e), 
both in AD patients and controls. Specificity of the Dkk-3 signal was verified by 
blocking with recombinant Dkk-3, which eliminated all signal (Fig. 1f ).
 Interestingly, in AD patients we detected co-localization of Dkk-3 with Aβ in 
senile plaques in the cortex and hippocampus (representative staining of serial 
hippocampus sections in Fig. 2a, b, c (Aβ) and Fig. 2d, e, f (Dkk-3)). In some 
regions of the tissue sections, co-localization was more intense (Fig. 2a+d, and 
b+e) than in other regions (Fig. 2c+f ). In addition, in 2 out of 7 control subjects 
we found sporadic Aβ plaques, which were also positive for Dkk-3, indicating 
co-localization does not solely occur in AD patients. 
To analyse Dkk-3 co-localization with Aβ in more detail, we performed co-staining 
experiments with Thioflavin S, which marks fibrillar Aβ in dense core plaques but not 
in diffuse Aβ plaques. We observed that Dkk-3 co-localized with both fibrillar and 
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non-fibrillar Aβ plaques (Fig. 3), although in some cases Thioflavin S-positive plaques 
stained more intensely for Dkk-3 than Thioflavin S-negative plaques (Fig. 3a).
In addition, we performed co-staining experiments with an Aβ40-specific 
antibody. Aβ40 was very sparsely present in plaques and in some blood vessel 
walls with amyloid deposits. Examination of the Aβ40-positive plaques confirmed 
that Dkk-3 did not solely co-localize with Aβ40-positive plaques (Fig. 4a-c), but also 
with Aβ40-negative plaques (Fig. 4d-f ). Because Dkk-3 was strongly expressed in 
vessels, we studied possible co-localization of Dkk-3 with Aβ40 in CAA. Although 
Dkk-3 was expressed in CAA, no differences were observed in the staining 
pattern for Dkk-3 between Aβ-positive and Aβ-negative vessels (Fig. 4 g-h). In 
addition, we investigated the secretion of Dkk-3 by blood vessel associated cells, 
i.e. leptomeningeal smooth muscle cells (SMCs). We found that SMCs produced 
measurable amounts of Dkk-3. However, after stimulation with Aβ40 or Aβ42, we 
could not demonstrate any influence of either peptide on Dkk-3 secretion (data 
not shown). 
Dkk-3 is a potential Aβ-associated protein
Fig. 1) Dkk-3 in brain tissue. Hippocampus extract from a representative AD case, containing 
40 µg of total protein, was separated by SDS-PAGE and analyzed by western blot and a band of 
approximately 65 kDa was visible (a). Hippocampus (b, d-f ) and cortex (c) from representative 
AD cases immunostained for Dkk-3. Staining was found in larger blood vessels (b), microvessels 
(c), pyramidal neurons (d) and occasionally in other neurons (e). Non-demented controls showed 
similar staining in these areas. Blocking with recombinant Dkk-3 eliminated all signal (f ). Counter 
staining was performed with haematoxylin. Scale bar = 50 µm.
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Dkk-3 levels in CSF and serum
In order to investigate whether Dkk-3 can function as a biomarker for AD, we 
measured the protein levels in body fluids. We found abundant presence of Dkk-3 
in CSF, easily detected both by ELISA (Fig. 5a) and by western blotting (Fig. 5a inset). 
We did not detect significant differences in CSF Dkk-3 levels between AD (1387 ng/
ml ± 722), DLB (1085 ng/ml ± 369) and FTD patients (1401 ng/ml ± 825) and non-
demented controls (1232 ng/ml ± 477) (Fig. 5a). Dkk-3 correlated weakly with age 
(all samples: r=0.32, p<0.01) and total protein levels (all samples: r=0.32, p<0.01). The 
mean age of the AD and control group were significantly different, however when 
age was included as a covariate, Dkk-3 levels remained similar in both groups.
As expected, Aβ42 was decreased in CSF of AD patients compared to controls 
(p<0.001; AUC 0.88) (Table 2). Next, we investigated whether the ratio Aβ42/Dkk-3 
might enhance discriminative power, as described previously [418]. However, we 
observed that this ratio resulted in a lower discriminating power (AUC 0.82) than 
Aβ42 alone (Table 2).
CSF Aβ40 levels were increased in AD and FTD, but not in DLB patients (Table 
2). Interestingly, CSF Dkk-3 levels were positively correlated with Aβ40 levels in 
all groups (all samples: r=0.69, p<0.0001) (Fig. 5c). Only a weak correlation was 
found between CSF Dkk-3 and Aβ42 levels (all samples: r=0.23, p<0.05) (Fig. 
5d).
T-tau and p-tau levels were increased in AD patients compared to non-demented 
controls. CSF Dkk-3 levels correlated with t-tau (all samples: r=0.48, p<0.0001), 
but only in the control and AD groups (r=0.66 and 0.68 respectively, p<0.0001). 
Similarly, p-tau levels correlated with Dkk-3 (all samples: r=0.50, p<0.0001), only 
in the AD group (r=0.68, p<0.0001) and in the control group (r=0.54, p<0.01).
Finally, we measured Dkk-3 concentrations in serum. Dkk-3 levels were 
approximately 18 times lower in serum than in CSF, suggesting that CSF Dkk-3 
is predominantly of cerebral origin. We observed similar levels of Dkk-3 in serum 
from AD patients (73 ng/ml ± 16) and non-demented controls (80 ng/ml ± 23) 
(Fig. 5b). Since mean age differed in the AD and control group, age was included 
as a covariate in the statistical analysis. However, this did not affect the results.
Discussion
In this study we investigated the secreted Wnt family protein Dkk-3 as a 
possible AAP and biomarker in AD. Our main findings are: (1) Dkk-3 co-localizes 
with Aβ in senile plaques, (2) Dkk-3 is expressed in cerebral blood vessel walls 
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and leptomeningeal SMCs secrete Dkk-3 in vitro, (3) Dkk-3 levels in CSF are 
comparable in AD, DLB, FTD and controls and (4) Dkk-3 levels in CSF are highly 
correlated with CSF Aβ40 and tau levels.
From baiting experiments followed by mass spectrometric analysis, we detected 
Dkk-3 as a potential binding partner for Aβ40. To support this observation, we 
investigated the presence of Dkk-3 in brain tissue. To our knowledge we are 
the first to study the presence of Dkk-3 in AD brains. We showed that Dkk-3 co-
localizes with Aβ in plaques, both in hippocampal and cortical brain areas of 
AD patients. Specific staining for Aβ40 demonstrated that Dkk-3 did not solely 
deposit with Aβ40 positive, but also with Aβ40 negative plaques, that consist 
mainly of Aβ42 [391]. In addition, we demonstrated the presence of Dkk-3 in 
pyramidal cells of the hippocampus, both in controls and AD patients. This is in 
accordance with previous data obtained with control cases [418, 419].
Furthermore, we observed that Dkk-3 is localized in cerebral blood vessels, 
with a similar intensity and frequency in AD and non-demented control 
tissue. In addition, we found Dkk-3 expression in CAA, but at a similar staining 
intensity as in unaffected vessels. The distinct Dkk-3 staining in blood vessels 
is not in line with previous studies on Dkk-3 protein and mRNA localization in 
the brain, as those studies did not report Dkk-3 staining in vessels [418-420]. 
Fig. 2) Co-localization of Dkk-3 with Aβ in senile plaques in hippocampus. Representative AD 
cases with clear co-localization immunostained for Aβ (a,b) and Dkk-3 (d,e) and an AD case 
with less intense co-localization of Aβ (c) and Dkk-3 (f ). Arrows indicate co-localization in senile 
plaques. Scale bar = 50 µm.
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However, upregulation of Dkk-3 in blood vessels has been demonstrated in 
and adjacent to tumours originating from a variety of different tissues [421]. 
More specifically, Dkk-3 has been demonstrated in tumour endothelium and 
it may function to support capillary formation [420]. These data indicate that 
Dkk-3 might be generated and secreted by vascular cells. In accordance with 
this, we demonstrated that vascular leptomeningeal SMCs secreted Dkk-3 in 
vitro, which may implicate that these cells are a potential source of the Dkk-3 
observed in blood vessels. Stimulation of these cells with either Aβ40 or Aβ42 
did not result in increased secretion, indicating that Aβ probably does not 
influence the levels of secreted Dkk-3 in blood. Indeed, we demonstrated that 
Dkk-3 levels in serum were equal in AD and control groups, supporting the 
finding that Dkk-3 secretion is not affected by Aβ levels. Previously, a positive 
correlation of plasma Dkk-3 levels with age have been reported [422]. In this 
Fig. 3) Co-localization of Dkk-3 with Aβ in Thioflavin S-positive and -negative plaques. Cortex 
from an AD case fluorescently immunostained for Dkk-3 (red; a), Thioflavin S (green; b) and total 
Aβ (blue; c). Dkk-3 co-localizes both with Thioflavin S-positive plaques (arrowheads) and with 
Thioflavin S-negative plaques (arrows). Panel d represents an overlay of all three staining. Scale 
bar = 50 µm.
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Fig. 4) Presence of Dkk-3 in Aβ40-positive and Aβ40-negative senile plaques and blood vessels. 
Hippocampus from an AD case fluorescently immunostained for Dkk-3 (green; a, d, g) total Aβ 
(red; b,e) and Aβ40 (blue; c,f,h). Dkk-3 co-localizes both with Aβ40-positive plaques (a-c) as with 
Aβ40-negative plaques (d-f). Dkk-3 was present both in vessels that contained Aβ deposits and 
in vessels that were negative for Aβ40 (g-h). Total Aβ was stained with rabbit polyclonal 40-4 
antibody and Aβ40 with mouse monoclonal G2-10. Arrows indicate Aβ40-negative plaques/
vessels, arrowheads indicate Aβ40-positive plaques/vessels. Scale bars are 50 µm.
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study, however, we did not find such a correlation in serum.
In addition, it has been reported before that epithelial cells in the choroid 
plexus strongly express Dkk-3, which may thus be a potential source of 
the protein in CSF [418]. Indeed, we showed high levels of Dkk-3 in CSF, 
approximately 18 times higher than in serum. However, Dkk-3 CSF levels did 
not differ between AD, DLB and FTD patients and controls. This is in contrast 
with a previous report, which described slightly elevated levels of Dkk-3 in 
CSF of AD patients compared to healthy controls, but not in patients with mild 
cognitive impairment. Furthermore, an increased diagnostic differentiation 
power was reported for CSF Aβ42/Dkk-3 ratio compared to Aβ42 solely [418]. 
Fig. 5) Dkk-3 in body fluids. (a) Levels of Dkk-3 in CSF from AD, DLB and FTD patients and 
controls are similar. Inset: Dkk-3 is abundantly present in CSF. Two ul of CSF was analyzed 
by western blotting and a clear band of ~65 kDa was visible.
(b) Levels of Dkk-3 in serum from AD patients and controls are similar. (c) Strong correlation 
between CSF Aβ40 and Dkk-3 levels, in all samples combined (p<0.0001 and r=0.69). 
Correlations in each study group: AD (p<0.0001 and r=0.80), DLB (p<0.05 and r=0.51), FTD 
(p<0.01 and r=0.70) and controls (p<0.01 and r=0.54). (d) Correlations between CSF Aβ42 
and Dkk-3 levels were weak, in all samples combined (p<0.05 and r=0.23).
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We also compared the discriminative power of the ratio of Aβ42/Dkk-3 with 
Aβ42 and found a higher AUC for Aβ42 compared to Aβ42/Dkk-3. Therefore, we 
could not replicate the previously suggested diagnostic values of Dkk-3, which 
might be attributed to biological variation between samples or different ELISA 
detection methods.
Interestingly, comparison of CSF Dkk-3 levels with Aβ40 and Aβ42 revealed a 
strong positive correlation with Aβ40 and only a weak correlation with Aβ42. 
In addition, we showed correlations between Dkk-3 and t-tau and p-tau, 
particularly in the AD and control groups. These latter correlations have been 
reported before [418]. The observation that Dkk-3 correlates with Aβ40 levels 
in AD patients, may be related to the association of Dkk-3 with blood vessels 
and CAA. 
Dkk-3 is known as a signalling protein in the Wnt pathway, which is involved 
in, among others, cell proliferation, differentiation, adhesion and apoptosis. 
Although the precise function of Dkk-3 within these pathways is still unknown 
and reports are sometimes contradicting, Dkk-3 most likely possesses a Wnt 
inhibiting function and induces apoptosis as demonstrated, for instance, in 
cancer cells [421, 423]. One assumed toxic mechanism in AD is the induction of 
apoptosis by Aβ oligomers, mediated by e.g. disruption of calcium homeostasis 
and production of reactive oxygen species [424]. It can be speculated that 
enhanced production and secretion of Dkk-3 in the proximity of senile plaques 
is an additional mechanism that induces apoptosis in AD.
In addition, evidence is accumulating that Wnt signalling interferes with 
pathogenic AD pathways, as some Wnt pathway components have been 
described to be altered in AD [425, 426]. In the canonical Wnt pathway, 
Wnt proteins act via the Frizzled receptor to induce the β-catenin protein 
by inhibition of its destruction. It has been shown that β-catenin levels are 
decreased in the brains of familial AD patients carrying a presenilin-1 mutation, 
which potentiates neuronal susceptibility for Aβ-induced apoptosis [427]. 
Another study showed that Aβ fibrils induce destabilization of β-catenin both 
in vitro in neuronal culture and in vivo in rat hippocampus [428]. These findings 
of decreased β-catenin  levels in AD may be explained by the observation that 
Aβ binds to the Frizzled receptor and as such is able to inhibit the Wnt signaling 
pathway [429]. Low density lipoprotein receptor-related protein (LRP) 5 and 
6 are co-receptors of Frizzled in the Wnt pathway [430]. A family member of 
LRP5/6, LRP1, is a well-known receptor that binds to Aβ and may be involved in 
the transport of Aβ across the blood-brain-barrier [431-433]. In addition, LRP1 
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may play an important role in the processing of the amyloid precursor protein 
(APP) to Aβ [432], and is thus in more than one way strongly implicated in AD 
pathology. However, whether LRP1 is functionally involved in the Wnt pathway 
is not well established, as to our knowledge, only one study demonstrated that 
LRP1 might interfere in the Wnt pathway. In this study, it was shown using a 
minireceptor construct of LRP1, that LRP1 binds the Frizzled receptor, resulting 
in repression of Wnt signaling [434]. Vice versa, for its family members LRP5 
and LRP6 there is no evidence to support their role in AD pathology, since an 
interaction with Aβ has not been demonstrated for these receptors.  Finally, 
other links between the Wnt pathway and AD pathology have been proposed. 
Most important is Dkk-1, a family member of Dkk-3 that shares 39% homology 
with Dkk-3 and homology of two highly conserved cysteine rich domains [435]. 
Dkk-1 is also a Wnt pathway inhibitor and has been linked to AD in multiple 
ways [425]. For instance, the protein was upregulated in degenerating neurons 
from AD patients and co-localized with neurofibrillary tangles and dystrophic 
neurites [436]. In transgenic mice expressing familial AD mutations, Dkk-1 was 
elevated in hippocampus and cortex and co-localized with p-tau-containing 
neurons and neurons surrounding Aβ plaques [437].
Besides a proposed role for Dkk-3 in the Wnt pathway, recent evidence is 
pointing towards an additional function for Dkk-3 in the immune system. 
It was suggested that Dkk-3 is involved in the activation, differentiation 
and tolerance of T lymphocytes [438, 439] and the function and fate of B 
cells [440]. In addition, Dkk-3 was upregulated in a mouse model for brain 
inflammation [438]. Interestingly, in AD the immune system is believed to be 
disregulated and inflammatory responses are observed in the proximity of Aβ 
deposits [66, 441, 442]. Glial cells are attracted to the sites of senile plaques 
and pro-inflammatory factors are upregulated in AD brains [63, 443]. However, 
a potential role for Dkk-3 in the AD-related inflammation pathology remains 
speculative, because Dkk-3 seems to be implicated in the adaptive immune 
system, mediated by lymphocytes, while in AD disregulation of the innate 
immune system is involved. These observations, together with our findings, 
suggest that Dkk-3 may appear as an AAP in AD, possibly as a consequence of 
disturbed Wnt signalling pathways or immune response. However the exact 
role of Dkk-3 in AD remains obscure. Further investigations that examine 
the role of Dkk-3 in complex systems, for instance involving cell culture or 
transgenic mice, are desired to shed more light on this.
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nanoLC settings
Column Trap column: Acclaim PepMap100, 5 μm, 100 Å, 300 μm i.d. × 5 mm
Analytical column: 15 cm fused silica emitter (New Objective, Tip: 8 +/- 1 μm, ID: 100 μm)
packed with 3 μm Reprosil C18 beads (Dr. Maisch)
LC method Gradient (total 76 minutes):
- From 0% buffer B to 5% buffer B in 1 minute 
- From 5% buffer B to 35% buffer B in 60 minutes 
- From 35% buffer B to 80% buffer B in 5 minutes
Column washing: 
- 80% buffer B for 10 minutes 
Buffer A 0.1% formic acid
Buffer B 0.1% formic acid in acetonitrile
Flow rate 300 nl/min
MS settings
Data-dependent mode Sequencing of the four most abundant ions
Dynamic exclusion 600 s, 1 repeat count, 1.5 amu precursor mass tolerance
Mass range FT ICR MS 350-2,000 m/z
Resolution FT ICR MS 100,000
Charge state rejection 1+, 4+ and unnassigned charge states
Database search settings (Mascot)
Enzymatic cleavage Trypsin
Precursor ion tolerance 15 ppm
Fragment ion tolerance 0.5 Da
#13C 1
Charge state 1+, 2+ and 3+
Fixed modification Carbamidomethylation (C)
Variable modifications Oxidation (M), Acetyl (Protein N-terminus)
Supplemental Experimental Procedures
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Validation criteria
Single peptide hits Mascot peptide score ≥ 50
Modified delta score* ≥ 10
Maximum amount of variable modifications = 1
Proteins identified > 1 peptide Mascot peptide score ≥ 30
Modified delta score* ≥ 10
Maximum amount of variable modifications = 3
*The modified delta score is derived from the Mascot delta score and denotes the difference in 
score between the first-ranked peptide hit and the next peptide hit with a different sequence 
compared to the first-ranked peptide hit
table S1 : List of the nanoLC-MS/MS measurement settings, database search settings and 
validation criteria
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Abstract
Aims. In Alzheimer’s disease (AD), the most important genetic risk factor is 
the gene encoding for apolipoprotein E (ApoE). In addition, the ApoE protein 
influences the aggregation and clearance of the amyloid-β protein (Aβ). The 
two proteins interact with each other and form complexes. Previous studies 
showed that the complex formation is dependent on the ApoE isoform. 
The ApoE ε4 isoform forms weaker complexes and is also the isoform that 
increases the risk of developing AD. A change in the levels of Aβ/ApoE 
complex may therefore be associated with AD.  We aimed to develop a 
method to quantify these complexes and apply this method to investigate the 
potential of Aβ/ApoE complexes as biochemical biomarker for AD in serum. 
Methods. We designed and characterized an enzyme-linked immunosorbent 
assay (ELISA) that specifically detects Aβ/ApoE complexes. We applied 
this ELISA to quantify levels of Aβ/ApoE complexes in serum samples of 
AD patients or patients with frontotemporal dementia, dementia with 
Lewy bodies and vascular dementia and of non-demented controls. 
Results. The ELISA specifically detected synthetic Aβ/ApoE 
complexes, but not the individual proteins. Furthermore, Aβ/ApoE 
complexes were successfully detected in serum of all patients, 
but levels of these complexes were similar in all dementia groups. 
Conclusion. In conclusion, this study does not provide evidence that Aβ/
ApoE complexes are a serum biomarker to differentiate the various dementia 
subtypes.
Introduction
An estimated 36 million people suffered of dementia in 2010 worldwide, and 
these numbers are predicted to double every 20 years [444]. Although clinical 
diagnostic criteria for each of the major forms of dementia, such as Alzheimer’s 
disease (AD), frontotemporal dementia (FTD), dementia with Lewy bodies 
(DLB) and vascular dementia (VaD) have been defined [106, 369, 399]; the 
assignment of an individual patient to a specific clinical dementia syndrome 
remains a challenge due to the lack of exact biomarkers. Biochemical markers 
such as the quantification of the proteins amyloid-β42 (Aβ42), total tau and 
phosphorylated tau in the cerebrospinal fluid (CSF), or molecular ligands 
for positron emission tomography imaging such as Pittsburgh compound B 
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[445] may support the diagnosis of AD. However, although these biomarkers 
may accurately discriminate AD patients from non-demented controls, 
the differentiation of AD from other dementia syndromes remains more 
challenging [386, 387].
AD is the most common type of dementia with the majority of cases developing 
late-onset AD. According to the amyloid cascade hypothesis, Aβ is the main 
factor that causes development of the disease. The protein exists in different 
isoforms with 38-43 amino acids, of which Aβ40 is the most common isoform and 
Aβ42 is most prone to form aggregates that are toxic for neurons. Aβ aggregates 
accumulate in the brain with age, which might be caused by a decrease in Aβ 
clearance [41]. Except for age, the most important genetic factor that increases 
the risk of developing AD, is the ε4 allele of apolipoprotein E (ApoE) [11]. This 
34 kDa protein occurs in three isoforms, i.e. ApoE2, -E3 and -E4. The primary 
function of ApoE is transport of lipoproteins and cholesterol in the circulation, 
but the protein also interacts with Aβ, influences Aβ clearance from the brain, 
e.g. via interaction with low-density lipoprotein receptor-related protein 1, 
which is the major receptor for transport of Aβ across the blood-brain barrier, 
and may stimulate Aβ aggregation and thus its cerebral accumulation. Effects 
of ApoE are isoform-dependent, and ApoE4 is more strongly associated with 
senile plaques, toxic Aβ oligomers, and impaired clearance of Aβ [41, 104, 
446, 447]. Several studies showed that the two proteins bind to each other 
and form complexes, the strength of which is dependent on the ApoE isoform 
[95, 448, 449]. In general, endogenous ApoE4 forms weaker bonds with Aβ 
than ApoE3 [10]. A weaker interaction of Aβ with the ApoE4 isoform, thus 
less complex formation, might subsequently lead to an increase in free Aβ 
levels and aggregation, which might be a reason why ApoE4 poses a greater 
risk for disease development. Supporting this hypothesis, levels of Aβ/ApoE 
complexes are decreased in post-mortem CSF of AD patients carrying the ε4 
allele versus non-ε4 carriers [99]. In the same study it is also reported that 
complex levels are decreased in human synaptosomes of the parietal cortex 
and in post-mortem CSF of AD patients compared to controls, and therefore 
Aβ/ApoE complexes compose an interesting biomarker for AD. Since Aβ is 
cleared from the brain and transported towards the blood [450] and both 
Aβ and ApoE are present in serum as well, we hypothesized that Aβ/ApoE 
complexes also appear in serum.. If so, and if its levels are different in AD 
compared to other dementias, the Aβ/ApoE complex could serve as a novel, 
blood-based biomarker for AD. To investigate the biomarker potential of 
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Aβ/ApoE complexes, we designed an enzyme-linked immunosorbent assay 
(ELISA) for specific detection of those complexes. We demonstrate that this 
assay detects synthetic Aβ/ApoE complexes in a concentration-dependent 
manner, but not the individual proteins. We applied this assay to measure the 
levels of Aβ/ApoE complexes in serum of patients with AD, FTD, DLB, VaD and 
non-demented controls.
Materials and Methods
Subjects
Serum from 20 AD, 26 FTD, 25 DLB, 22 VaD patients, and 17 non-demented 
controls (table 1) was obtained at the Radboud University Medical Center, 
Nijmegen. Patients with AD, FTD, DLB or VaD had been tested by clinical and 
neuropsychological examination, and routine laboratory investigation. Dementia 
was diagnosed by a multidisciplinary team using the following diagnostic 
criteria: NINCDS-ADRDA criteria for AD [366], NINDS-AIREN criteria for VaD 
[369], and published consensus criteria for DLB [399] and FTD [368]. Cognitive 
function had been assessed by mini-mental state examination (MMSE). Control 
subjects had been assessed for neurological disorders but were either diagnosed 
without a neurological disorder or with a systemic disease without neurological 
manifestations. Serum samples were obtained as part of the clinical diagnostic 
work-up of a patient. Patients were informed that their data, including serum, 
could be used for further scientific purposes and were given the option to object 
against this use, in which case their data were not used. Serum was collected by 
vena puncture, and was, after routine investigation, centrifuged, aliquoted and 
stored at -80°C within two hours after collection. Left-over samples were pooled 
and stored at -20°C before use for assay validation purposes.
Antibodies and peptides
For detection of Aβ/ApoE complexes on Western blot we used monoclonal 
mouse-anti-apoE clone E6D7 (Abcam, Cambridge, UK) and polyclonal rabbit-
anti-Aβ 40-4 (kindly provided by Dr. van Nostrand; Stony Brook, NY, USA). As 
secondary antibodies, we used Alexa 680-labelled goat-anti-mouse IgG (Life 
Technologies, Carlsbad, CA, USA), and IRDye800-labelled goat-anti-rabbit IgG 
(Rockland, Limerick, PA, USA). For quantification of Aβ/ApoE complexes  by ELISA, 
goat-anti-ApoE (Meridian, Memphis, TN, USA) was used as capture antibody, 
and mouse monoclonal antibody clone Nab-228 (Sigma-Aldrich, St. Louis, MO, 
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USA), which is directed against Aβ, was used as detection antibody. Antibody 
Nab-228 was biotinylated using the Biotin Label Kit – NH2 (Abnova, Taipei City, 
Taiwan). Streptavidin conjugated to multiple horse-radish peroxidases (SA-
polyHRP; Pierce, Rockford, IL, USA) was used to detect biotinylated antibodies. 
Synthetic Aβ42 was purchased from 21
st Century Biochemicals (Marlboro, MA, 
USA), and was dissolved in hexafluoroisopropanol (HFIP) (Sigma-Aldrich) to 
bring it in a monomeric state and dried overnight by air. Peptide films were 
stored at -80°C. Prior to use, the peptide films were dissolved in dimethyl 
sulfoxide at a concentration of 5 mM. Recombinant human ApoE3 protein was 
obtained from Fitzgerald (North Acton, MA, USA).
Preparation of Aβ/ApoE complex
Synthetic Aβ42 (50 µM) and recombinant ApoE3 (500 nM) were diluted and 
mixed in phosphate-buffered saline (PBS; Roche, Mannheim, Germany). The 
mixtures were incubated at 37°C for 24 hours, and stored at -20°C until further 
use.
Detection of Aβ/ApoE complexes by Western Blot
Aβ/ApoE complexes, or samples containing only Aβ or ApoE, were mixed 
3:1 with non-reducing sample buffer and incubated at 37°C for 15 min. 
Samples were separated on 12% Tris-glycine gel for SDS-PAGE and proteins 
were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, 
Billerica, MA, USA) which was subsequently blocked with Odyssey Blocking 
Buffer (LI-COR Biosciences, Lincoln, NE, USA), 1:1 diluted in PBS, for 1 h at 
room temperature. The PVDF membrane was incubated with E6D7 antibody 
(dilution 2500x, over-night at 4°C), washed with PBST (PBS, 0.05% Tween-20) 
and incubated with the Alexa 680-labelled goat-anti-mouse IgG (dilution 
5000x, for 1 h at room temperature). Again, the membrane was washed and 
subsequently incubated with antibody 40-4 (dilution 2000x, for 1 h at room 
temperature). After washing, the membrane was incubated with a IRDye800-
labelled goat-anti-rabbit IgG (dilution 10,000x, for 1 h at room temperature). 
All antibodies were diluted in blocking buffer. Protein bands were visualized 
using the Odyssey Infrared Imaging System (LI-COR Biosciences).
Detection of Aβ/ApoE complexes by ELISA
An ELISA was developed to quantify Aβ/ApoE complexes in serum. Goat-
anti-ApoE antibody was diluted to 0.33 µg/ml in PBS and coated on a Nunc 
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MaxiSorp flat-bottom 96-well plate (eBioscience Inc; San Diego, CA, USA) 
over-night at 4°C. Subsequently, and after each incubation step, the plate was 
washed 5 times with PBST using a Tecan Hydroflex plate washer (Männedorf, 
Switzerland). The plate was blocked with 200 µl Odyssey Blocking Buffer per 
well, for 2 h at room temperature. Next, the synthetic Aβ/ApoE complex (used 
as a standard) was serially diluted in sample diluent (obtained from the hTau 
Innotest, Fujirebio, Ghent, Belgium) to concentrations that corresponded to 
ApoE3 concentrations of 0.66 - 42.5 ng/ml. Serum samples were serially diluted 
Fig. 1) Detection of Aβ/ApoE protein complex by using Western Blot.  
Proteins (ApoE3  and Aβ42) are separated on a 12% SDS-PAGE gel, and the blot is stained with 
antibodies directed against ApoE (green) and Aβ (red). ApoE3 is visible in lane 1 and 3 (open 
arrow). Aβ42 is visible in lane 2 and 3 mainly as a band with MW <10 kDa. Aβ/ApoE complex is 
visible in lane 3 with MW ~42 kDa (black arrow); the intensity of the red signal in this figure 
overshadows the green signal. In addition, complexes with higher MW are detected. Key: ApoE3 = 
apolipoprotein E3, Aβ42 = amyloid-β 42, MW = molecular weight
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in sample diluent for assay verification purposes, and 2x for final analysis. As 
negative controls, a zero-standard (buffer), and antigen-solutions containing 
either only ApoE3 or Aβ42 (concentrations corresponding to the highest 
standard concentration) were used. Samples were incubated for 2 h at room 
temperature on a shaking device (600 rpm). Then, the biotinylated detection 
antibody Nab-228 was added at a 250x dilution in PBST with 0.1% bovine 
serum albumin (BSA; Sigma-Aldrich) and incubated at room temperature for 1 
Control AD FTD DLB VaD p-value1
Number of 
patients
17 20 25 25 22
ApoE genotype
(non-ε4 carrier/
ε4 carrier)2
2/2 5/11 11/7 6/6 13/3
Gender (m/f) 8/9 10/10 17/8 19/6 15/7 NS (p = 0.23)
Mean age 
(years)3
64.6 ± 10 71 ± 6.2 67.3 ± 8.3 72.9 ± 9 77.6 ± 6.3 p < 0.0001
Disease duration 
(months)3
NA 31.1 ± 33.4 17.5 ± 32.4 15.4 ± 18.3 24.7 ± 26.9 NS (p = 0.54)
MMSE score3 NA 18.8 ± 5.1 21.9 ± 5.7 18 ± 8.1 16.6 ± 4.2 NS (p = 0.07)
Aβ/ApoE serum 
levels
(ng/ml of 
ApoE input for 
standards)
28.5 ± 40.4 19.6 ± 17.3 14.9 ± 9 16.0 ± 13.0 21.6 ± 9.6 NS (p = 0.24)
table 1 : Group characteristics 
Values are expressed as means ± standard deviations. 1Gender differences between groups 
were determined using Chi-square test. Mean age of groups was compared using ANOVA and 
Bonferroni’s post-hoc test for multiple comparison. Disease duration, MMSE score, and Aβ/ApoE 
complex levels were compared between groups using Kruskal-Wallis test and Dunn’s post-hoc 
test for multiple comparison. 2ApoE ε4 carriers carried either one or two ε4 alleles.  3At the time 
of lumbar puncture. Disease duration data was not available for six AD, eleven FTD, fourteen DLB 
and fifteen VaD cases. The MMSE score had not been determined for six AD, eleven  FTD, sixteen 
DLB and eleven VaD cases. Key: AD = Alzheimer’s disease; FTD = Frontotemporal dementia; DLB 
= Dementia with Lewy bodies; VaD = Vascular Dementia; MMSE = mini mental state examination; 
NA = not applicable; NS = not significant; Aβ = Amyloid β; ApoE = apolipoprotein E
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h on a shaking device (600 rpm). Subsequently, the plate was incubated with 
100 ng/ml SA-polyHRP for 30 min at room temperature while shaking (600 
rpm). Finally, 3,3’,5,5’-Tetramethylbenzidine substrate (Sigma-Aldrich) was 
added for color generation. The reaction was stopped with 1N H2SO4 and 
signals at OD450 nm were measured using a Tecan plate reader. 
Fig. 2) Validation of the ELISA for detection of Aβ/ApoE complexes.  
(A) Standard curve of synthetic Aβ/ApoE complexes. Samples were measured in duplicate. The 
Aβ/ApoE complex concentrations are depicted as the corresponding ApoE input concentrations. 
(B) Mean (with standard deviation) of the signal obtained in five independent experiments using 
Aβ/ApoE complexes (complex), the ApoE protein only (ApoE), the Aβ42 peptide only (Aβ), buffer 
only (no antigen) or omission of the capture antibody when assaying the complex (no capture)  
in ELISA. (C) Mean (with standard deviation) signal of Aβ/ApoE complexes in undiluted (100%), 
two times (50%), four times (25%) and eight times (12.5%) diluted pooled sera. Samples were 
measured in triplicate. (D) ELISA signal of Aβ/ApoE levels in pooled, undiluted or two times 
diluted serum, which were either undepleted (closed dots) or depleted (open dots) for ApoE and 
Aβ/ApoE complexes with anti-ApoE-coated beads. Key: OD450 = optical density at 450 nm.
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Depletion of serum from Aβ/ApoE complexes
Protein A/G plus agarose beads (50 µl) (Thermo Scientific) were washed 3 
times with 10 mM sodium acetate (NaAc) at pH 5.0 and each time centrifuged 
at 2500 rcf for 1 min. Then, beads were incubated with 5 µl goat-anti-ApoE 
(1 mg/ml) in NaAc for ~16 h at 4°C while rotating. Next, beads were washed 
3 times with PBS and resuspended in 100 µl serum. Serum was depleted for 
~16 h at 4°C with constant rotating, after which samples were centrifuged and 
supernatant (depleted serum) was analyzed in the Aβ/ApoE ELISA.
Data analysis
The limit of detection (LOD) of the Aβ/ApoE ELISA was calculated as the 
mean of 18 replicates of the zero standard plus three times the standard 
deviation. Intra-assay variation was determined from 2 samples measured 3 
times, and inter-assay variation from 3 samples, which were measured on 3 
different occasions. All samples were measured in duplicates. Levels of Aβ/
ApoE complexes are depicted as concentrations of ApoE in the samples. Three 
serum samples were measured on each plate and were used to correct for 
inter-plate variability. Statistics were performed in Graph Pad Prism version 
5 (La Jolla, CA, USA), and groups were compared by Kruskal-Wallis test and 
Dunn’s post-hoc test for multiple comparison. P-values less than 0.05 were 
considered significant. 
Results
Aβ/ApoE complex formation
Successful formation of the Aβ/ApoE complex was confirmed by Western 
blotting. ApoE3 was detected as a single band at the predicted molecular 
weight (MW) of ~34 kDa (figure 1, lane 1). Aβ42 was mainly visible as monomers 
(~4.5 kDa) (figure 1, lane 2). Upon co-incubation of both proteins, an additional 
band at ~42 kDa, the expected size of an Aβ/ApoE complex, appeared, that 
was detected by both the anti-Aβ and anti-ApoE antibodies (figure 1, lane 3). 
Characterization of the ELISA to detect the Aβ/ApoE complexes
An ELISA was designed to specifically detect the synthetic Aβ/ApoE complexes. 
The ELISA was validated for its suitability and specificity to also detect Aβ/ApoE 
complexes in serum. To generate a standard curve, we used synthetic Aβ/ApoE 
complex at different dilutions (figure 2A).  The assay was linear (r = 0.99) at 
Serum levels of complexes of Aβ and ApoE
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concentrations of the complex which corresponded to an ApoE3 concentration 
of 0.66-42 ng/ml. The limit of detection was calculated at concentrations of the 
complex which corresponded to an ApoE3 concentration of 3.5 ng/ml. Mean 
intra-assay coefficient of variation (CV) was 4%, and mean inter-assay CV was 20%. 
Specificity of the signal was determined by testing several negative controls. The 
signal was reduced to control levels (when no antigen was added) if only ApoE or Aβ 
were added instead of the protein complex or if the capture antibody was omitted 
(figure 2B), showing that the assay specifically measures Aβ/ApoE complexes. 
Different serum dilutions were analyzed in the ELISA to determine the optimal 
dilution for quantification of Aβ/ApoE complexes. At a two times dilution, 
levels of Aβ/ApoE complexes were measured in the linear part of the standard 
curve (figure 2C). To further determine the specificity of the ELISA for Aβ/ApoE 
in serum, we depleted pooled serum samples (either undiluted or diluted 
twice in sample diluent) for ApoE and Aβ/ApoE complexes. After depletion, the 
obtained signal for the Aβ/ApoE complexes was significantly reduced (figure 
2D). The overall efficiency to deplete the Aβ/ApoE complexes from serum was 
between 50-80%.
Fig. 3) Quantification of Aβ/ApoE complexes in serum samples of dementia patients and non-
demented controls. 
Scatterplot of Aβ/ApoE complex levels in controls, AD, FTD, DLB and VaD patients, depicted as 
corresponding ApoE input levels that has been used for in vitro preparation of the standard. 
Horizontal lines represent mean values.
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Quantification of Aβ/ApoE complexes in serum of demented
and non-demented patients
Samples were matched for gender and disease duration. Age was significantly 
different between groups (p < 0.0001, table 1). Mean Aβ/ApoE protein complex 
levels in serum from non-demented controls were 26.7 ± 40.3 ng/ml (table 1, 
figure 3). Mean Aβ/ApoE levels in serum of AD, FTD, DLB, and VaD patients 
were not significantly different from each other and from non-demented 
controls (p = 0.24; table 1; figure 3). Results did not change, when age was 
added as a covariate and an ANCOVA was performed. The ApoE genotype was 
available for 65 subjects (patients and non-demented controls). No differences 
were detected in the concentrations of Aβ/ApoE complex levels between the 
different genotypes (ε4 versus non-ε4) when all patients were combined 
(Mean ε4 carriers = 21.6 ± 29.3 ng/ml; Mean non-ε4 carriers = 18.5 ± 12.1 ng/
ml; p = 0.65; data not shown).
Discussion
In this study, we successfully assembled synthetic Aβ/ApoE complexes in vitro, and 
we designed and validated an ELISA method that is able to specifically detect the 
complexes. Complex levels were quantifiable in serum samples, however, levels 
of Aβ/ApoE complex did not differ between the investigated patient groups.
Aβ and ApoE interact with each other Synthetic Aβ and recombinant ApoE 
were used to assemble Aβ/ApoE complexes in vitro. Such complexes have 
been demonstrated on SDS-PAGE as a 40 kDa band [409, 451], which we could 
confirm. There are multiple lines of evidence that suggest that ApoE and Aβ 
closely interact with each other in the brain. More than two decades ago, it 
was already demonstrated that ApoE and Aβ co-localize in senile plaques of 
AD patients [92], and recently, Aβ/ApoE complexes were also detected and 
quantified in human synaptosomes and post-mortem CSF [10]. Aβ either binds 
directly to ApoE, or is linked by heparin, which has both Aβ and ApoE binding 
sites [452]. Direct interaction of Aβ and ApoE is influenced by the lipidation 
state of ApoE, since one of the Aβ binding sites within ApoE is also the site for 
lipid binding [49, 453]. Importantly, the strength of the interaction with Aβ is 
determined by the ApoE isoform, since lipidated ApoE4 (for instance derived 
from plasma) forms weaker complexes with Aβ than ApoE3 [95-97, 99]. 
Serum levels of complexes of Aβ and ApoE
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ELISA specifically quantifies Aβ/ApoE complexeSOnly recently
 the first ELISA 
has been described that is able to detect Aβ/ApoE complexes in mouse and 
human brain tissue, and in post-mortem obtained cerebrospinal fluid [99]. 
In the past, Western blotting was mainly used to study Aβ/ApoE complexes. 
However, for quantification purposes, an ELISA is superior to Western Blot, 
since it is more sensitive, quantitative and allows detection of the Aβ/ApoE 
complex in an SDS-free environment. In this study, we showed for the first 
time that Aβ/ApoE complexes can also be quantified in serum. Our ELISA is 
comparable to the design of the previously described ELISA [99], but makes 
use of different capture and detection antibodies. For detection, we further 
used streptavidin conjugated to multiple HRP molecules, which increases 
the signal compared to a single HRP molecule that is either conjugated 
to streptavidin or to a secondary antibody (data not shown). The specific 
detection of the synthetic complex and the decrease in signal after depletion 
of ApoE (and thus the complex) in serum provided proof that the ELISA was a 
good tool for quantification of Aβ/ApoE complexes, which we subsequently 
applied to determine complex levels in the serum of different patient groups 
with dementia.
Aβ/ApoE complex levels in serum do not differentiate between
dementia types
We did not identify differences in serum complex levels between AD, FTD, DLB, 
VaD and non-demented controls, neither did we detect any differences in Aβ/
ApoE complex levels between ε4 and non-ε4 carriers. In previous studies, it 
has been reported that the complex itself is less likely to cross the blood-brain 
barrier (BBB) [454-456]. Therefore, Aβ/ApoE complexes that are measured in 
serum are probably formed in the circulation by interaction of soluble Aβ and 
ApoE. Both Aβ and ApoE are produced in the brain, but also in the periphery. A 
major source of ApoE is the liver [457], whereas platelets are a systemic source 
of Aβ [458]. Furthermore, it was recently shown that total plasma Aβ measured 
in central veins, is increased by Aβ efflux from the brain only by ~7.5%, and 
this percentage might further decrease quickly by dilution [459]. Therefore, it 
is possible that Aβ/ApoE complex levels in serum do not reflect pathological 
events in the brain, which could explain the similar levels between different 
patient groups. 
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Although using serum to measure biomarkers has several advantages, such as 
easy accessibility and a collection method that is well tolerated by patients, 
the BBB interface prevents direct contact with the brain, where pathological 
events in neurodegenerative diseases occur. While levels of Aβ42 are similar 
in blood of AD patients compared to controls [460, 461], Aβ42 levels in CSF 
of AD patients have been extensively demonstrated to be decreased. The 
same type of discrepancy may account for the Aβ/ApoE complex, since it was 
reported previously that concentrations of the complex are decreased in post-
mortem ventricular CSF of AD patients compared to controls [99]. It should 
be noted however that post-mortem ventricular CSF may differ in its protein 
composition from ante-mortem obtained lumbar CSF [462], since it may 
contain higher levels of proteins due to disruptions of the BBB and released 
proteins due to cell lysis. Therefore, analysis of lumbar CSF for the Aβ/ApoE 
complex levels may hold promise, but the protein levels are expected to be 
lower than in ventricular CSF. Indeed, with our ELISA, it was not possible to 
detect and quantify Aβ/ApoE complexes in lumbar CSF, and to our knowledge 
this is also not been reported elsewhere. Complex levels in ante-mortem 
lumbar CSF may be too low for quantification using regular ELISA or the 
complexes may be completely absent. The latter may be supported by a report 
showing that Aβ and ApoE only minimally form complexes with each other 
in CSF. Furthermore, in the same report it was shown that in vitro only about 
5% of cell-derived Aβ assembled into complexes with reconstituted, lipidated 
ApoE when physiological concentrations, comparable with those in CSF, were 
used [49]. Thus, more sensitive techniques using more sophisticated detection 
systems may be needed to quantify levels of these low-abundant Aβ/ApoE 
complexes in CSF.
Conclusion
In this study, we did not find proof that Aβ/ApoE complexes in serum or CSF can 
be used as biochemical marker to differentiate AD from other dementia types 
or non-dementia. With our ELISA we designed a tool that is able to quantify 
Aβ/ApoE complexes in serum. This tool might also be applied in the brain. 
Serum levels of complexes of Aβ and ApoE
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Abstract
Small heat shock proteins (sHSPs) are molecular chaperones, the expression 
of which increases under stress conditions. Previous evidence suggests sHSPs 
might play a role in Alzheimer’s disease (AD) and interact with the amyloid-
β(Aβ) protein. For instance, small HSPs can affect Aβ aggregation and toxicity. 
In this study we investigated the association characteristics of the small HSP 
αB-crystallin (αB-cry) and Aβ and studied if complexes between these two 
proteins may serve as biomarkers for AD. We were able to produce stable cross-
linked complexes predominantly consisting of αB-cry monomers associated 
with two Aβ molecules. In addition, the optimal ratio for complex formation in 
vitro was determined. Equimolar Aβ:αB-cry concentrations or excess amounts 
of Aβ compared to αB-cry promoted the formation of Aβ/αB-cry complexes. αB-
cry was able to associate with both Aβ40 and Aβ42, indicating amino acids 41/42 
are not crucial for binding. To determine whether physiological complexes of 
Aβ and αB-cry can be detected in biological samples, we developed ELISAs to 
specifically detect Aβ/αB-cry complexes. However Aβ/αB-cry complexes could 
neither be detected in human brain extracts nor in cerebrospinal fluid (CSF), 
indicating that these complexes are either not present, or their levels are too 
low to be detected.
Introduction
A characteristic pathologic event in Alzheimer’s disease (AD) is aggregation and 
extracellular accumulation of the amyloid-β protein (Aβ). Aβ occurs as various 
isoforms, of which the 40 amino acids variant (Aβ40) is the most abundant. 
The less abundant Aβ42 peptide is more prone to self-associate than Aβ40 and 
readily forms aggregates, both in vitro and in vivo. Aβ can either aggregate 
in an amorphous (non-amyloidogenic) and a fibrillar (amyloidogenic) way. In 
the non-amyloidogenic way, unordered aggregates are formed, existing in a 
wide range of differently sized and shaped species [463, 464]. Alternatively, 
aggregation can lead to highly ordered structures, referred to as mature fibrils. 
The majority of deposits in the AD brain, so called senile plaques, mainly consist 
of fibrillar Aβ. However, the physiological kinetic aggregation pathways appear 
to be extremely complex and remain still elusive [463]. Both in amyloidogenic 
and non-amyloidogenic pathways intermediate oligomeric species can 
be formed, which are regarded as the most cytotoxic components [362]. 
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Proposed mechanisms of toxicity include membrane pore formation, receptor 
deregulation, synaptic dysfunction and finally neuronal cell death [465].
A range of proteins has been described to associate with Aβ and influence 
its aggregation. One of these Aβ-associated proteins is αB-crystallin (αB-
cry), also named heat shock protein (HSP)B5, a protein that is abundantly 
present in the eye lens, but is expressed in a wide variety of different tissues 
and organs including the brain [75, 466]. αB-cry is a member of the small HSP 
family, a group of proteins that is up-regulated during stressful situations 
such as heat shocks, pH shifts or hypoxia. HSPs have a cytoprotective function 
by acting as molecular chaperones to prevent aggregation of unfolded or 
misfolded proteins [467]. Unlike their larger family members, small HSPs are 
ATP-independent. They are believed to bind misfolded proteins in order to 
attenuate aggregation [75, 76]. αB-cry has been described to bind to unfolded 
or partially folded monomeric proteins [468, 469]. Subsequently, these proteins 
can either be refolded by larger HSPs or they are directed for degradation by 
proteasomes or autophagosomes [467, 468, 470].
αB-cry, among other small HSPs, is induced in several neurodegenerative 
conformational disorders, including AD [471]. αB-cry expression is 
upregulated in astrocytes in AD brains [85] and in microglia adjacent to and 
inside senile plaques [81, 84]. In addition, αB-cry mRNA levels were elevated 
in the cerebellum and superior frontal gyrus of post-mortem AD brains 
[472]. In experiments with C. elegans, a homologue protein of αB-cry was co-
immunoprecipitated with Aβ [473]. In vitro interaction between Aβ and αB-
cry has been intensively studied. Observations on the influence of αB-cry 
on Aβ aggregation rate and toxicity are highly inconsistent and appear to 
depend on experimental methods and conditions (for an overview see [468]). 
Nonetheless, there are multiple indications that both proteins are able to 
interact and form complexes. First, a good binding affinity for recombinant 
αB-cry to Aβ has been demonstrated [86]. Second, analyses using fluorescent 
energy transfer indicated both proteins interact upon co-incubation in vitro 
[474]. Third, NMR spectroscopy revealed that αB-cry binding to Aβ involves 
similar amino acid regions as are involved in Aβ aggregation [475]. Finally, it 
was reported that αB-cry was present in non-fibrillar Aβ aggregates that were 
highly toxic to neurons in vitro [87].
In this study we investigated the association abilities of Aβ and αB-cry and 
studied if Aβ/αB-cry complexes are present in brains and body fluids.
Preparation and detection of complexes of Aβ and αB-crystallin
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Materials & Methods
Proteins
Lyophilized Aβ42 was obtained from Quality Controlled Biochemicals (QCB) 
(Hopkinton, MA, USA) or from 21th Century Biochemicals (Marlborough, 
MA, USA). Aβ40 was purchased from QCB. The Aβ peptides were dissolved 
in hexafluoroisopropanol (HFIP), air dried and dissolved in DMSO at a 
concentration of 5 mM before use. Recombinant human αB-crystallin was 
expressed and purified as described previously [86]. The purity of the 
preparation was 95%. Transglutaminase from guinea pig liver was obtained 
from Sigma-Aldrich (St. Louis, USA).
CSF samples
CSF from 5 cases (3 AD patients, 3 males, age 72.6 ± 12.0; and 2 non-demented 
controls, (1 male, 1 female, age 67.4 ± 17.8) was used for ELISA analysis. CSF 
was obtained by lumbar puncture via standard procedures in polypropylene 
tubes, directly transported to our laboratory, centrifuged and stored at -80 °C. 
Patients were informed that their data, including CSF, could be used for further 
scientific purposes and were given the option to object against this use, in 
which case their data were not used. All patient information was decoded to 
maintain patient confidentiality. Dementia diagnoses were based on accepted 
clinical criteria, i.e. the NINCDS-ADRDA criteria for probable AD [366]. More 
recent diagnostic criteria [106] were not applied, since the patient’s samples 
were collected prior to the introduction of these criteria.
Tissue samples
Human hippocampal tissue was obtained and homogenized in carbonate buffer as 
described before [417]. Tissue from 3 AD patients (3 females; age 81 ± 7 years; post 
mortem delay 4 ± 1 hours; Braak & Braak V-VI; CERAD +++) and 1 non-demented 
control (male, age 71 years; post mortem delay 6 hours; Braak & Braak 0; CERAD -) 
were chosen for analysis. Informed consent was obtained according to European 
guidelines. Post-mortem diagnosis and grading of AD patients and control cases 
was based on immunohistochemistry staining using antibodies directed against Aβ 
(4G8; Covance, Princetown, NJ, USA) and phosphorylated tau (AT8; Innogenetics, 
Gent, Belgium), and was performed and judged by a neuropathologist, according 
to the criteria established by Braak & Braak and CERAD [338, 339].
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Complex formation
Aβ and αB-cry were co-incubated in a final volume of 25 µl PBS, containing 2.5 
µg Aβ42 and 11.25 µg αB-cry (molar ratio 1:1). Complexes were allowed to form 
for 1 hour at room temperature (RT).
Cross-linking of protein complexes with tissue transglutaminase
Cross-linking reactions were performed essentially as described previously, 
inducing the formation of dipeptide bonds between lysine in αB-cry and 
glutamine in the Aβ protein [476]. In brief, Aβ, αB-cry or both proteins (molar 
ratios ranging from 21:1 to 1:16 [Aβ:αB-cry]; containing 1 - 21 µg Aβ42 and 
4.5 - 70 µg αB-cry) were pre-incubated for 30 minutes at RT to allow complex 
formation. 2.5 - 5 µg tissue transglutaminase (tTG) per reaction was pre-
activated for 15 minutes at 37 °C in 2x concentrated cross-linking buffer (final 
working concentration 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 15 mM DTT and 
20% glycerol). Next, the cross-linking reaction was initiated by mixing equal 
volumes of sample containing synthetic/recombinant proteins or CSF and tTG 
in cross-linking buffer and the addition of CaCl2 to a final concentration of 5 
mM. Dipeptide bonds were allowed to form for 2 hours at 37 °C.
Electrophoresis and Western blot analysis
For native polyacrylamide gel electrophoresis (PAGE), samples containing 
1-1.2 µg of Aβ and/or αB-cry proteins, were diluted in non-reducing sample 
buffer (containing Tris/HCl, glycerol and bromophenol blue) and heated for 
15 minutes to 37 °C. Next, the samples were separated on Tris/Glycine native 
gels containing 5% acrylamide-bisacrylamide. To enable the identification of 
proteins a precision plus prestained protein standard (Bio-Rad, Veenendaal, 
The Netherlands) and a Low-Range Rainbow prestained protein standard 
(GE Healthcare, Hoevelaken, The Netherlands) were used. Proteins were then 
transferred to a PVDF membrane by wet blotting. Subsequently, blots were 
blocked for one hour at RT with Odyssey blocking buffer (LI-COR, Lincoln, 
USA) diluted two times in PBS. The membranes were then probed either 
with a mouse antibody directed against Aβ, clone NAB 228 (Sigma-Aldrich) 
or a rabbit antibody directed against the C-terminus of αB-cry (previously 
generated by W. Boelens [477]), both diluted 1:2000 in blocking buffer. After 
washing with PBST (0.05 % Tween-20 in PBS), membranes were incubated 
with Alexa-680-labeled goat anti-mouse and goat anti-rabbit antibodies (Life 
Technologies, Bleiswijk, The Netherlands) or with IRDye800-labeled goat anti-
Preparation and detection of complexes of Aβ and αB-crystallin
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rabbit antibodies (Tebu-bio, Heerhugowaard, The Netherlands) for 1 hour at 
RT. Proteins were visualized using the Odyssey infrared imaging system (LI-
COR).
For SDS-PAGE, tTG-treated samples containing 0.5 µg Aβ, 1.5 - 2.2 µg αB-cry or a 
combination of both proteins were diluted in non-reducing sample buffer and 
analyzed similar to the native PAGE procedure, except samples were separated 
on a Tris/Glycine gel containing SDS and 12% acrylamide-bisacrylamide.
ELISAs
Cross-linked complexes of Aβ and αB-cry were detected in two ELISA designs. 
For ELISA 1, 100 µl mouse anti-Aβ clone NAB 228 was coated overnight at 4 
°C in a 96 wells plate at a concentration of 2 µg/ml in 0.1 M NaHCO3, pH 9.6. 
After each incubation step, the plate was washed 5 times with PBST. Wells were 
blocked for 1 hour with 250 μl of 1% BSA in PBS at RT. Next, 100 μl of cross-
linked Aβ42, αB-cry or a combination of both proteins, diluted in INNOTEST 
sample diluents (Fujirebio Europe, Gent, Belgium), was added and incubated 
Fig. 1) Native interaction of Aβ42 with αB-cry. Proteins were co-incubated at equimolar ratios and 
allowed to associate for 1 hour at room temperature. Co-incubated proteins or single proteins, as 
indicated, were separated by native PAGE and visualized on western blot. Blots stained for αB-cry 
(A) and Aβ (B) are shown.
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for 2 hours at RT on a shaking device. Alternatively, hippocampal tissue 
extracts (diluted 1:4) or CSF (diluted 1:1 with INNOTEST sample diluent or 1:1.4 
in cross-linking mixture) was added. Then 100 μl of rabbit anti-αB-cry, diluted 
1:5000 in antibody buffer (PBS/0.1% BSA/0.05% Tween-20), was incubated for 
1 hour at RT on a shaking device. Finally, the plate was incubated with HRP-
labeled goat anti-rabbit in antibody buffer for 1 hour. 100 μl of TMB solution 
was added as a substrate and the reaction was stopped with 50 μl of 1M H2SO4. 
OD values were measured at 450 nm using a Sunrise ELISA plate reader (Tecan, 
Männedorf, Switserland).
ELISA 2 was performed similarly, except rabbit anti-αB-cry was used as a 
capture antibody (1:1000) and anti-Aβ clone NAB 228 (1:2000) and HRP-
labeled goat anti-mouse were used for detection. PBS/ 0.1 % BSA was used as 
an antigen buffer.
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Fig. 2) Transglutaminase (tTG)-catalyzed stabilization of Aβ42/αB-cry complexes. Aβ42, αB-cry or a 
combination of both (ratio 1:1) were incubated at 37°C, either in the presence or absence of tTG. 
Samples were separated by SDS-PAGE and visualized by western blotting with anti-Aβ antibodies 
(A) and anti-αB-cry antibodies (B). Monomeric proteins are indicated by black arrowheads, 
oligomeric proteins (homomers) by open arrowheads and bands representing complexes are 
indicated by brackets, with a, b and c corresponding to complexes of αB-cry with respectively 1, 2 
and 3 molecules of Aβ. Molecular weight markers (in kDa) are indicated on the left.
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Results
Association of Aβ and αB-cry
To examine a possible spontaneous association of Aβ42 with αB-cry in vitro, 
we co-incubated both proteins at equimolar concentrations and studied the 
product for potential interactions. Using SDS-PAGE, we did not detect any 
bands representative for a protein complex (data not shown), possibly due to 
the denaturing characteristics of SDS. However, using native PAGE followed by 
western blotting, we observed an effect of co-incubation with αB-cry on the 
migration of Aβ. While Aβ by itself was mainly present at the bottom of the 
gel (Fig. 1B), after co-incubation with αB-cry there was an upward shift of Aβ 
to the top of the gel, in the same area where αB-cry was present (Fig. 1A). We 
did not detect a shift of αB-cry after co-incubation with Aβ (data not shown). 
Fig. 3) Efficiency of complex formation of Aβ42 and αB-cry at different ratios. Aβ42 and αB-cry were 
co-incubated at different ratios (ranging from 1:15 up to 21:1) and subsequently cross-linked 
by tTG. Samples were analyzed by SDS-PAGE and western blotting. Either equal amounts of Aβ 
were loaded (0.3 µg) with decreasing amounts of αB-cry, followed by staining of the blot for Aβ 
(A), or equal amounts of αB-cry were loaded (approximately 1 µg) with increasing amounts of 
Aβ, followed by staining for αB-cry (B). Monomeric proteins are indicated by black arrowheads, 
oligomeric proteins by open arrowheads and bands representing complexes by brackets. 
Molecular weight markers (in kDa) are indicated in the middle.
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Both antibodies were specific and did not detect the other protein, as judged 
from analysis of samples containing only one of the proteins (data not shown).
Cross-linking of Aβ and αB-cry complexes
In order to stabilize the formed complexes and study their characteristics on 
SDS-PAGE, a cross-linking technique using tTG was applied. tTG is a calcium-
dependent enzyme that catalyzes the formation of isodipeptide bonds between 
lysine and glutamine and has been described to cross-link Aβ with small HSPs, 
including αB-cry [476]. Following incubation of Aβ and αB-cry with tTG, we were 
able to visualize complexes consisting of both proteins after separation by SDS-
PAGE (Fig. 2). In the absence of αB-cry, Aβ42 was mainly present in monomeric 
form (molecular weight (Mw) approximately 4.5 kDa) and as tetramers of about 
18 kDa (Fig. 2A, left). Treatment of Aβ with tTG especially reduced the tetrameric 
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Fig. 4) Complex formation of αB-cry with Aβ40 and Aβ42. αB-cry was co-incubated with either 
Aβ40 or Aβ42 at a 1:1 molar ratio and subsequently cross-linked by tTG. Samples were analyzed 
by SDS-PAGE followed by western blotting. Blots stained for Aβ (A) and anti-αB-cry antibody (B) 
are shown. Monomeric proteins are indicated by black arrowheads, oligomeric proteins by open 
arrowheads and bands representing complexes by brackets. Molecular weight markers (in kDa) 
are indicated on the left.
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band and induced the formation of other oligomeric forms, in particular trimers 
and multimers > 20 kDa (Fig. 2A, middle). Similarly, αB-cry in the absence of 
Aβ occurred mainly as monomers (Mw of approximately 20 kDa) and a small 
percentage as dimers (Mw of 40 kDa) (Fig. 2B, left), while tTG treatment enabled 
formation of larger multimers > 60 kDa and an increase in dimers (Fig. 2B, middle).
When Aβ and αB-cry were cross-linked together, new bands appeared that 
Fig. 5) Detection of Aβ/αB-cry complexes by ELISA. An ELISA designed to capture Aβ and detect 
αB-cry (A) or with a reversed design (B) were used to detect in vitro prepared, cross-linked 
complexes of Aβ42 and αB-cry. Both ELISAs demonstrate concentration dependent signals for 
complexes (2 nM), and do not detect single Aβ or αB-cry (2 nM) proteins.
Fig. 6) Detection of Aβ/αB-cry complexes in CSF. A standard curve was generated in vitro with 
cross-linked synthetic Aβ42 and recombinant αB-cry using ELISA 1 (A). CSF samples from 3 AD 
patients (AD1-3) and 2 non-demented controls (Con1-2) were analyzed in ELISA 1, both untreated 
(B, left) and treated with tTG (B, right) to stabilize potentially present complexes. The control 
signals are indicated with horizontal bars. No reliable signals above control levels were detected 
for the CSF samples.
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presumably represent complexes of the proteins consisting of 1 αB-cry molecule 
associated with either 1, 2 or 3 molecules of Aβ (Mw of approximately 25, 29 
and 34 kDa) (Fig. 2A and B, right, indicated with a, b, and c, respectively). The 
band around 29 kDa band is the most prominent, suggesting that complexes 
of 1 αB-cry and 2 Aβ molecules are preferentially formed.
To study the optimal association conditions, different molar ratios of Aβ42 
and αB-cry were used for co-incubation and subsequently cross-linked. When 
Aβ was in excess, a band with approximate Mw of 29 kDa is prominent on 
both the Aβ- and αB-cry-stained blots, increasing in intensity when more Aβ 
is present (Fig. 3A and B). This band is similar to the previously determined 
band representing the complex of 1 αB-cry molecule with 2 Aβ molecules. 
Interestingly, when αB-cry was present in excess, two highly intense bands 
are visible on the Aβ-stained blot at approximately 23 and 27 kDa (Fig. 3A 
, left). These bands did not stain with anti-αB-cry (Fig. 3B, left), indicating 
these are multimers of Aβ, presumably pentamers and hexamers. Thus, high 
concentrations of αB-cry appear to promote the formation of Aβ pentamers, 
hexamers and high molecular weight aggregates (> 100 kDa). These results 
point to an efficient complex formation with equimolar Aβ:αB-cry amounts or 
higher amounts of Aβ compared to αB-cry.
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Fig. 7) Detection of Aβ/αB-cry complexes in brain tissue. Hippocampal tissue from 3 AD patients 
(AD1-3) and 1 non-demented control was extracted and samples were applied to ELISA 1. No 
signal above control level was detected. In vitro cross-linked αB-cry and Aβ (both 200 pM) was 
used as a positive control. AD2 and AD3, N=1; others N=2.
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Complex formation with Aβ42 vs. Aβ40
Since Aβ40 has a slightly shorter C-terminus and in addition a lower 
hydrophobicity than Aβ42, binding capacity and affinity of these peptides with 
other proteins may differ. To examine whether Aβ40 was also able to associate 
with αB-cry, both proteins were co-incubated at a ratio of 1:1 and cross-linked. 
Similar to Aβ42, complex formation with Aβ40 resulted in a complex visualized as 
a band on western blot at 28-29 kDa, representing the formation of complexes 
consisting of 1 αB-cry molecule and 2 Aβ molecules (Fig. 4).
Detection of Aβ/αB-cry complexes by ELISA
To investigate the presence of Aβ/αB-cry complexes in biological samples, we 
designed two ELISAs to specifically measure the complexes. ELISA 1 was set 
up to capture Aβ molecules and detect αB-cry and ELISA 2 was designed the 
other way around. tTG cross-linking was used to prepare stable complexes and 
with both ELISA designs concentration dependent signals were detected for 
complexes of recombinant αB-cry with synthetic Aβ42 (Fig. 5 A and B for ELISA 
1 and 2 respectively). To verify whether the ELISAs specifically measured Aβ/
αB-cry complexes and did not detect the single proteins, samples containing 
only Aβ or αB-cry were tTG treated and measured in both ELISAs. No signal was 
detected for these preparations (Fig. 5A and B).
Subsequently, we analyzed CSF samples in ELISA 1, both untreated and 
treated with tTG to stabilize potentially available protein complexes. We used 
complexes of synthetic Aβ and recombinant αB-cry to generate a standard 
curve (Fig. 6A). However, no measureable signal was detected for either tTG-
treated or untreated CSF (Fig 6B). In addition, hippocampal tissue extracts, 
untreated with tTG, were also measured in ELISA 1, however no signals above 
detection limits were obtained (Fig. 7).
Discussion
In this report we investigated the association abilities of Aβ and αB-cry and 
studied the biomarker potential of Aβ/αB-cry complexes in AD. We showed 
that: (1) Aβ/αB-cry complexes were formed, as shown previously, upon co-
incubation of Aβ and αB-cry in vitro, however these were not SDS-stable; 
(2) Complex formation between Aβ and αB-cry was most prominent in the 
presence of excess amounts of Aβ; (3) Both Aβ40 and Aβ42 were able to form 
complexes with αB-cry; (4) Complexes could specifically be detected by ELISA 
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methods; however (5) levels of these complexes were yet undetectable in 
human CSF and hippocampal homogenates by common ELISA.
First, we investigated whether Aβ and αB-cry interacted and formed 
complexes in vitro. With native electrophoresis, we found evidence that both 
proteins interacted upon co-incubation. Both αB-cry itself and a mixture of 
co-incubated Aβ/αB-cry were present as a smear at the top of the native gel. It 
has been demonstrated before that αB-cry forms large oligomeric aggregates 
that have a high apparent Mw on native PAGE (1,100 ± 138 kDa), visualized as 
a smear that suggests heterogeneity in aggregate size [478].
Aβ/αB-cry complexes, however, appeared not to be stable in the presence 
of SDS. To enable further analysis of their characteristics, we cross-linked 
the complexes. We were able to successfully prepare and stabilize Aβ/αB-cry 
complexes, using a cross-linking technique that was described before [476]. We 
found evidence that monomeric αB-cry forms complexes with preferentially 
two molecules of Aβ, which is in accordance with a previous study that 
demonstrated tTG cross-linked monomeric αB-cry with one and more Aβ 
molecules [476]. In addition, we demonstrated that both Aβ40 and Aβ42 are 
binding partners for αB-cry and αB-cry co-incubation with excess amounts of 
Aβ led to a more intense complex band on western blot. It remains unclear 
whether these results represent the characteristics of physiological Aβ/αB-cry 
complex formation.
sHSPs in vivo have been described to exist as large dynamic aggregates, 
consisting of 15 to up to 40 molecules [75], from which subunits separate 
to bind their target protein and execute their chaperone function [466, 468, 
479]. These target proteins are mostly damaged or denatured proteins at risk 
of aggregation, and the HSP subunits that bind their target are predicted to 
consist of dimers or small oligomers [479]. In our study, cross-linking might 
influence the composition of the Aβ/αB-cry complexes by favoring the 
stabilization of certain complexes. Although tTG is found abundantly in Aβ 
deposits [480-482] and was hypothesized to contribute to Aβ polymerization 
and deposition in AD [483-485], the physiological role of tTG in enabling the 
cross-linking of complexes of Aβ with amyloid associated proteins remains 
elusive.
Another finding we report here, is that excess amounts of αB-cry seemed to 
induce the formation of SDS-stable Aβ pentamers and hexamers. An earlier 
study also demonstrated the formation of SDS-stable Aβ40 oligomers at the size 
of hexamers, upon incubation with αB-cry for 6 days [476]. Numerous studies 
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have investigated the effects of small HSPs on Aβ aggregation, unfortunately 
without consensus on the results. Some studies report enhanced and others 
decreased aggregation propensities of Aβ, or the stabilization of defined 
intermediate oligomeric forms of Aβ (for an overview see [468]). Still, whether 
upregulation of αB-cry expression contributes to AD pathology in a positive 
or negative fashion remains speculative. It is hypothesized that αB-cry might 
redirect Aβ proteins from the fibril forming pathway to formation of more easily 
degradable amorphous aggregates [486]. The αB-cry mediated formation of 
Aβ pentamers and hexamers might support this theory.
In order to investigate the presence of Aβ/αB-cry complexes in biological 
samples, we successfully designed ELISA methods for specific detection. 
Unfortunately we were unable to detect such complexes in human brain 
tissue and CSF. This is not likely due to absence of either protein in CSF, as 
CSF samples from both AD patients and non-demented controls are known 
to contain concentrations of both Aβ40 and Aβ42 that are measurable by 
ELISA methods [487]. In addition, αB-cry has been detected before in CSF by 
western blot in 88% of neurologically healthy controls [488]. A more sensitive 
technique, such as ELISA, might be able to measure low levels of αB-cry in even 
more individuals. Although we did not confirm the presence of Aβ and αB-cry 
separately in the samples used in this study, these previous findings suggest 
both proteins are likely present in the majority of the samples tested, however 
possibly not in all samples. We hypothesized that a reason why we were 
unable to detect Aβ/αB-cry complexes in CSF might be that these complexes 
are not stable enough for the conditions attributed in our assays. Therefore, 
we investigated whether enzymatic cross-linking stabilized the detection of 
Aβ/αB-cry complexes. However, treatment of CSF with tTG did not result in 
improved detection of these complexes in CSF. In addition, we were unable 
to detect Aβ/αB-cry complexes in non-cross-linked human hippocampal 
homogenates. Previously, a western blot method was also unable to detect 
Aβ/αB-cry complexes in the temporal cortex of AD patients and healthy 
controls [476]. For future studies, treatment of tissue homogenates with tTG 
might stabilize potentially present complexes and increase their detection. 
Alternatively, the levels of these complexes might be below the detection 
limit of these methods or are not formed in vivo. Therefore, more sensitive 
protein detection methods, such as modified ELISA methods that are bead-
based or rely on signal enhancement by luminescent proximity [489-491], or 
fluorescence cross-correlation spectroscopy methods [492], may enhance the 
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detection of Aβ/αB-cry complexes in biological samples and provide proof 
whether these complexes are formed in vivo in brain tissue or CSF.
In conclusion, Aβ and αB-cry are able to associate into protein complexes and 
tTG cross-linking can be attributed to stabilize such complexes. Specifically 
designed ELISAs confirm the formation of these complexes in vitro, but the 
ELISA method is not yet suitable for detection of these protein complexes in 
human brain and CSF.
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Abstract
Alzheimer’s disease (AD) pathology is characterized by amyloid-β (Aβ) 
deposits in the brain. These deposits are accompanied by local inflammatory 
reactions, manifested by the presence of activated microglial cells. In AD 
brains, typically an upregulation of the production and secretion of various 
pro-inflammatory cytokines, including interleukin (IL)-6, is observed. Both 
Aβ and the amyloid-associated small heat shock proteins (sHsps) are capable 
of inducing secretion of cytokines. In this study we aimed to investigate the 
cumulative effects of sHsps and Aβ on IL-6 secretion by microglia, in order to 
gain more insight into the role of these proteins in neuroinflammation. We 
show that IL-6 secretion in a murine microglial cell line was increased upon 
stimulation with the sHsps Hsp20, HspB2/B3 and HspB8. Furthermore, this 
response was markedly suppressed when cells were incubated with both 
sHsps and Aβ40 or Aβ42 peptides. Blocking of toll-like receptors (TLRs) 2 and 
4 resulted in an inhibition of sHsp-mediated IL-6 production, suggesting that 
sHsps bind TLRs. Immunofluorescent microscopy of these microglial cells 
revealed that sHsps and Aβ peptides co-localized. In conclusion, our results 
suggest that Aβ might interfere in the sHsp-mediated inflammatory response 
by protein-protein association, probably hindering interaction of sHsps with 
the TLRs. However, the underlying pathway of this interference by Aβ is still 
unclear and additional studies are essential to gain more insight into these 
mechanisms and their role in neuroinflammation in AD pathology.
Introduction
One of the main pathological hallmarks of Alzheimer’s disease (AD) is deposition 
of extracellular amyloid-β (Aβ) aggregates in the brain parenchyma. Reactive 
microglial cells and astrocytes are associated with senile plaques. Microglial 
cells may counteract plaque formation, as they are activated and attracted by 
extracellular Aβ to remove the toxic protein by means of phagocytosis [442, 
493, 494]. However, since this phagocytosis apparently fails, a consequence 
of this frustrated phagocytosis may be that sustained microglial activation 
results in a chronic inflammatory response, manifested by the production of 
pro-inflammatory cytokines. This immune response is believed to aggravate 
AD pathology, causing neuronal dysfunction by secreted neurotoxic mediators 
such as cytokines and reactive oxygen species [66, 495]. In the brains of AD 
patients, upregulation of a variety of inflammatory factors, such as interleukin 
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(IL)-6, IL-1β, IL-8, transforming growth factor beta1 (TGF-beta1) and CD40 
ligand, has been described [66-69, 443]. In addition, IL-6 was predominantly 
found in early stage plaques, suggesting a contribution to plaque formation 
and the development of dementia [70, 71]. In addition, several studies showed 
that Aβ was able to induce cytokine production in vitro [496-500]. 
Other proteins capable of inducing cytokine production are the small heat 
shock proteins (sHsps) [79, 498]. The human sHsp family consists of ten 
members with a molecular weight of approximately 20 kDa, and includes 
Hsp20, HspB8, αB-crystallin, Hsp27, HspB2 and HspB3 [72]. αB-crystallin and 
Hsp27 expression are upregulated in astrocytes in AD brains [83-85] and 
previously we demonstrated that Hsp20, HspB8 and HspB2 co-deposit with 
Aβ in senile plaques [80, 81]. Both sHsps and their larger family members are 
stress-induced proteins, which possess a chaperone function and thus play 
a role in correcting protein misfolding. Therefore, they may also interact 
with misfolded Aβ to prevent its aggregation [467, 468, 501]. In addition, 
Hsps may act as pro-inflammatory agents as they can induce cytokine 
production [498]. For instance, Hsp70 may associate with antigen-presenting 
immune cells and upregulate the expression of pro-inflammatory cytokines 
via both Toll-like receptor 2 (TLR2) and TLR4 [502-504]. This mechanism is 
dependent on CD14, a TLR co-receptor that is also activated by the potent 
pro-inflammatory bacterial endotoxin lipopolysaccharide (LPS) [505, 506]. In 
addition, our previous reports demonstrated that sHsps are able to induce an 
inflammatory response in cerebral cells as well, manifested by the secretion 
of several cytokines [77, 507]. Also, HspB8 has been demonstrated to activate 
TLR4 in dendritic cells [508]. Therefore, since both sHsps and Aβ may be potent 
activators of neuroinflammation in AD, we hypothesized that sHsps may act 
synergistically with Aβ in the induction of a neuroinflammatory response. In 
order to investigate this, we determined the IL-6 secretion by microglial cells 
upon incubation with various sHsps, either in the presence or absence of Aβ. 
In addition, we studied the (sub)cellular association of sHsps and Aβ with 
microglial cells in vitro and investigated a potential involvement of TLRs in 
mediating this inflammatory response.
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Materials & Methods
Materials & Proteins
Lyophilized Aβ42 was obtained from Quality Controlled Biochemicals (QCB) 
(Hopkinton, MA, USA) or from 21th Century Biochemicals (Marlborough, 
MA, USA). Aβ40 was purchased from QCB. The Aβ peptides were dissolved 
in hexafluoroisopropanol (HFIP), air dried and dissolved in DMSO at a 
concentration of 5 mM before use. Aliquots were stored at -80 °C. Recombinant 
human Hsp20, HspB8, HspB2 and HspB3 were previously expressed and 
purified as described [77, 86, 509]. HspB2/B3 was produced and used as a 
complex, as it has previously been shown to occur as a complex in vivo [510]. 
The purity of the preparations was ≥ 95%.
Cell culture media RPMI-1640 (Lonza, Basel, Switzerland) and DMEM/F12 with 
HEPES (Life Technologies, Bleiswijk, The Netherlands) were used. L-glutamine 
and fetal calf serum (FCS) were obtained from Lonza, Insulin-Transferrin-
Selenite supplement (ITS) from Roche Diagnostics (Basel, Switzerland) and 
Bovine Serum Albumin, Fraction V, Fatty Acid Free (BSA-FAF) from Merck 
(Kenilworth, USA). Lipopolysaccharide (LPS) and Polymixin B (PMB) were 
obtained from Sigma-Aldrich (St. Louis, USA).
Cell culture
The MMGT12 murine microglial cell line [511] was obtained from Fujirebio 
(Ghent, Belgium). MMGT12 cells were cultured in DMEM/F12, supplemented 
with 2% FCS, 5 µg/ml insulin, 5 µg/ml transferrin, 30 nM sodium selenite, 3 µg/ml 
BSA-FAF, 20% WeHi-3B conditioned medium and 2.5 µg/ml gentamycin. The cells 
were grown in a humidified atmosphere of 5% CO2 at 37 °C and passaged twice 
a week, using a cell scraper.
WeHi-3B cells were a generous gift from the department of Cell Biology, RUMC 
Nijmegen, The Netherlands. WeHi cells were cultured in RPMI, supplemented 
with 10% FCS and 2 nM L-glutamine and 2.5 µg/ml gentamycin (Centrapharm, 
Etten-Leur, The Netherlands). In order to obtain conditioned medium, cells were 
cultured in T-175 flasks until a concentration between 6*105 and 1*106 cells/ml 
was reached. Subsequently, culture medium was collected, centrifuged and 
filtered using a 0.22 µm filter. Supernatants were stored at -20 °C until use.
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Microglial stimulation
The MMGT12 cells were seeded in 24-wells or 96-wells plates at a concentration 
of 150,000 - 250,000 cells/ml in 400 and 100 µl culture medium, respectively. After 
24 hours, medium was replaced with DMEM/F12 supplemented with 2% FCS for 
approximately 4 hours. Next, duplicate or triplicate wells were incubated with 
Aβ40 or Aβ42 (0.8 – 50 µM) and/or sHsps (1 µM) or LPS (100 ng/ml). DMSO was used 
as a vehicle control, at the highest volume used in the Aβ-supplemented wells. 
To exclude the possibility of interference by LPS, a potent IL-6 inducer, in most 
experiments (indicated in figure legends), PMB (10 µg/ml) was co-incubated with 
the sHsps [512]. To block TLR2 or TLR4, cells were pre-incubated with either mouse 
TLR2 neutralizing antibody (InvivoGen, San Diego, USA), 100 ng/ml for 1 hour or 
with TLR4 signaling inhibitor CLI-095 (InvivoGen) 50 nM for 5 hours, before the 
addition of LPS or Hsp20.
After 24 hours of stimulation, culture media were collected and cells were harvested 
by scraping on ice in RIPA buffer (50 mM TRIS HCl pH 7.4, 150 mM NaCl, 1% Nonidet 
P40, 0.5% sodium deoxycholate and 0.1% SDS in MilliQ) to prepare cell lysates. 
Both culture media and lysates were stored at -20 °C and centrifuged before use.
IL-6 ELISA
Murine IL-6 levels were measured in cell culture supernatants using an ELISA 
kit from R&D Systems (Minneapolis, USA), according to the manufacturer’s 
instructions. To correct for differences in cell density, IL-6 levels were 
normalized to total protein levels, which were measured in the cell lysates 
using a BCA assay (Thermo Fisher Scientific, Rockford, USA) according to the 
manufacturer’s instructions.
Immunocytochemistry
8-well chamber slides (Nunc GmbH & Co. KG, Wiesbaden, Germany) were seeded 
with microglial cell suspension per well at a concentration of 250,000 cells/
ml in culture medium. After 24 hours, the medium was replaced by DMEM/
F12 supplemented with 2% FCS for approximately 4 hours. Subsequently, cells 
were stimulated as described above. 24 hours after stimulation, wells were fixed 
with 100 µl 2% paraformaldehyde for 10 minutes. Fixed cells were subsequently 
incubated with mouse anti-Aβ antibody 4G8 (Covance, Princetown, USA) (1 µg/
ml) and/or rabbit anti-Hsp20 (Abcam, Cambridge, UK) (1 µg/ml) for approximately 
1 hour at room temperature. Cells were washed and incubated with secondary 
antibody goat anti-mouse Alexa 488 and/or donkey anti-rabbit Alexa 594 
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(Invitrogen, Carlsbad, USA) (both 1:200) for 1 hour at room temperature. The 
antibodies were diluted in PBS/1% BSA, which also served as a negative control. 
Following each incubation, cells were washed 3 times with PBS. Slides were 
mounted using DAPI Fluoromount G (Southern Biotech, Birmingham, USA) and 
analyzed by fluorescence microscopy (Leica Microsystems, Wetzlar, Germany).
Statistical analysis
Statistical analysis was performed using ANOVA with Bonferroni’s post hoc 
test, using Graphpad prism software.
Results
Effects of amyloid-β and small heat shock proteins on IL-6 secretion by 
microglial cells
As a measure of the inflammatory response of microglial cells, IL-6 levels were 
determined in cell culture supernatants. When microglial cells were incubated 
for 24 hours with Aβ42, no change in IL-6 levels was detected (Fig. 1A), even 
when Aβ42 concentrations of up to 50 µM were used. Stimulation with sHsps, 
on the other hand, induced IL-6 secretion into the supernatant. All tested 
sHsps, HspB2/B3 (Fig. 1A; p<0.01), HspB8 (Fig. 1B; p<0.01) and Hsp20 (Fig. 1C; 
p<0.001), strongly induced IL-6 secretion by microglial cells. Interestingly, 
Aβ42 had an inhibitory effect on IL-6 secretion induced by HspB2/B3 (Fig.1A; 
p<0.01), HspB8 (Fig.1B; p<0.05) and Hsp20 (Fig. 1C; p<0.001).
To study the inhibitory effect of Aβ in more detail, we investigated the effect of 
a concentration range of both Aβ42 and Aβ40 on sHsp-induced IL-6 production. 
First, we showed that the inhibition of Hsp20-induced IL-6 secretion by Aβ42 was 
concentration dependent, significantly reducing IL-6 levels at concentrations 
above 6.25 µM (Fig 2A). Second, co-incubation of Hsp20 with a concentration 
range of Aβ40 demonstrated that this peptide also had the potential to 
suppress Hsp20-induced IL-6 levels, at concentrations above 25 µM (Fig. 2B). 
Finally, in order to determine whether Aβ suppressed IL-6 induction caused 
specifically by sHSPs, or if Aβ also reduces IL-6 secretion induced by other 
factors, microglial cells were incubated with LPS in the absence and presence 
of Aβ42. Stimulation with 100 ng/ml LPS resulted in a significant increase in 
IL-6 secretion, as expected, but this was not affected by co-incubation with 10 
µM Aβ42 (Fig. 2C). In addition, IL-6 levels induced by 250 ng/ml LPS were even 
further induced by 50 µM Aβ42 (data not shown).
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Co-localization of exogenous amyloid-β42 and Hsp20 in cell culture
The location of both Aβ42 and Hsp20 after 24 hours of incubation in the 
presence of microglial cells, was studied by ICC. Aβ42 and Hsp20 co-localized 
almost completely (Fig. 3A). A more detailed investigation at higher 
magnification showed that often, Aβ42 and Hsp20 were present in perinuclear 
positions, suggesting both proteins were taken up by the microglial cells 
(Fig. 3B). In addition, Aβ42 and Hsp20 accumulated together outside the cells. 
Controls omitting either the primary or secondary antibody were negative 
and the possibility of a cross-reaction between antibodies was excluded in an 
experiment where cells were incubated with either Aβ42 or Hsp20 and probed 
with a mixture of both antibodies (data not shown).
Potential mediation of toll-like receptors in Hsp20-induced IL-6 production
To gain more insight into the pathway underlying the inflammatory effect of 
sHsps, we investigated the involvement of TLR2 and TLR4. Microglial cells were 
incubated with blockers for either TLR2 or TLR4 and subsequently exposed to 
Hsp20. Both TLR2 and TLR4 blockers had no individual effect on IL-6 secretion 
but reduced IL-6 levels that were induced by Hsp20 (Fig. 4A). LPS was used as 
a positive control, since it is a well-known TLR4 ligand. However, in contrast to 
our expectations, not only the TLR4 blocker, but also the TLR2 blocker reduced 
IL-6 levels that were induced by LPS (Fig. 4B).
Discussion
In this study we investigated the inflammatory response of murine microglial 
cells to Aβ and sHsps. We observed that sHsps Hsp20, HspB8 and HspB2/B3, 
but not Aβ, induced an inflammatory response in MMGT12 microglial cells 
by increased secretion of IL-6. Both Aβ40 and Aβ42 reduced the sHsp-induced 
IL-6 secretion in a concentration-dependent manner. This inhibiting effect 
seems sHsp-specific, since IL-6 induction by LPS was not affected by Aβ. In 
addition, we showed that exogenous Aβ and Hsp20 in microglial cell cultures 
co-localized almost completely. Finally, blocking TLR2 and TLR4 inhibited both 
the sHsp- and LPS- induced IL-6 secretion.
We did not find an effect of Aβ40 or Aβ42 on IL-6 secretion by the murine 
microglial cell line MMGT12. In human primary microglia we previously 
found a slight increase in IL-6 secretion induced by 12.5 µM Aβ40, Aβ42 and 
Aβ40 containing the Dutch (Glu22Gln) mutation (resp. an 3.6, 3.8 and 5.2 fold 
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increase compared to control) [507]. Furthermore, Aβ40, but not Aβ42, increased 
cytokine secretion in the human CHME3 microglia cell line and primary rat 
microglial cells [496-498], while Aβ42 significantly stimulated IL-1 and bFGF 
secretion by rat microglia [499]. It has been demonstrated that adult microglia 
respond differently to Aβ peptides than postnatal microglia with regard to 
TNFα production and phagocytosis [513]. These findings suggest Aβ might 
posses a pro-inflammatory action, although, as we show in the current study, 
results are still controversial. Also, different conformations and aggregation 
states of Aβ can be critical for induction of cytokine release [500, 513, 514]. 
The ambiguity in results demonstrates that Aβ isoform and conformation and 
the microglial source can all be critical variables in inflammation experiments.
Hsps have been studied for their chaperone function for a long time, but 
their pro-inflammatory role was only recently explored as these proteins are 
considered intracellular proteins. It has been suggested that Hsps leak into the 
extracellular space as a consequence of neuronal death [498], but alternative 
mechanisms are not excluded. There is evidence that Hsps can be actively 
secreted, either in secretory vesicles or by release by endolysosomes at the cell 
surface [515]. It was shown before that Hsps can induce cytokine production 
in vitro (reviewed by [79]). In addition, we previously demonstrated, using 
primary human brain leptomeningeal smooth muscle cells, astrocytes and 
pericytes, that also sHsps possess a pro-inflammatory capacity [77, 507]. In the 
current study, we show that Hsp20, HspB2/B3 and HspB8 strongly increased 
IL-6 production in microglial cells. This supports the hypothesis that sHsps 
contribute to a cerebral inflammation.
Both Aβ40 and Aβ42 peptides reduced sHsp-induced IL-6 levels, and this response 
was dose-dependent. Potential mechanisms that might explain this inhibition 
are depicted in figure 5. We hypothesize that complex formation between 
Aβ and sHsps may prevent the interaction of sHsps with its receptor, thereby 
decreasing the inflammatory potential of sHsps (Fig. 5, pathway 1). Several 
sHsps, e.g. Hsp20, HspB8, Hsp27 or αB-crystallin may indeed closely interact 
with Aβ, as demonstrated by various techniques [80, 86, 476]. Alternatively, 
Aβ might function as a carrier protein, inducing microglial uptake of sHsps 
complexed to Aβ, thereby reducing available sHsps to induce an inflammatory 
response (Fig. 5, pathway 2). Supporting this hypothesis, we demonstrated 
that Aβ and Hsp20 show a high degree of co-localization in cell culture, 
including perinuclear staining that potentially represents a localization in the 
cytosol. A final explanation for our findings may be that Aβ, by binding to a 
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Fig. 1) Secretion of IL-6 by murine microglial cells stimulated with Aβ42 and sHsps. Cultured 
microglial cells were incubated with 50 µM Aβ42 and/or 1 µM HspB2/B3 (A), HspB8 (B) or Hsp20 
(C) and IL-6 secretion was measured in the culture medium by ELISA. Aβ alone did not induce 
IL-6 secretion (A), in contrast to HspB2/B3, HspB8 and Hsp20. sHsp-induced IL-6 secretion was 
significantly reduced in the presence of Aβ. * p<0.05, ** p<0.01, *** p<0.001. Mean IL-6 levels 
± SEM are shown. HspB2/B3 + Aβ, Hsp20 and Hsp20 + Aβ were measured in triplicate, all other 
conditions in duplicate. The experiment with Hsp20 was performed in the presence of PMB.
Fig. 2) Influence of Aβ on Hsp20-induced IL-6 secretion by murine microglial cells. Cultured 
microglial cells were incubated with 1 µM Hsp20 and a concentration range of Aβ42 (0.8 µM-50 
µM) (A) or Aβ40 (0.8 µM-50 µM) (B), or with 100 ng/ml LPS in the absence or presence of Aβ42 
(10 µM) (C). Neither Aβ42, nor Aβ40 induced IL-6 production. Hsp20-induced IL-6 secretion was 
decreased upon co-incubation with both Aβ42 and Aβ40, in a concentration dependent manner, 
where the highest concentrations correspond to the largest decrease (A+B). LPS-induced IL-6 
secretion was not reduced upon co-incubation with Aβ (C). ** p<0.01, *** p<0.001. Mean IL-6 
levels ± SEM are shown. All measurements were in duplicate. Experiments with Hsp20 were 
performed in the presence of PMB.
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receptor other than TLRs, induces a signaling pathway resulting in inhibition 
of the inflammatory state induced by sHsps (Fig. 5, pathway 3). Indeed, Aβ 
is known to interact with other receptors than TLRs, e.g. the low density 
lipoprotein receptor-1 (LRP-1) [516]. However, it would be expected that such 
an Aβ-induced signaling pathway does not only inhibit sHsp-dependent IL-6 
secretion, but also the induction by LPS, which we could not demonstrate, 
making this third hypothesis less likely.
Previous research demonstrated that Hsps 90, 70 and 32-induced IL-6 production 
was almost completely abolished in TLR4-mutant microglia [498]. In addition, 
NF-κB degradation and p38 MAPK phosphorylation were significantly reduced 
in these microglia, suggesting the Hsps induce the activation of NF-κB and 
p38 MAPK via TLR4, a stress-related pathway [517, 518], similar to the pathway 
involved in LPS-mediated effects. We observed that blocking of either TLR2 or 
TLR4 receptors resulted in decreased IL-6 induction by sHsps. In addition, LPS-
induced IL-6 production was also decreased after blocking of TLR2 as well as 
blocking of TLR4. LPS is a well-known TLR4 ligand [519], however commercially 
produced LPS has been described to contain contaminating components that 
activate TLR2 [520, 521], which can possibly explain our findings. In addition, 
this might also be the case for the sHsp preparations that we used in our 
study, since these were recombinantly produced in E.coli. Although the sHsps 
solutions were filtered to ensure sterility and we used PMB to neutralize any 
contamination of LPS in the sHsp preparations, there may be other potential 
contaminants that could induce IL-6 that were not removed or neutralized. The 
importance of purity of Hsp preparations was emphasized in a previous review 
study. Here it was stressed that only with experiments under completely sterile 
conditions it can be confirmed that an observed inflammatory response is 
indeed Hsp-mediated [79]. For future studies investigating the involvement of 
TLR2 and TLR4 in sHsps-induced inflammation, extremely pure Hsp solutions 
would be recommended, free of contaminating lipopeptides and bacterial 
components. Previously, a method of extensive phenol extraction has been 
described to remove TLR2-activation contaminations [520, 521]. In addition, 
besides studying IL-6 production as an output, measurement of other secreted 
cytokines can give a more complete picture of the effects of Aβ on microglial 
inflammation. In addition, NF-κB degradation and p38 MAPK phosphorylation 
can be investigated to gain more downstream information about the pathways 
involved.
Our finding that Aβ inhibits Hsp-induced IL-6 secretion is in contrast to a 
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Fig. 3) Immunofluorescent staining of Aβ42 and Hsp20 in murine microglial cell culture. Murine 
microglial cells were incubated with 10 µM Aβ42 and 1 µM Hsp20. Staining for Aβ (green) and 
Hsp20 (red) were mostly co-localized (overlay, yellow). (A) Both cell-associated (arrow) and non 
cell-associated (arrowhead) staining displayed co-localization. (B) Cell-associated staining was 
mainly present around the nucleus. Nuclei are counterstained in blue.
Fig. 4) Inhibition of IL-6 secretion by TLR blockers. Cultured microglial cells were pre-treated with 
blockers for TLR2 and TLR4 and subsequently co-incubated with Hsp20 (1 µM) (A) or LPS (100 ng/
ml) (B). Treatment with TLR2 and TLR4 blockers did not affect IL-6 production. Hsp20 induced a 
significant IL-6 secretion, which was decreased in the presence of both TLR2 and TLR4 blockers 
(A). LPS also increased IL-6 secretion, which was decreased in the presence of both TLR2 and TLR4 
blockers (B).*** p<0.001. Mean IL-6 levels ± SEM are shown. All measurements were in duplicate, 
except for the samples containing LPS in combination with TLR2 and TLR4 blockers, therefore 
these results could not be statistically analyzed. Experiments with Hsp20 were performed in the 
presence of PMB.
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previous study, in which IL-6 production induced by sHsps in primary human 
microglial was not affected by the presence of various Aβ peptides [507]. 
In another study, IL-6 and TNF-α levels induced by Hsp90, Hsp70 or Hsp32 
in rat microglial cells were not affected by the presence of Aβ42 [498]. These 
discrepancies are most likely explained by differences between various Hsps 
and by different cell origin.
To conclude, further investigation into the underlying pathways associated 
with Hsp-mediate cytokine production, both in vitro and in vivo studies, are 
required to gain more insight into the role and mechanism of sHsps and 
Aβ in the microglial immune response in AD. The influence of (s)Hsps on 
neuroinflammation is still mostly an untouched field of research that might 
play a significant role in AD pathology and can be of importance in therapeutic 
research on inflammation in AD brains.
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Fig. 5) Hypothetical mechanisms of Aβ-induced IL-6 inhibition. Activation of TLRs by sHsps 
may induce IL-6 secretion (A). Association of Aβ to sHsps might sterically prevent sHsp-TLR 
interaction, thereby reducing sHsp-mediated IL-6 secretion (pathway 1). Aβ/sHsp complexes 
might be phagocytosed by the microglial cells, which reduces the extracellular pool of sHsp and 
can therefore result in decreased TLR stimulation, followed by decreased IL-6 secretion (pathway 
2). Alternatively, Aβ may bind a yet undefined Aβ receptor (Aβ-R) that inhibits an inflammatory 
response downstream (pathway 3).
Aβ decreases small heat shock protein-induced IL-6 secretion
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Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and is 
characterized by memory loss and cognitive decline. Worldwide approximately 
40 million people are affected [522] and these numbers are predicted to be 
doubled by 2030 [523]. There is a great need for improved diagnosis and a 
better insight into its pathology, to ultimately provide treatment for AD 
patients. The major pathological proteins in AD are Amyloid- β (Aβ) and tau. In 
this thesis we focus on Aβ, a small protein known to accumulate and deposit 
in the brains of AD patients. We aimed to investigate different aspects of the 
Aβ protein, more specifically, we focused on oligomeric forms of Aβ, Aβ43 and 
amyloid associating proteins. 
Amyloid-β oligomers
Although initially amyloid plaques, consisting of  Aβ fibrils, were the central 
focus in AD pathology research, recent findings raised questions about 
the role of fibrillar Aβ. For instance, a poor correlation between severity of 
dementia symptoms and plaque density was demonstrated [32]. In addition, 
memory decline precedes plaque formation in mouse models, indicating 
another toxic mechanism is responsible for AD symptoms to occur [524]. This 
lead to the discovery of the more neurotoxic Aβ oligomers. These small soluble 
Aβ aggregates are believed to be intermediate species in the formation 
of insoluble, mature fibrils, but, in addition, specific oligomers may also be 
produced as end product of off-route pathways [525].
In Chapter 2 we reviewed different methods to detect Aβ oligomers. We 
concluded that a wide variety of techniques is available that can be used for 
specific applications. Techniques that are in use to detect Aβ oligomers are 
based on a variety of principles, such as separation, visualization, structure 
and conformation detection and quantification. We used one of these multiple 
techniques to investigate the biomarker potential of Aβ oligomers. In Chapters 
3 and 4 we described the design and development of two separate ELISA 
methods that specifically measure Aβ oligomers. The method in chapter 3 uses 
the NAB228 antibody, both as capture and detecting antibody, and the method 
in chapter 4 the VU-17 antibody, using the same principle. Both methods 
were successful in the detection of oligomers and were verified not to detect 
monomers. Using the NAB228-ELISA, we also demonstrated Aβ oligomers are 
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increased in human hippocampus extracts and in APP/PS1 transgenic mice. In 
addition, we reported that Aβ oligomer levels in human CSF were unaltered 
in AD patients compared to non-demented controls. Similarly, the VU-17 ELISA 
detected equal levels of Aβ oligomers in non-demented controls, patients with 
mild cognitive impairment (MCI) and AD patients. In addition, the latter ELISA 
also found a positive correlation between Aβ oligomers and MMSE scores, with 
Aβ oligomer levels decreasing in patients with declining cognition at follow up 
(Chapter 4).
Aβ oligomers and pathological mechanisms in AD
Research focusing on the pathological mechanisms underlying AD is crucial, 
since it can provide new leads for therapies and diagnostic methods. Therefore, 
Aβ oligomers and their toxicity are a major topic of interest. The term oligomers 
represents a very heterogeneous group, consisting of aggregates ranging in size 
from about 10 kDa up to > 100 kDa [362]. Also a wide diversity in conformations 
and shapes has been reported. To complicate research matters, synthetic Aβ 
probably does not behave exactly similar to the endogenous protein. In our 
studies, we used for instance oligomers and protein complexes generated with 
synthetic Aβ, however Aβ produced in cell culture or isolated from the brain 
or CSF could be preferred. In addition, it is challenging to obtain an accurate 
picture of the biological oligomer population, since protein complexes and 
oligomers that are isolated from in vivo systems might not be stable during 
handling and storage [526]. Different oligomeric species possess different 
levels of toxicity, however there is still debate concerning which oligomers are 
most toxic [527]. For instance, spherical shaped oligomers containing a pore 
were reported to be extremely neurotoxic [528, 529], whereas other studies 
focused on dimers and trimers [530] or aggregates with a molecular weight of 
56 kDa (dodecamers) [531] as toxic agents. Aβ oligomers have been shown to 
disrupt synaptic function and plasticity (reviewed by [532]). Several receptors 
have been proposed to function as oligomer ligands [362]. There is for instance 
multiple evidence for involvement of the glutamatergic NMDA receptor [533]. 
In addition, according to most recent believes, oligomers might assemble a 
receptor complex including among others the cellular prion protein (PrPc), the 
Wnt receptor Frizzled and insulin receptors [532]. Still, the exact mechanisms by 
which oligomers exert their neurotoxicity remain unclear.
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Aβ oligomers as CSF biomarkers for AD
Since the discovery of Aβ oligomers as one of the main toxic actors in AD, the 
quantification of oligomers in biological samples has gained much interest. 
Protein levels in CSF may reflect pathological processes in the brain, and 
therefore CSF is often regarded as the optimal source for biomarker detection 
in neurological disorders. Levels of Aβ oligomers in CSF are low, estimated at 
even less than 1% of total Aβ, and therefore challenging to detect [534]. In 
recent years, multiple attempts have been made, some more successful than 
others, to study the biomarker potential of Aβ oligomers in CSF. In several 
studies ELISA methods similar to ours were used, in which one monoclonal 
antibody is used both as capture and detection (using a biotin-label) antibody 
to specifically quantify Aβ oligomers [315, 324, 326-330, 535, 536]. However, to 
our knowledge, only two other studies reported the successful measurement 
of oligomers in CSF using an ELISA method similar to ours, more specifically 
they showed elevated levels in AD patients compared to non-demented 
controls [329, 537]. Other techniques have also been applied to compare levels 
of Aβ oligomers in CSF from AD patients and non-demented controls. For 
instance, approaches using FRET either or not combined with flow cytometry 
[359, 363, 538] and nanotechnology based techniques, which apply particles 
and beads to enhance sensitivity [355, 539] were reported. Also, one study 
used an Aβ aggregate binding peptide as bait, followed by a conventional Aβ40 
ELISA [540], and another study precipitated Aβ oligomers and quantified them 
by immunoblotting [383]. Others used techniques based on fluorescence 
correlation spectroscopy, that are able to measure as little as single Aβ 
aggregates [358, 379]. Finally, an ELISA method with an Aβ oligomers selective 
antibody was used [541]. All these studies, except one [538], reported increased 
levels of Aβ oligomers in AD CSF compared to controls. This is in contrast to 
our findings that levels of oligomers are unaltered in AD CSF (Chapters 3 and 4). 
We believe the specific composition of the oligomers that are detected in each 
separate assay might largely contribute to the outcome of results. Oligomers are 
believed to possess a size-dependent neurotoxicity [527], and specific sizes might 
be more relevant for the pathology and therefore for biomarker research. For 
our NAB228- and VU-17 ELISA, we demonstrated that small oligomers (between 
10 – 25 kDa) were preferentially measured. Differences in detected oligomer 
sizes might explain our contrasting findings compared to most other reports. 
Other studies did not determine the size of the detected oligomers or reported 
that especially large oligomers [329] or oligomers in the range from 10 kDa up 
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to >50 kDa aggregates were detected [537]. One study specifically analyzed 
levels of trimers and Aβ oligomers of 56 kDa and demonstrated both species 
to be elevated in AD CSF [383]. Concluding from these reports, high molecular 
weight oligomers or a very restricted group such as trimers, might potentially be 
successful discriminators for AD, which comprise Aβ oligomer species that were 
not specifically detected by our assays. In addition, we demonstrated in Chapter 
3 that human-anti-mouse-antibodies, endogenously present in CSF, are able 
to generate a false positive signal in some ELISAs using the same antibody for 
capture and detection. The possible interference of these heterophilic antibodies 
might also lead to discrepancies in results between different ELISA designs [542]. 
In one of our studies, we found a positive correlation between Aβ oligomers 
and MMSE scores, with Aβ oligomer levels decreasing in patients with declining 
cognition at follow up (Chapter 4). In contrast, other studies reported a negative 
correlation between Aβ oligomers and MMSE score [329, 363, 379]. Again, these 
differences might be related to variation in detected oligomeric species.
Besides, it remains uncertain how accurate oligomeric Aβ in CSF reflects the AD 
pathology. In brain tissue oligomers are present in elevated amounts in human 
AD post-mortem samples [314, 328, 539, 543]. Indeed, we also demonstrated 
increased levels of Aβ oligomers in human hippocampi extracts and in APP/PS1 
transgenic mice (Chapter 3). However, the relative levels and the composition 
of the Aβ oligomer subset in the CSF might be different from those deposited in 
the brain. Oligomers might aggregate or disaggregate continuously in the CSF 
environment. For instance, one study demonstrated that especially CSF from AD 
patients promotes Aβ aggregation [544]. Oligomers are known to be able to act 
as seeds and recruit monomeric Aβ molecules [545], by which the aggregation 
process might accelerate in the CSF. In addition, it has been demonstrated that 
handling and treatment of CSF, with for instance a detergent, can have a significant 
impact on the size of the oligomers [538], so the oligomer composition in the CSF 
after withdrawal, freeze-thawing, preparation and measurement might not be 
similar to that in in vivo CSF.
In conclusion, our reports describing similar levels of Aβ oligomers in AD and 
control groups, are not supported in literature. Since oligomers are such a 
heterogeneous group, other assays that detect a different subset of oligomers 
might be more successful. Although levels of Aβ oligomers in CSF are predicted 
to be extremely low, the ELISA methods we developed proved to possess 
sufficient sensitivity. Some enhanced methods can provide an extremely 
sensitive detection of low abundant targets, however the techniques are often 
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complicated and expensive and require great expertise, making their suitability 
for routine biomarker measurements difficult. For future research, the emphasis 
should lay on the development of a relatively simple high throughput method, 
which does not preferentially measure the relatively small oligomers.
Amyloid-β isoforms
The Aβ protein is generated by processing of the amyloid precursor protein 
(APP). APP is first cleaved by β-secretases, resulting in a membrane bound 
C-terminal fragment, which is subsequently cleaved by γ-secretases into Aβ 
peptides. A range of differently sized peptides is generated, of which Aβ40 
and Aβ42 are by far most extensively studied in relation to AD pathology. In 
this thesis we investigated the less well-studied isoform Aβ43 (Chapter 5). 
Using specific ELISA methods, we measured levels of Aβ40, Aβ42 and Aβ43 in 
CSF and found a strong correlation between Aβ42 and Aβ43 levels and a weaker 
correlation between Aβ40 and Aβ43 levels. No appreciable correlation between 
Aβ40 and Aβ42 was detected. In addition, we studied the biomarker potential of 
CSF Aβ43 in various forms of dementia. We found Aβ43 levels to be decreased in 
AD CSF compared to non-demented controls. Next we investigated whether 
CSF Aβ43 levels provided improved diagnostic accuracy, compared to Aβ42. We 
found the biomarker potential of Aβ43 to be equal to Aβ42, both solely and in 
combination with tau proteins. To extend the study beyond AD, we quantified 
the Aβ43 peptide in CSF from patients suffering from dementia with Lewy 
bodies (DLB) and FTD. Aβ43 was lowered in DLB patients compared to non-
demented controls and unaltered in FTD patients. This was similar to the 
relative changes in Aβ42 levels. And indeed, also the biomarker potential to 
discriminate between AD vs DLB and AD vs FTD was similar for Aβ42 and Aβ43.
Aβ isoforms and pathological mechanisms in AD
Many Aβ isoforms are known to exist, for instance N-terminal- and C-terminal 
truncated peptides. N-terminal truncation is believed to occur by secretory 
proteases, such as insulin-degrading enzyme and neprilysin, and C-terminal 
variation is elicited by slightly varying γ-secretase cleavage during APP 
processing [546]. Both N-terminal truncations and a longer C-terminus have 
been demonstrated to increase the peptide’s proneness to aggregate and 
thereby its neurotoxicity [395, 547, 548]. The presence of Aβ variants longer 
than Aβ42 has been demonstrated in cell lines [389, 549], transgenic mice 
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[550-552] and human brain tissue [553, 554]. For instance, Aβ43 has been 
demonstrated to deposit more frequent in senile plaques than Aβ40 [395] and 
was recently shown to accumulate in the brains of both sporadic and familial 
AD cases, and not in non-demented controls [547]. Larger Aβ isoforms may 
therefore play an important role in the plaque formation.
Evidence suggests that Aβ is produced in a sequential manner, via cleavage of 
tri- and tetra-peptides [389, 555]. According to this hypothesis two cleavage 
pathways exist: Aβ49 > Aβ46 > Aβ43 > Aβ40 and Aβ48 > Aβ45 > Aβ42 > Aβ38 [390]. 
It was suggested that a preference for the former pathway exists [390]. 
Interestingly, in the brains of patients with a specific familial mutation in the 
presenilin 1 gene (part of the γ-secretase complex), an increased Aβ42/ Aβ40 
ratio was measured, but an unchanged Aβ43/ Aβ40 ratio [547]. This finding 
supports the two cleavage pathway hypothesis, as a mutation can specifically 
affect one pathway. In our study, we found a strong correlation between 
Aβ42 and Aβ43 levels and a weaker correlation between Aβ40 and Aβ43 levels 
(Chapter 5). This might indicate that isoforms that are generated in the same 
step but in parallel pathways (such as Aβ42 and Aβ43 in step three), are most 
intensely correlated and isoforms that are generated in different steps (such 
as Aβ40 and Aβ42 in step three and four), are least correlated. However, our 
finding that Aβ40 and Aβ43 correlate just weakly seems in contrast with the 
tripeptide hypothesis, since this hypothesis predicts that Aβ40 is cleaved from 
Aβ43. In short, the mechanism by which different isoforms are generated is still 
controversial.
Aβ isoforms as CSF biomarkers for AD
Aβ peptides with a range of different C-termini have also been demonstrated 
in the CSF. Aβ40 is most abundant in CSF and believed to account for about 
50% of the Aβ pool. Around 16% consists of Aβ38 and only 10% of Aβ42 [556]. 
Levels of CSF Aβ40 are unaltered in patients suffering from AD. However, Aβ42 
is decreased in AD patients and routinely used as a diagnostic marker for the 
disease, either by itself or as Aβ40/ Aβ42 ratio. In combination with increased 
total tau and phosphorylated tau, these levels provide a diagnostic specificity 
and sensitivity of around 80% to discriminate AD patients from non-demented 
controls [557]. 
In search of novel biomarkers, numerous studies have quantified specific Aβ 
isoforms in CSF and investigated their potential to discriminate AD patients 
from non-demented controls and distinguish different forms of dementia. 
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For instance Aβ1-16 was reported to be increased in AD CSF compared to 
controls [558], Aβ1-38 to be decreased [559] and Aβ2-42 to be decreased in AD, 
but not in frontotemporal dementia (FTD) [560]. And recently, the 43 amino 
acids long Aβ variant was described as an overlooked peptide, which might 
possess a biomarker potential for AD [395, 396]. Our finding that Aβ43 levels 
are decreased in AD CSF compared to non-demented controls confirmed 
earlier findings in AD/ mild cognitive impairment patients [396]. Studies on 
quantified levels of Aβ43 in CSF are very limited [561] and to our knowledge 
additional reports on its biomarker potential in AD or other dementias are still 
lacking. Concluding from our study, although CSF Aβ43 was demonstrated to 
differ significantly between AD and other forms of dementia, there seems to 
be no additional biomarker value to the currently used biomarker repertoire. 
Still, other truncated Aβ peptides or a ratio or combination of various isoforms 
might possess a yet undiscovered diagnostic potential. However, an issue to 
keep in mind is the possibility that isoforms detected in CSF do not entirely 
reflect isoforms generated in the brain, since C-terminus specific proteases 
might be present in the CSF [561, 562]. N-terminally truncated variants are 
possibly more stable and might possess undiscovered biomarker potential. 
Also alternatively modified peptides such as pyroglutamate-3-Aβ, which is 
believed to account for the largest part of the N-terminal truncated species 
[563], can be interesting biomarker targets.
Aβ-associated proteins
Besides Aβ, numerous proteins co-localize in senile plaques and/
or associate with soluble Aβ in CSF and plasma. These proteins are 
generally referred to as amyloid associated proteins (AAPs). The best-
known examples of AAPs are (small) heat shock proteins (sHsps), ApoE 
and ApoJ, α1-antichymotrypsin, serum amyloid P component, transthyretin 
and proteins of the complement system [408, 564-566]. In this thesis we 
investigated several AAPs. 
In chapter 6 we describe the discovery of a novel potential AAP. In this study 
we aimed to identify proteins binding to Aβ in CSF and developed a method 
involving the use of synthetic Aβ40 as bait. After elution of potentially bound 
proteins, we applied mass spectrometry and identified a range of proteins. 
Among these was dickkopf-related protein 3 (Dkk-3), a member of the Wnt 
signaling pathway. We immunohistochemically demonstrated the presence of 
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Dkk-3 in senile plaques, both in diffuse and classic plaques. In addition, Dkk-
3 was abundant in cerebral blood vessels, where Aβ is known to deposit in 
the form of cerebral amyloid angiopathy (CAA). We demonstrated in vitro that 
vascular cells such as leptomeningeal smooth muscle cells and endothelial 
cells secrete Dkk-3. Finally, we quantified Dkk-3 in CSF and detected similar 
levels in non-demented controls and AD, DLB and FTD patients.
In chapter 7, we investigated the biomarker potential of complexes of Aβ 
with ApolipoproteinE (ApoE). To specifically detect Aβ/ApoE complexes 
we developed a sandwich ELISA method, combining a capture antibody 
against ApoE and a detection antibody against Aβ. Aβ/ApoE complexes were 
successfully detected in serum samples, however levels were similar in serum 
from non-demented controls and patients suffering from AD, DLB, FTD and 
vascular dementia.
In addition, we aimed to detect complexes of Aβ and the sHsp αB-crystallin (αB-
cry) (Chapter 8). Firstly, we were interested in the association characteristics 
of both proteins. We produced complexes of synthetic Aβ40 or Aβ42 with 
recombinant αB-cry, chemically cross-linked for stabilization. Analysis of 
these complexes revealed a composition of an αB-cry monomer associated 
with one or up to three Aβ molecules. Furthermore, equimolar Aβ:αB-cry 
concentrations or excess amounts of Aβ compared to αB-cry promoted the 
formation of Aβ/αB-cry complexes. Next, we developed a sandwich ELISA 
method, following a similar approach as in chapter 7, to detect Aβ/αB-cry 
complexes in biological samples. The synthetic/recombinant complexes were 
used to verify the specificity of the assay. However, this method did not detect 
Aβ/αB-cry complexes in hippocampal tissue or CSF.
Finally, in chapter 9 we studied the cumulative effects of sHsps and Aβ on 
IL-6 secretion by microglia. In cell culture experiments, we stimulated a 
murine microglial cell line with different sHsps (Hsp20, HspB2/B3 and HspB8), 
and detected up-regulated IL-6 secretion. Interestingly, this secretion was 
markedly suppressed when cells were incubated with both sHsps and Aβ40 or 
Aβ42. Immunofluorescent microscopy analysis revealed that sHsps and Aβ co-
localized. Blocking of TLR2 and TLR4 resulted in an inhibition of sHsp-mediated 
IL-6 production.
Aβ-associated proteins and pathological mechanisms in AD
The identification of novel AAPs is of great interest, because by binding to Aβ these 
proteins can affect its physiological and pathological functions [564, 567]. They may 
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influence Aβ aggregation, deposition, toxicity, transport and degradation [408]. We 
discovered the novel AAP Dkk-3 (Chapter 6), which is a protein potentially involved 
in development, apoptosis and cell proliferation and migration. We were the first to 
demonstrate the presence of Dkk-3 in senile plaques and we conclude that Dkk-3 
might play a role in the AD pathology by interacting with Aβ. However, follow-
up studies are required to unravel whether Dkk-3 is an innocent bystander, or 
actually involved in the AD pathology. Kinetic analyses can demonstrate whether 
the presence of Dkk-3 affects Aβ aggregation and fibril formation. In addition, cell 
culture and mouse model experiments might predict whether Dkk-3 influences 
Aβ toxicity. Novel AAPs can open up new opportunities for AD therapies and are 
therefore of great interest for future research.
Another aspect of the AD pathology we investigated is the link between Aβ and 
chronic inflammation processes occurring in the AD brain. Aβ deposits in the 
brain are accompanied by a local inflammatory response, manifested by the 
presence of activated microglial cells and an up-regulation of pro-inflammatory 
cytokines [442]. sHsps are molecular chaperones involved in protein misfolding 
[501]. In addition, (s)Hsps are capable of inducing the secretion of pro-
inflammatory cytokines, such as interleukins (ILs) [498, 507]. In chapter 9, we 
aimed to gain more insight into the role of Aβ and small heat shock proteins 
(sHsps) on neuroinflammation in microglia. We found that the presence of Aβ 
reduced the sHsp-induced IL-6 response and that Aβ and sHsps co-localized 
closely, and therefore hypothesized that protein-protein association might 
hinder interaction of sHsps with their receptor. We suggested that sHsps bind 
toll-like receptors (TLRs), and indeed, blocking of TLR2 and TLR4 resulted in 
an inhibition of sHsp-mediated IL-6 production. However, additional studies 
are essential to gain more insight into these mechanisms. The involvement of 
signaling pathways, including TLRs, requires more thorough investigation for 
instance using knock-out cell lines or mouse models. Also, we could not confirm 
previous findings in literature that Aβ itself induces an inflammatory response. 
The conformation of Aβ might be of importance for both its inflammability and 
its association with sHsps. Recent evidence has shown that Aβ oligomers might 
induce the strongest inflammatory response and activate microglial cells in a 
unique manner compared to monomers and fibrils [568-570]. In our study we 
did not characterize the conformation state of the Aβ protein, however during 
incubation in cell culture conditions oligomerization might have occurred. 
For future research, it would be interesting to investigate the influence of the 
conformation of Aβ on the observed IL-6 secretion suppression.
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Aβ-associated proteins as CSF and serum biomarkers for AD
Binding partners of Aβ are also interesting targets for biomarker studies. 
Considering their putative roles in AD pathology, AAPs can undergo up- or 
downregulation in AD patients’ brains. In addition, AAPs might act as highly 
specific biomarkers, since they are closely related to the amyloid pathology in 
AD. Therefore, in chapter 6, we investigated the CSF and serum levels of the 
newly identified potential amyloid binding protein Dkk-3. We demonstrated 
that Dkk-3 levels in CSF were markedly higher than in plasma, as reported 
before [418], suggesting that the protein is of cerebral origin. However, we 
detected similar levels of Dkk-3 in CSF from non-demented controls and AD, 
DLB and FTD patients, which indicates that Dkk-3 is probably not a suitable 
biomarker to diagnose and discriminate different forms of dementia.
An alternative approach to use AAPs in biomarker analysis is the detection 
of complexes of Aβ with its binding partner. Such biomarker complexes can 
provide more specific diagnostic differentiation, since AAPs might display 
different binding affinities and preferences in demented patients compared 
to controls. However, detection of such complexes can be challenging. Firstly, 
because assay specificity is of great importance, single components of the 
complex should not be detected. Secondly, levels of Aβ/AAP complexes in 
body fluids are usually extremely low and sensitive methods are required. 
And thirdly, proteins complexes might be transient and unstable, hindering 
reliable detection.
In chapter 7 we investigated the biomarker potential of Aβ/ApoE complexes. 
ApoE plays a major role in transport of lipids and cholesterol [90, 91]. The 
protein exists in three isoforms, ApoE2, E3 and E4, which are related to the 
risk of developing AD. People carrying the ε4 allele are more likely to suffer 
from AD at old age than people carrying the neutral ε3 or the protecting ε2 
alleles. Multiple evidence suggests that ApoE co-localizes with Aβ in senile 
plaques [92, 93] and binds to Aβ in an isoform dependent manner [94-97]. 
Most studies show that Aβ binds with the highest affinity to lipidated ApoE2, 
followed by E3 and E4 [98]. Because of the important role Aβ and ApoE play 
in AD, we hypothesized that complexes consisting of both proteins might 
be able to improve the AD diagnosis and help discriminate AD from other 
forms of dementia. To our knowledge, we were the first to detect levels of 
Aβ/ApoE complexes in serum. However, our results did not provide evidence 
that serum Aβ/ApoE complexes can function as a biomarker to discriminate 
between different forms of dementia. Aβ/ApoE complexes in CSF on the other 
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hand, might be a more promising target. Compared to serum proteins, CSF 
proteins are superior in reflecting brain processes. Moreover, recent reports 
suggest that the complexes are less likely to cross the blood-brain barrier 
(BBB) [454-456]. In addition, Aβ/ApoE complexes detected in serum might 
be formed locally, and therefore might not reflect levels of associated Aβ and 
ApoE in the brain. Recently, a decrease in Aβ/ApoE complexes in post-mortem 
obtained CSF from AD patients was reported [99]. Using our assay, detection 
in CSF was unsuccessful, potentially because levels were below the detection 
limit of the assay. This was also supported by a report showing that Aβ and 
ApoE minimally associate with each other in CSF [49]. They demonstrated that 
only about 5% of cell-produced Aβ and lipidated ApoE formed complexes 
under physiological conditions. Alternatively, complexes of Aβ and another 
lipoprotein, ApoJ, might be a more interesting target for detection in CSF. 
ApoJ, also known as clusterin, is found associated with senile plaques [571, 
572]. Furthermore, clearance of Aβ42 from the brain is markedly enhanced 
when associated with ApoJ [454], indicating ApoJ plays an important role in 
the AD pathology. Previous reports have shown that ApoJ is more abundantly 
associated with Aβ than ApoE, both in CSF [409] and plasma [567], therefore 
Aβ/ApoJ complexes might be more readily detectable.
In chapter 8 we aimed to detect Aβ/αB-cry complexes. As mentioned before, 
sHsps are molecular chaperones that can prevent aggregation of misfolded 
proteins [501]. sHsps are known to associate with Aβ in the AD brain [81, 
85] and are suggested to affect Aβ aggregation and toxicity [80, 86, 507]. 
Although successful in measuring synthetic complexes, our ELISA method 
did not detect Aβ/αB-cry complexes in hippocampal tissue or CSF, potentially 
because the assay is lacking sensitivity, or because complexes are transient and 
unstable under experimental conditions. In summary, the results in this study 
did not confirm the presence of Aβ/αB-cry complexes in vivo and therefore 
their biomarker potential remains speculative. In order to provide definitive 
evidence of the presence or absence of the complexes in CSF, more sensitive 
methods are required. Although levels of both Aβ and αB-cry are detectable 
in CSF with ELISA or western blot [488], complexes of these proteins most 
likely only account for a small percentage of the total pool and their levels 
are therefore probably extremely low. Also the composition of Aβ/αB-cry 
complexes formed in the brain might be different from those we produced in 
vitro. Isolation of the complexes from brain tissue, followed by western blot 
analysis can provide more information about the association characteristics. 
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However, experimental conditions can disrupt protein bonds and stabilization 
such as chemical cross-linking might be required.
Concluding remarks and future prospects
In this thesis we aimed to gain more insight into the role and biomarker 
potential of Aβ(-associated) proteins in AD. We conclude that the heterogeneity 
in conformations and isoforms severely complicates Aβ research. Comparing 
results from different studies should be performed with great care. Also, 
it remains questionable how accurate in vitro methods are with regard to 
aggregation characteristics and how well the composition of in vitro formed Aβ 
aggregate mixtures resembles the endogenous Aβ pool. On the other hand, the 
variety in Aβ species provides opportunities for specific biomarker research. 
In this thesis we investigated several Aβ-related potential AD biomarkers. 
Although some of these appear to be more promising than others, all studies 
reported in this thesis provide novel and additional information about the AD 
pathology. Biomarkers for early detection of AD are still urgently required, and 
to find successful candidates the molecular mechanisms initiating the disease 
are of great importance. Since Aβ accumulation is believed to be one of the 
earliest events in AD, Aβ-related biomarkers, or a panel of biomarkers, deserve 
much interest.
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Samenvatting in het Nederlands
De ziekte van Alzheimer is een neurologische ziekte en de meest voorkomende 
vorm van dementie. Wereldwijd lijden op het moment rond de 40 miljoen 
mensen aan de ziekte en de verwachting is dat dit aantal in 2030 is verdubbeld. 
Het ziekteverloop wordt getypeerd door een achteruitgang van de structuur 
en functie van de hersenen. Gedurende het ziekteproces sterven steeds 
meer hersencellen af, wat leidt tot vergeetachtigheid, veranderingen in 
persoonlijkheid, desoriëntatie en verlies van spraakvermogen. Patiënten met 
de ziekte van Alzheimer hebben een sterk verminderde levensverwachting; 
gemiddeld leven mensen nog 8 jaar nadat de diagnose is gesteld.
De ziekte van Alzheimer ontstaat door ophoping van eiwitten; om precies te 
zijn het amyloïd-beta (Aβ) eiwit dat samenklontert (aggregeert) tussen de 
hersencellen als amyloïde plaques en het tau eiwit dat binnenin zenuwcellen 
ophoopt. In dit proefschrift besteden we aandacht aan Aβ, omdat dit eiwit 
het vroegst in het ziekteproces voor problemen zorgt, waarschijnlijk al 
decennia voordat de eerste symptomen zich openbaren. Ophoping van Aβ in 
de hersenen van Alzheimer patiënten ontstaat door een teveel van het eiwit. 
Bovendien wordt bij mensen met de ziekte van Alzheimer in de hersenen 
meer van een Aβ variant gevonden die 42 aminozuren (bouwstenen) lang is, 
tegenover de normale vorm die bestaat uit 40 aminozuren. Deze langere vorm 
wordt Aβ42 genoemd en heeft sterker de neiging om te gaan aggregeren en 
amyloïde plaques te vormen en is daardoor giftig voor het zenuwstelsel.
Door het meten van Aβ42 en tau in hersenvocht (verkregen via een ruggemerg 
punctie), kan vastgesteld worden of een patiënt de ziekte van Alzheimer heeft. 
Deze eiwitten worden daarom biomarkers – signaalstoffen – voor Alzheimer 
genoemd. Deze testen zijn echter niet met grote nauwkeurigheid in staat om 
in een vroeg stadium te voorspellen of iemand de ziekte gaat ontwikkelen, en 
ook kan het bij sommige patiënten lastig zijn om op basis van symptomen en 
Aβ42 en tau metingen te onderscheiden of er sprake is van Alzheimer of een 
andere vorm van dementie. Daarom is het van belang dat er nieuwe biomarkers 
worden gevonden. In dit proefschrift hebben we geprobeerd methoden met 
nieuwe biomarkers te ontwikkelen. Hoewel in de amyloïde plaques vooral 
lange ketens van Aβ gevonden worden, wordt er gedacht dat de kleinere 
aggregaten die ontstaan voordat de ketens gevormd zijn – zogenaamde 
oligomeren –, giftiger zijn voor de hersenen. Ten eerste hebben we twee 
testen ontworpen en opgezet waarmee we Aβ oligomeren kunnen meten in 
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hersenvocht. In hoofdstuk 3 beschrijven we één van die methoden. De test is 
specifiek voor oligomeren, wat wil zeggen dat de niet-geaggregeerde vorm 
van Aβ niet gemeten wordt. Hoewel de verwachting is dat Aβ oligomeren 
in erg lage concentraties voorkomen in het hersenvocht, was onze test toch 
in staat om ze hierin te meten. In dit hoofdstuk hebben we ook laten zien 
dat oligomeren meer voorkomen in de hippocampus (het hersengebied dat 
verantwoordelijk is voor geheugenprocessen) van Alzheimer patiënten dan 
in de hippocampus van patiënten zonder dementie. Bovendien kunnen we 
met de test ook in muizen met een menselijk Alzheimer-gen laten zien dat ze 
steeds meer Aβ oligomeren in de hersenen ontwikkelen als ze ouder worden. 
Tenslotte hebben we monsters van hersenvocht van Alzheimer patiënten 
vergeleken met dat van niet-dementerende personen. Helaas hebben we 
vergelijkbare hoeveelheden van Aβ oligomeren gemeten in deze groepen. 
Deze test kunnen we dus niet gebruiken om de diagnose van Alzheimer te 
ondersteunen.
Hoofdstuk 4 beschrijft een tweede test die we ontwikkelden om Aβ oligomeren 
te meten. Met deze test hebben we vergelijkbare resultaten verkregen 
met metingen in hersenvocht; ook hiermee vonden we geen verschillen in 
hersenvocht van Alzheimer patiënten en niet-demente personen. Wel liet 
deze test zien dat Aβ oligomeren verminderden in de tijd bij patiënten waarbij 
de hersenfunctie ook afnam, waardoor de test mogelijk geschikt is om de 
achteruitgang van individuele patiënten in de gaten te houden.
Er zijn verschillende studies van andere onderzoekers gepubliceerd die ook 
Aβ oligomeren hebben gemeten in hersenvocht, soms met een vergelijkbare 
methode als de onze of met andere methoden. Meestal lieten deze 
onderzoeken verhoogde hoeveelheden van oligomeren zien in Alzheimer 
patiënten. In hoofdstuk 3 en 4 laten we ook zien dat onze beide testen vooral 
kleine oligomeren meten. Het is mogelijk dat deze niet verhoogd voorkomen 
in het hersenvocht van Alzheimer patiënten, maar grotere oligomeren wel.
Hoofdstuk 5 beschrijft een test die we ontwikkelden om een speciale vorm 
van Aβ te meten, namelijk van 43 aminozuren lang. Aβ43 komt vaak voor in 
amyloïde plaques en is mogelijk nog giftiger voor hersencellen dan Aβ42. We 
hebben daarom onderzocht of Aβ43 kan dienen als biomarker voor de ziekte 
van Alzheimer. We hebben deze vorm van Aβ gemeten in hersenvocht van 
patiënten met Alzheimer en met andere vormen van dementie, namelijk 
dementie met Lewy bodies en frontotemporale dementie. De waarden 
hebben we vergeleken met die van niet-demente personen. We vonden een 
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verlaging van Aβ43 bij zowel de ziekte van Alzheimer als Lewy body dementie. 
In combinatie met metingen van tau waarden waren deze biomarkers met 
goede nauwkeurigheid in staat om de ziekte van Alzheimer vast te stellen. 
We hebben echter ontdekt dat de verlaging in Aβ43 sterk overeenkomt 
met de al bekende verlaging van Aβ42 in Alzheimer patiënten en ook het 
diagnosticerende vermogen van de test is gelijk. Deze nieuwe test voegt 
dus geen extra informatie toe aan de al bestaande testen waarin Aβ42 en tau 
worden gemeten.
Vervolgens hebben we ook onderzoek gedaan naar eiwitten die vaak 
in combinatie met Aβ in plaques voorkomen en die binden aan Aβ, de 
zogenaamde amyloïd geassocieerde eiwitten. Het onderzoeken van deze 
eiwitten is van groot belang omdat het inzicht kan geven in de oorzaak en het 
ziekte proces van Alzheimer. Bovendien kunnen deze eiwitten mogelijk dienen 
als biomarker voor de ziekte. In hoofdstuk 6 beschrijven we de ontdekking 
van een nieuw potentieel amyloïd geassocieerd eiwit, genaamd Dkk-3. We 
ontdekten dat dit eiwit aan Aβ kan binden in hersenvocht. Bovendien toonden 
we de aanwezigheid van Dkk-3 aan in amyloïde plaques. Dit is een belangrijke 
bevinding, omdat het eiwit niet eerder beschreven is in de hersenen van 
Alzheimer patiënten. Voor vervolgonderzoek kan het erg interessant zijn om 
te bestuderen of het eiwit een rol speelt in het ziekteproces van Alzheimer 
en of het aggregeren van Aβ  kan beïnvloeden. Tenslotte hebben we de 
hoeveelheden van Dkk-3 in hersenvocht vergeleken in monsters van patiënten 
met de ziekte van Alzheimer, Lewy body dementie en frontotemporale 
dementie. We hebben ontdekt dat er geen verschillen zijn tussen de waarden 
van deze patiënten, Dkk-3 is dus niet geschikt om als biomarker voor de ziekte 
van Alzheimer te gebruiken. 
In hoofdstukken 7 en 8 hebben we complexen van Aβ en geassocieerde 
eiwitten bestudeerd. Als zo’n complex te meten is in hersenvocht zou het 
kunnen dienen als een specifieke biomarker voor Alzheimer. In hoofdstuk 7 
bestudeerden we complexen van Aβ en ApoE. ApoE speelt een belangrijke 
rol in de ziekte van Alzheimer, vooral bij de afvoer van Aβ uit de hersenen. 
Ook is bekend dat mensen met een bepaalde vorm van ApoE een verhoogde 
kans hebben om Alzheimer te ontwikkelen. We hebben Aβ/ApoE complexen 
gemeten in serum en vergeleken monsters van patiënten met Alzheimer, 
Lewy body dementie, frontotemporale dementie en vasculaire dementie. 
We vonden dat Aβ/ApoE complexen in alle groepen in gelijke hoeveelheden 
aanwezig waren. Mogelijk verschillen de hoeveelheden van het complex in 
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hersenvocht wel, want eiwitten in hersenvocht reflecteren de processen die 
plaatsvinden in hersenen beter dan serum. De test die we opgezet hebben 
was echter niet in staat om complexen in hersenvocht te meten. Mogelijk zijn 
de hoeveelheden van de complexen hierin extreem laag, waardoor de test niet 
gevoelig genoeg is.
In hoofdstuk 8 bestudeerden we complexen van Aβ met een ander amyloïd 
geassocieerd eiwit, namelijk αB-crystalline. αB-crystalline behoort tot de 
groep van de kleine heat shock eiwitten, die een functie hebben in het 
reguleren van de juiste vouwing van andere eiwitten. Er wordt gedacht 
dat αB-crystalline ook een rol speelt bij de vouwing van Aβ. Bovendien is 
beschreven dat αB-crystalline het klonteren van Aβ kan beïnvloeden. In dit 
hoofdstuk onderzochten we de vorming van Aβ/ αB-crystalline omplexen 
en ontwikkelden we een test om deze te meten. We hebben o.a. ontdekt dat 
αB-crystalline met zowel Aβ40 als Aβ42 complexen kan vormen en dat een 
overmatige hoeveelheid van Aβ t.o.v. αB-crystalline de complexvorming 
bevorderde. De test die we vervolgens ontwikkelden was goed in staat om 
door onszelf gevormde complexen te meten, maar we konden geen Aβ/ αB-
crystalline complexen meten in hersenweefsel of hersenvocht. Mogelijk zijn 
de hoeveelheden van deze complexen te laag, of zijn de complexen instabiel 
en vallen ze uit elkaar gedurende de meting.
Tenslotte beschrijven we in hoofdstuk 9 ons onderzoek naar de invloed van 
zowel Aβ als kleine heat shock eiwitten op hersencellen. We bestudeerden 
daarbij microglia cellen, belangrijke cellen in het afweersysteem van 
de hersenen. Er is bekend dat bij mensen die lijden aan Alzheimer een 
ontstekingsreactie optreedt in de hersenen, wat de ziekte kan verergeren. 
In celkweek experimenten behandelden we microglia cellen met Aβ en 
verschillende kleine heat shock eiwitten en een combinatie van beide. 
Vervolgens maten we de hoeveelheid van ontstekingsfactor interleukine-6 
die de cellen uitscheidden. We ontdekten dat stimulatie met Aβ geen effect 
had op de uitscheiding van interleukine-6 en dat kleine heat shock eiwitten 
een verhoging van interleukine-6 uitscheiding veroorzaakten. Interessant 
was dat een combinatie van Aβ en heat shock eiwitten leidde tot minder 
interleukine-6 in de celkweekvloeistof dan behandeling met heat shock 
eiwitten alleen. Het lijkt er dus op dat Aβ een remmend effect heeft op de 
ontsteking-stimulerende werking van de heat shock eiwitten. Microscopisch 
onderzoek liet zien dat Aβ en de heat shock eiwitten op dezelfde plek in en 
om de cellen voorkwamen. We speculeerden daarom dat Aβ en de heat shock 
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eiwitten een complex vormen, waardoor de heat shock eiwitten minder goed 
in staat zijn een ontstekingsreactie tot stand te brengen in de microglia cellen. 
Om het mechanisme achter deze bevindingen te onderzoeken is echter nog 
vervolgonderzoek nodig.
In dit proefschrift hebben we verschillen mogelijke nieuwe biomarkers voor de 
ziekte van Alzheimer onderzocht en kunnen concluderen dat ziekteprocessen 
die plaatsvinden in de hersenen niet altijd leiden tot meetbare verschillen in 
hersenvocht van patiënten. Bijvoorbeeld oligomeren van Aβ zijn wel verhoogd 
aanwezig in hersenweefsel van Alzheimer patiënten, maar we hebben geen 
verhoging kunnen meten in hersenvocht. Ook hoeveelheden van Dkk-3, 
een eiwit dat neerslaat met Aβ in plaques, zijn niet verhoogd of verlaagd in 
hersenvocht. Verder hebben we ontdekt dat Aβ complexen kan vormen met 
verschillende andere eiwitten en hebben we methoden ontwikkeld om deze 
te meten, maar kunnen we concluderen dat deze complexen waarschijnlijk 
in erg lage hoeveelheden voorkomen in hersenvocht. Ons onderzoek naar 
verschillende vormen van Aβ en amyloid geassocieerde eiwitten draagt 
bij aan een beter begrip van de ziekte en de onderliggende pathologische 
processen. Zo hebben we beschreven dat kleine heat shock eiwitten een 
ontstekingsreactie kunnen veroorzaken in microglia cellen en dat Aβ hier een 
belangrijk effect op heeft, een proces wat in hersenen van Alzheimer patiënten 
mogelijk ook plaatsvindt.
Momenteel bestaat er nog geen therapie om het ziekteproces van Alzheimer te 
stoppen, daarom blijft elk onderzoek dat meewerkt aan een vroege diagnose 
en inzicht het verloop van de ziekte van groot belang.
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